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Acronyms and Abbreviations 
ALC absolute lymphocyte count 
BCML B-cell monoclonal lymphocytosis 
CBC complete blood count  
CDC Centers for Disease Control and Prevention 
CLL chronic lymphocytic leukemia 
CML chronic myelogenous leukemia 
DDT dichlorodiphenyltrichloroethane 
DOE U.S. Department of Energy 
EEOICPA Energy Employees Occupational Illness Compensation Program Act 
ERR excess relative risk 
Hct Hematocrit 
HERB Health-related Energy Research Branch 
Hgb Hemoglobin 
IARC International Agency for Research on Cancer 
INEEL Idaho National Engineering and Environmental Laboratory 
LET linear energy transfer 
MBL monoclonal B-cell lymphocytosis 
MGUS monoclonal gammopathy of unknown significance  
MM multiple myeloma 
NCRP National Council on Radiation Protection 
NHL non-Hodgkin’s lymphoma 
NIOSH National Institute for Occupational Safety and Health 
OERP Occupational Energy Research Program 
RBC red blood cell count 
RECA Radiation Exposure Compensation Act 
RR relative risk 
SMR Standardized Mortality Ratio 
Sv Sievert 
WBC white blood cell count 
WHO World Health Organization 
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Background and Purpose 
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western world. 
While the etiology of CLL is largely unknown, it is currently the only cancer assigned a 
probability of causation by ionizing radiation of zero under the US Energy Employees 
Occupational Illness Compensation Program Act (EEOICPA).  In support of this decision many 
epidemiologic studies have shown no evidence of an association between external ionizing 
radiation and CLL. However, uncertainties remain, and recently new evidence was presented that 
suggest that this decision should be revisited (Richardson et al. 2005). 
 
While the decision to treat CLL as non-radiogenic was based on a review of medically and 
occupationally exposed Western populations, additional studies may be informative.  
In the appropriations language for fiscal year 2004, the U.S. Congress directed the National 
Institute for Occupational Safety and Health (NIOSH) to conduct epidemiologic research and 
other activities to “establish the scientific link between radiation exposure and the occurrence of 
chronic lymphocytic leukemia.”  To this end, a focus on CLL radiogenicity was added to 
existing research conducted under the NIOSH Occupational Energy Research Program (OERP). 
 
On July 21, 2004, NIOSH conducted a 3-hour public meeting to: 1) discuss available research 
strategies for investigating the potential relationship between the incidence of CLL and worker 
exposures to ionizing radiation and 2) identify gaps in current research. The meeting was 
announced in the Federal Register on June 10, 2004.  This document summarizes the meeting 
proceedings and provides an updated report of related research activities.   
 
 
 
Public Meeting Proceedings of July 21, 2004 - Input on Gaps in CLL Radiogenicity Research 
 2
Expert Panelists: Six experts in epidemiologic and molecular CLL research were invited to 
provide opinions. The table below lists names and information about the panelists. 
 
Panelist Affiliation Title Research Interests 
Glyn Caldwell, MD University of Kentucky, 
College of Public 
Health 
Professor Infectious disease, 
cancer, environmental 
and radiation 
epidemiology 
David Hoel, PhD Medical University of 
South Carolina 
Professor Cancer epidemiology 
and risk assessment 
Geoffrey Howe, PhD Columbia University 
Mailman School of 
Public Health 
Professor Radiation and cancer; 
nutrition and cancer; 
methodological issues 
in epidemiology 
Martha Linet, MD, MPH National Cancer 
Institute (NCI) 
Chief, Radiation 
Epidemiology Branch, 
Division of 
Epidemiology and 
Genetics 
Radiation 
epidemiology, risk 
factors for leukemia  
Gerald Marti, MD, PhD Food and Drug 
Administration (FDA) 
Section Chief, 
Laboratory of Stem 
Cell Biology; Division 
of Cellular and Gene 
Therapy; Office of 
Therapeutics Research 
and Review 
Cytogenetic markers for 
chronic lymphocytic 
leukemia, risk factors 
for leukemia and other 
B-cell diseases 
Lew Pepper, MD, MPH Boston University 
School of Public Health 
Professor Environmental health, 
occupational medicine 
 
Twenty-five people attended the meeting, including the six panel members, NIOSH and other 
federal staff, and the public. The meeting began with introductions of the panelists and all 
attendees, followed by a brief overview of the CLL literature and a focused discussion of 
research gaps and methods. 
 
The meeting was not transcribed. What follows is a compilation of notes recorded at the meeting.  
Some panelist provided detailed written responses during the review of the proceedings.  These 
instances are indicated by an asterisk (*) following the panelist’s name.  
I. Overview of Chronic Lymphocytic Leukemia – Mary Schubauer-Berigan, PhD, 
NIOSH  
The presentation slides used by Dr. Schubauer-Berigan are provided in Appendix A.  The 
following is a summary of information presented to the panel during her presentation. 
A. Subtypes/Diagnosis 
Leukemia subtypes include lymphoid, myeloid (aka myelogenous and granulocytic), 
monocytic, and others (specified and unspecified). 
 
Lymphoid leukemia has additional subtypes, including acute lymphocytic (excluding 
acute exacerbation of chronic), chronic lymphocytic, subacute lymphocytic, and others. 
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Chronic lymphocytic leukemia is divided into two subtypes: B-lymphocyte, which is 
approximately 95% of cases, and T-lymphocyte. B-lymphocyte CLL is characterized by 
the accumulation of B-cells through impeded apoptosis. While CLL is primarily 
identified by the expression of the CD-5 cell surface receptor, inhibition of the p53 tumor 
suppressor protein can also be an indicator. CLL may have an inherited component. 
 
CLL is routinely diagnosed as an elevated lymphocyte count in the complete blood count. 
The use of automated instrumentation and diagnostic algorithm greatly increase the pre-
clinical diagnosis of CLL. If infections and autoimmune complications are recognized, 
increased treatment is necessary. Half of early-stage CLL progresses to advanced stage 
and death. 
B. Prevalence and Incidence of CLL 
The adult lifetime probability of developing any leukemia (white male age 20–95+) is 
1.51%. By subtype, the probability of developing CLL = 0.56%, chronic myelogenous 
leukemia (CML) = 0.20%, acute lymphocytic leukemia (ALL) = 0.06%, and acute 
myelogenous leukemia (AML) = 0.46%. 
 
In 2001, the U.S. prevalence of CLL cases (0–11 years post-diagnosis) was 58,574 cases. 
CLL is most common among white males. The prevalence for myeloid and monocytic 
leukemia was 33,017. 
 
There is no clear secular trend for the incidence of CLL. CLL is especially low among 
Asians and Native Americans. The probability of having CLL increases greatly with age. 
C. Etiology of CLL 
The current epidemiologic evidence does not conclusively show a relationship between 
exposure to ionizing radiation and the development of CLL in medically, occupationally, 
or environmentally exposed populations. 
 
The existing evidence has several limitations. Exposures of Japanese A-bomb survivors 
and U.S. workers are not comparable. A-bomb survivors primarily received acute, 
external exposures to radiations of low linear energy transfer (low LET), while U.S. 
workers have chronic, low and high LET exposures. Death certificate-based studies are 
not the best approach for the study of CLL given that leukemia subtypes are often not 
specified and CLL is usually a chronic illness not leading to death. Studies with primarily 
internal, high LET exposures are inconclusive.  
 
The importance of other etiologic factors is unclear. Recently, a review panel determined 
that exposure to Agent Orange defoliant has shown some evidence of linkage to risk 
factors for non-Hodgkin’s lymphoma and B-CLL [Institute of Medicine (IOM) of the 
National Academies 2003].  
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D. Current NIOSH studies 
NIOSH has three ongoing CLL research studies.  
 
o A multi-site leukemia case-control study of 257 cases and 1027 controls. 
Approximately 40 of the cases are CLL. Cases are identified according to the 
underlying cause of death. Exposure measurements include bone-marrow doses for 
gamma, x-ray, neutron, and plutonium. Some limited exposure data are also available 
for chemical exposures such as benzene and carbon tetrachloride. 
 
o A cohort mortality study of the Idaho National Engineering and Environmental 
Laboratory (INEEL) workforce. This study includes 63,561 workers and over 10,000 
deaths. Of the 73 underlying and non-underlying leukemia deaths among radiation-
monitored workers, 21 were due to CLL. 
 
o An analysis of risk for CLL among nuclear workers. NIOSH has contracted with the 
International Agency for Research on Cancer (IARC) to conduct this analysis as an 
add-on to a large, 15-country, 400,000-person cohort study of nuclear workers 
conducted by IARC. The CLL analysis and report will be completed following the 
report of the full study.  
 
In addition, NIOSH is evaluating the literature to determine if a meta-analysis of existing 
studies of radiation-exposed populations is feasible. The meta-analysis would use 
published studies and possibly unpublished data, if available from the investigators.  
E. Possibilities for Future Research 
Epidemiologic Studies:  Some possible study designs that warrant feasibility assessment 
include:  
o additional epidemiologic analyses of occupational or radiotherapy cohorts 
o exploring the inclusion of CLL cases recorded as non-underlying cause of death 
o incidence studies  
o DOE-wide exposure-based cohort studies involving internal exposures, including 
plutonium and uranium, and neutron exposures, to address major gaps in the 
epidemiologic knowledge with respect to CLL’s associations with high-LET forms of 
radiation  
 
Other research needs include:  
o basic radiobiological research on CLL  
o biomarkers (or other pre-clinical disease markers for CLL)  
o other non-radiological etiologic studies to better understand risk factors for CLL 
II. Discussion 
Following the presentation, panelists provided comments on several topics. Time was 
allotted for comments from the public after panel discussion was completed on each 
discussion topic.  
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A. Epidemiologic Studies 
The panelists discussed several prominent studies of radiation exposure such as the 
Japanese Atomic Bomb Survivor Lifespan study, commonly used for radiation risk 
analysis.  Some of the discussion stems from studies described in the Annotated 
Bibliography (Appendix B), which was provided to panelists prior to the meeting. 
 
G. Howe:   
An important concern related to the Japanese Atomic Bomb Survivor Lifespan study is 
that CLL is rare in Asian populations, and there is a lack of defined CLL diagnostic 
criteria to identify a true CLL case.  
 
G. Caldwell: 
Studies of CLL and radiation are predominantly negative.  There is considerable interest 
in finding a link between CLL and radiation.  There is a need to study all cohorts 
individually and analyze CLL separately.  Researchers should not consider the “case 
closed” on whether CLL is caused by radiation.  Also, more incidence studies are needed. 
 
D. Hoel:   
There are a number of limitations with existing epidemiologic studies: 
o CLL diagnostic problems with death certificate information 
o A-bomb cohort – not started until 5 years out  
o Ankylosing spondylitis studies are not conclusive. “Pre-leukemics selectively 
eliminated.”  
The Savannah River Site Study showed an increase in CLL with radiation exposure (W. 
E. Fayerweather, R. M. Hall, and M. E. Karns. Epidemiologic study of a possible link 
between occupational radiation exposure and respiratory cancer, prostate cancer, and 
leukemia in Savannah River Plant employees. Draft Westinghouse Savannah River 
Company report. February 7, 1991.)   
Tumor registry studies do not show increases in CLL.   
There is also the issue of internal emitters. General studies have not found increases from 
α-emitters on bone surfaces.   
More radiobiological evidence is needed to understand plausibility.  Researchers should 
consider studying B-CLL, non-Hodgkin’s lymphoma (NHL), and multiple myeloma 
(MM) together as a group  
 
L. Pepper: 
Most investigations start with the common assumption that CLL is not radiogenic. This 
assumption affects the published literature. Intriguing issues were raised in the NIOSH 
literature review: blood versus lymph tissue as point of origin, and distinguishing CLL 
from non-CLL. 
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There is a predominant paradigm that CLL is a disease of aging. Questions include: What 
are the key issues related to aging in producing CLL? The timing of exposure may be a 
factor; it has not been adequately addressed for CLL and should be further explored.  
 
Genetic susceptibility has not been adequately studied for CLL or most other cancers.  
 
M. Linet*: 
Initial descriptions of leukemia mortality and incidence were restricted to all forms of 
leukemia combined. Because death certificates and early population-based cancer 
registries often did not designate leukemia subtype, evaluation and comparison of long-
term trends in leukemia occurrence across populations is restricted to total leukemia prior 
to 1980, and to major leukemia subtypes subsequently. The landmark French-American-
British (FAB) classification (first proposed in 1976 for the acute leukemias and for the 
chronic B- and T-cell lymphoid leukemias in 1989) achieved international consensus on 
morphologic criteria.  Subsequent efforts to incorporate developmental and functional 
aspects of hematopoiesis according to lineage as well as key aspects of pathogenesis, and 
cytogenetic and immunophenotypic characteristics in the 1990s culminated in the World 
Health Organization (WHO) classification of neoplastic and related hematopoietic and 
lymphoid tissue diseases in 2001. The WHO classification was incorporated in the third 
revision of the International Classification for Diseases in Oncology.  
 
For decades, there were differences between North American and European expert 
hematopathologists on whether CLL was considered as a separate entity or part of a 
spectrum of well-differentiated forms of non-Hodgkin’s lymphoma. CLL was not 
included as part of non-Hodgkin’s lymphoma in the Working Formulation classification 
developed primarily by North American expert hematopathologists, but CLL and well-
differentiated NHL were considered as a combined grouping in the Kiel classification 
employed by European expert hematopathologists. With the advent of the WHO 
classification, CLL is classified with the lymphomas as one of the peripheral 
lymphoproliferative diseases. Morphologically, CLL appears as a homogeneous disease 
of small lymphocytes, but the increasingly wide application of flow cytometry and 
molecular analysis reveals that CLL is not homogeneous, but can be classified into two 
major subtypes based on the pattern of immunoglobulin gene mutations of pre- and post-
germinal center CLL. Several cytogenetic abnormalities have been described in CLL 
cases, with the commonest including interstitial deletions of 13q and trisomy 12 (both of 
which are most likely involved in tumor progression). Complex chromosomal 
abnormalities may arise along with disease progression.  
 
In the past, there has been some disagreement among expert hematopathologists and 
hematologists about the CLL diagnostic criteria and in some instances the disagreement 
has likely led to the under-diagnosis of CLL. In addition, approximately 25% of CLL 
cases are identified in individuals with no specific symptoms attributable to CLL, but 
who are seeking treatment for other diseases. 
 
Compared with other leukemia subtypes, CLL demonstrates the greatest amount of 
familial aggregation, but occurrence of multiple cases of CLL or other 
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lymphoproliferative malignancies in close family members only occur in a small percent 
of CLL cases.  
 
CLL has not been found to be increased in populations with exposure to low- or high-
LET forms of ionizing radiation, but the critical studies have been conducted in 
populations with low incidence of CLL (e.g., Japanese atomic bomb survivors or other 
Asians) or in populations that are too small to provide stable estimates of increased or 
decreased risk.  
 
Little evidence has supported a relationship between CLL and benzene exposure. A few 
studies have described excesses of lymphocytic leukemia or CLL among petroleum 
industry workers (see Appendix B, Part V., CLL and Solvent Exposure), but no excess 
was found in other studies or in a leukemia subtype-specific analysis of 208,000 workers 
with potential exposure to benzene (Wong and Raabe 1995). Excess risks of lymphocytic 
leukemia were observed in large cohorts of rubber manufacturing workers in the United 
Kingdom in reports published in the mid-1970s and early 1980s. These were followed by 
more detailed investigations that linked solvent exposures with increased risks of 
lymphocytic leukemia based on small numbers of cases. More recent studies in rubber 
workers in the United Kingdom showed no excess CLL or lymphocytic leukemia, but an 
IARC committee reported a small increase in a detailed review of 12 cohort studies in 
1998 (Kogevinas et al. 1998). Findings of excess lymphatic leukemia and lymphoma in 
three small Swedish cohorts were replicated in some, but not most subsequent studies. 
Early studies reporting excesses of leukemia and lymphoma in small cohorts were 
followed by inconsistent results for workers exposed to monomeric styrene and 
butadiene. A retrospective study of 40,683 European workers employed in the reinforced 
plastics industry revealed no excesses overall nor evidence of increasing risk with longer 
duration of exposure, but mortality from leukemia and lymphoma rose twofold 20 years 
after first exposure (Kogevinas et al. 1993). 
 
Some studies have implicated farming and related exposures with elevated risks for CLL. 
Specific agricultural exposures linked with excess risk of CLL, generally in small studies 
or via self- or proxy-report within interviews include DDT, animal breeding, and 
employment in flour mills. 
 
Among the difficulties in many epidemiologic studies of CLL is the difficulty of 
determining whether or not CLL is increased in mortality studies because death 
certificates often lack specificity of subtype in listing leukemia as an underlying cause of 
death. Hence, mortality studies could fail to identify excess risks for CLL, even if there is 
a causal association. There are similar problems with meta-analysis, including the rarity 
of CLL and changes over time or differences across populations in the classifications 
used for leukemias and lymphomas. An additional problem is the difficulty of combining 
cohort occupational studies focusing on incidence of CLL if a substantial proportion of 
CLL cases are identified from death certificates with incomplete specification of subtypes 
of leukemia or lymphoma rather than when the workers are still alive.  
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G. Howe: 
The problem of diagnostic uncertainty among CLL cases was encountered while 
conducting a study of 100,000 Chernobyl clean-up workers in Ukraine (Dyagil et al. 
2002; Gluzman et al. 2005). The study used an internal panel with much diagnostic 
disagreement on whether cases were NHL or CLL.   
 
G. Marti: 
There have been recommendations made to conduct a study of B-cell monoclonal 
lymphocytosis in CLL, but there is much uncertainty in its feasibility. Flow cytometry 
has been used with very small numbers of cases. A colleague, Robert Vogt of the Centers 
for Disease Control and Prevention (CDC), became interested in reported excesses of 
CLLs at Superfund sites, as they were beginning to see CD5+ B-cells in nearby residents. 
However, only 11 cases were observed, of whom 10 were from Superfund sites. They 
calculated an incidence of 0.7% among the exposed residents, which was much higher 
than expected.  
 
M. Linet: 
Accurate case attainment from death certificates and other sources has been a problem 
because of incomplete specification of leukemias according to subtype, or differences 
among expert hematopathologists from different countries. North American expert 
hematopathologists tend to consider CLL as an entity distinct from the NHL, while 
European expert hematopathologists generally used classifications that combined CLL 
and well-differentiated forms of NHL.  
 
To correct problems of under ascertainment of CLL even in studies focusing on cancer 
incidence, it would have been necessary to review medical records for cohort members 
diagnosed with NHL, even in North American studies, to identify CLL cases designated 
as well-differentiated NHL cases.  
 
G. Howe: 
CLL research may use occupational cohorts, which may be the most feasible, but they 
lack power due to low numbers of cases. A large number of studies lack power. For 
example, the multi-national study of nuclear radiation workers (Cardis et al. 1995) is the 
largest CLL study. There were a total of 27 CLL cases; 1 CLL case was reported in the 
>100 millisievert (mSv) category. An occupational cohort of >400,000 may be required 
to yield a significant result for CLL.  
 
M. Linet: 
According to the annotated bibliography prepared by NIOSH-HERB (see Appendix B), 
most radiation epidemiologic studies have excluded CLL or not even reported risks for 
CLL in epidemiologic studies because many investigators assumed that “CLL is not 
radiogenic.” 
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D. Hoel: 
Prevalence in medical radiological technologists has also suggested that CLL is non-
radiogenic. 
 
L. Pepper: 
This common assumption affects published literature and potentially creates a publication 
bias; i.e., if they do conduct dose-response analysis for CLL, it is not reported.  
Researchers need to develop an appropriate statistical model for radiation-induced CLL. 
 
G. Howe: 
In large occupational studies, it is difficult to indicate the role of low dose rates of 
radiation exposure. Researchers cannot afford to dismiss high-dose studies and should 
include high-dose and low-dose cohorts in the study populations for CLL research. Such 
populations include Chernobyl, A-bomb, DOE workers, radiotherapy patients, ankylosing 
spondylitis patients, and Mayak workers. Researchers could conduct dosage studies to get 
more thorough results on dose rate effects.  
 
In general, for leukemia, dose rate has not been much of a factor. Is dose rate 
multiplicative or additive, and is this relation independent of the different radiation 
energy levels?  
 
D. Hoel: 
Researchers need radiobiological evidence to determine the effect of α-emitters on bone 
and stem cells.  
 
G. Howe: 
Bone seekers like plutonium deposit on the surface of bones, but the effects of radiation 
are unknown. What is the fate of the bone marrow?  Is the dose reaching the bone 
marrow?  
 
A meta-analysis could be useful, especially if a sufficient number of cases and study 
results are available. However, a meta-analysis does not prove association and may not 
be a useful tool to make inferences. For CLL research, a meta-analysis is not the most 
practical methodology due to the rarity of the disease and inadequate identification of 
true CLL cases. Instead of conducting a meta-analysis, re-analyzing the data is suggested, 
i.e., doing a pooled analysis. This would require researchers to obtain original data sets 
from previous studies and reanalyze the individual data sets. (Researchers usually need to 
look at whether among-cohort heterogeneity exists to explain results.) A pooled analysis 
would require greater amounts of detailed epidemiologic data, cooperation from outside 
researchers, and additional money and time. One such example is a pooled analysis for 
the miners/radon study (Darby et al. 1995).  This type of study would lead to a more 
precise risk estimate and greater statistical power. 
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David Richardson (public comment): 
Most of the discussion has been driven by epidemiology. Limitations of the available 
epidemiologic research include statistical power. Is meta-analysis possible given the large 
number of studies with a very small number of cases?  Many studies have no cases. 
Therefore, how can we talk about dose-response? Findings from low-dose studies are an 
example: we should look at the total number of cases and their distribution by dose 
category. For example, in the IARC 1995 study only one case was observed with a dose 
> 100 mSv (Cardis et al. 1995).  
 
In CLL research, the use of an inappropriate lag period could lead to exposure 
misclassification. Many studies use a 0–2 year lag assumption. This lag period is more 
appropriate for acute forms of leukemia, not chronic forms. CLL is a slow-progressing 
disease with a protracted latent period. For CLL research, it is necessary to increase lag 
assumptions to avoid exposure misclassification. Question: What are the effects of age-
at-exposure and time since exposure?  
 
Richard Miller (public comment): 
After submitting a claim for CLL, workers are receiving a letter explaining that there is a 
0% probability that CLL is attributed to work-related exposures. The Radiation Exposure 
Compensation Act (RECA) and Energy Employees Occupational Illness Compensation 
Program Act (EEOICPA) specifically exclude CLL. Is it appropriate to exclude CLL 
from compensation? This exclusion of CLL raises very direct, meaningful policy 
implications on the radiogenicity of CLL. Question: How long will it take to complete 
CLL research? Is it possible to come up with an interim excess relative risk per sievert 
(ERR/Sv) coefficient that could be used for worker compensation? How long will it take 
before CLL claims will be considered eligible for compensation? Congressional mandate 
is in the beginning phase of requiring the inclusion of CLL in worker compensation.  
B. Molecular Studies 
G. Caldwell: 
We must understand relationships with CLL subsets and multiple myeloma and NHL. 
Molecular studies are very important, but not a major function of NIOSH. 
 
D. Hoel: 
More molecular etiologic work is needed. 
 
G. Howe: 
Studying CLL on molecular/etiologic levels is important, but there are some doubts as to 
how fruitful molecular research is for CLL. Questions: The molecular approach may be 
informative but what questions can it answer? Is it biologically plausible that there is an 
association with radiation exposures? How can the pre-clinical markers be used to 
evaluate association between dose and disease? What is the biological plausibility of 
radiation as the cause for the deletions that are observed? What kind of molecular or 
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cellular markers exist? How strong is the link between genetic susceptibility and the 
development of CLL?   
 
Keeping biological specimens/samples in exposed populations is important. Most useful 
would be a marker of genetic susceptibility present in a reasonable proportion of the 
population. Examples: Ataxia-telangiectasia heterozygotes constitute 1% of population. 
Are they more susceptible? Caution should be observed when considering the ultimate 
utility of molecular approaches.  
 
G. Marti: 
Molecular research could potentially identify a marker for genetic susceptibility and 
approximate its proportion in the population. CLL molecular research could also assist in 
defining the relations between CLL subsets, MM and NHL using 4–6 color flow 
cytometry. Molecular detection for the 13q14 deletion would also be useful. 
 
L. Pepper: 
In response to R. Miller’s comments on policy implications, these studies will have a 
long path to completion. What can be done in the interim? It would be most useful to 
identify a marker for genetic susceptibility for CLL that is present in a percentage of the 
population, especially because elevated prevalence of biological markers has been 
identified in populations living near hazardous waste. If a marker for genetic 
susceptibility is identified, researchers could explore the gene-environment relation in 
CLL.  
 
There is some interest in looking at individual gene loci. This has been proven very 
helpful in understanding beryllium sensitization.  
 
M. Linet: 
There is a problem of substantial under-diagnosis of CLL: about 25% of CLL cases are 
identified during routine examinations.  
 
An international consortium of investigators is looking at risk factors in “loaded” families 
(i.e., with a high prevalence of CLL). 
 
NCI is studying leukemia incidence and mortality in a cohort of U.S. radiologic 
technologists. Leukemia incidence and mortality are also being studied in Chinese and 
Japanese cohorts of radiologic technologists. The British radiologist studies have 100 
years of follow-up. From early in the 20th century through the 1940s, there were mortality 
studies of U.S. radiologists, but follow-up stopped a few decades ago. Can epidemiologic 
investigations of U.S. radiologists be resuscitated? 
 
G. Marti: 
Diagnosis is usually a trivial matter: a count of > 5000 lymphocytes per microliter that 
persists for >30 days. Historically, diagnosis has required a bone marrow aspirate, but 
flow cytometry has replaced this. In patients who present with CLL, the physician can 
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always track back the complete blood count to extrapolate back a number of years (one 
patient was found whose lymphocyte doubling began at age 4). Earliest known reported 
case of CLL was in a 12-year-old child. It is suggested that investigations of patients 
whose disease incidence went back a number of years be performed. What kinds of 
molecular or cellular markers exist?   
 
Flow cytometry and cluster analysis of a small number of cells has significant power. 
Researchers can now do single-cell polymerase chain reaction and count the number of 
identically sequenced B-cells. “Presence of light chain restriction,” e.g., BCML aka MBL 
(monoclonal B-cell lymphocytosis) may be important. A need exists to identify a cohort 
of people who could be studied. In the Rawstron cohort (Rawstron et al. 2003), 
approximately 1 out of 3 BCML cases progressed to CLL; 2 out of 3 BCML cases 
stabilized or decreased. In the Superfund population, 12 BCML positives were found. 
Nine out of 12 need additional follow-up, 5 are dead of CLL, 4 are alive, and 1 BCML 
status decreased after retirement.  
 
Will there be a genetic marker?  A possible marker is 13q14 deletion, which is found in 
55% of CLL patients. This would help identify molecular and cellular markers that 
potentially exist. 
 
Unknown Name (public comment): 
Target organs, other than bone marrow (thymus gland, lymphatic system, circulating 
lymphocytes), should be considered for study.  
  
D. Richardson (public comment): 
What is the biologic plausibility of radiation as cause of the deletions that are observed? 
 
Brant Ulsh (public comment): 
Molecular approach is great way to go, but what kinds of questions can it answer?  
“Is it plausible that there’s an association?” This may not be sufficient for risk modeling. 
 
How can these pre-clinical markers be used to evaluate the association between dose and 
disease? Some of these markers are very stable. What is the correlation between BCML 
(MBL) and CLL? 
 
G. Marti: 
An investigator in Leeds, England (Rawstron) has a cohort with two of three individuals 
having stable or decreased MBL cells. The other one of three did progress to disease. A 
blood donor population would be good potential cohort.  
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C. Animal Studies 
G. Caldwell: 
Animal models may not be the most useful tools for CLL epidemiological studies. CLL is 
not observed often in large animals. There is not a readily apparent counterpart to CLL in 
animals.  
 
D. Hoel: 
Hematopoietic cancers in animals do not relate directly to CLL. Vogel and others were 
working with Argonne National Laboratory data looking at neutron and gamma exposure 
in Sprague-Dawley rats (Vogel and Jordan 1960). Also, others were looking at beta and 
alpha exposures in the lung to evaluate relative biological effectiveness (Lafuma et al. 
1989). Still, this doesn’t relate to leukemia. A review of the National Council on 
Radiation Protection (NCRP) report on similarities between men and animals is 
suggested. There is also a large leukemia project at the University of Colorado, and one 
being done at UC Berkeley. Obtaining information from a number of radiobiologists may 
prove useful in understanding the relevance of animal studies in CLL research. 
  
G. Marti: 
No animal studies show evidence of radiation causing hematopoietic disease; 
hematopoietic cancers in animals do not directly relate to CLL. German Shepherd dogs 
do show high background levels of CLL. Mice are an excellent model for effects of aging 
on producing a lymphoma. The New Zealand mouse is a good model of CLL (it is a 
model of lymphoma rather than CLL). There may be possibilities of studying cell lines 
from CLL. These are quite rare, but might be useful.  
 
G. Howe: 
Animal models are not extremely helpful here. Hematology needs to be comparable, but 
we are very far from being able to do this. Can animal studies be used to elucidate 
mechanisms? These are not of much short-term use.  
 
Richard Miller (public comment): 
A more diverse group of panelists would encompass different views. 
III.  Additional Written Comments Received Following the July 21, 2004 Meeting 
G. Marti: 
(1)  Re-analysis (pooled analysis) or meta-analysis remain good ideas. (2) Careful review of 
CLL patient medical records and their radiation exposure is needed. Researchers need to 
evaluate the number of potential records available and consider other factors such as sex, age 
of onset, family history, and other exposures. Complete blood count (CBC) metrics [white 
blood cell count (WBC), hemoglobin (Hgb), hematocrit (Hct), red blood cell count (RBC), 
absolute lymphocyte count (ALC), and platelets] that were collected prior to diagnosis could 
be plotted as a function of time in order to identify the first indications of CLL. The diagnosis 
could be questioned and any cytotometry or cytogenetic information on the patient evaluated. 
(3) As pointed out earlier, the best surrogate tumor marker is the flow cytometric multicolor 
detection of MBL, which is the cellular analogue of a monoclonal gammopathy of unknown 
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significance (MGUS). Researchers need to know the prevalence of this finding in the 
radiation exposed group. I would envision the following groups: blood donors over the age of 
forty years as controls; other occupational exposures; and radiation exposed group. Of course 
first degree relatives of wild type and familial CLL are examples of extreme positive 
controls. Ideally one would like to define a cohort of radiation exposed individuals to follow. 
 
D. Richardson: 
Numerous radiation epidemiologic studies include limited numbers of CLL cases so they 
may be unsuitable for meta-analysis or for pooled studies. Even fewer cases would have 
exposure records that confirm exposures to 5 rem or greater. Lags of one or two decades 
need to be analyzed due to the natural history of CLL. One panelist stated the logical fallacy 
of drawing conclusions about the radiogenicity of CLL from multiple low power 
epidemiologic studies. Dr. Howe made persuasive arguments for pooled analysis over meta-
analysis so that multiple temporal factors could be tested. A two stage approach is 
recommended. First, determine if radiation exposure influences CLL incidence. Second, 
estimate the magnitude of the association. The first line of investigation could include 
molecular studies as well as epidemiology.  
 
G. Caldwell: 
The following suggestions are offered as potential improvements to CLL research: 
 
• Expand the investigation of CLL within the radiation occupational cohorts and 
include other exposures in the analysis such as chemicals and non-ionizing radiation. 
 
• Incidence studies would be more informative as could be studies of medical personnel 
who administer radiation therapies.  
 
• Synergistic interactions could be evaluated. Studies could be conducted among 
workers exposed to chemicals such as benzene, toluene, xylene, carbon disulfide, 
carbon tetrachloride, trichloroethylene, perchloroethylene, plasticizers, individual 
pesticides and individual herbicides. Such studies could be conducted among farmers, 
furniture manufacturers, and petroleum workers. Multiple chemical exposures in 
these populations could be considered.  Evaluate CLL risks associated with 
radiomimetic drugs and other cancer chemotherapy agents.  
 
• Evaluate genetic and immunological influences on CLL incidence by following 
families with multiple cases and include those with NHL. Attempt to merge genetic 
and molecular studies with epidemiology, particularly B-cell abnormalities.  
 
• Develop additional studies on CLL and immunological factors. Merge flow 
cytometry with epidemiologic analysis, refine the definition of CLL, refine the 
diagnostic criteria for CLL, and evaluate the links among CLL, NHL and MM. 
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• Complete the update of existing cohorts to examine the radiogenicity of CLL and 
conduct meta-analysis where feasible. Lower priority options are to conduct 
incidence studies as well as relationships between cosmic radiation and secondary 
cancers among CLL patients.  
 
G. Caldwell: 
The National Cancer Institute’s Surveillance, Epidemiology, and End Results Program have 
collected incidence data as well as exposure data since the early 1970’s. NIOSH should 
determine the feasibility of using that large database to further its CLL research.  NIOSH 
should investigate the applicability of the radiation exposure data and other occupational 
exposure data that may be available in the database.  These data may be matched to the 
current case entries in the occupational studies already underway and supported by NIOSH. 
 
NIOSH should consider a combined study of all “lymphocytic” malignancies.  Such a study 
would counter problems stemming from misdiagnosis and promote the collection of a larger 
pool of cases.  There is some uncertainty in whether a study of both molecular biology and 
epidemiology falls under NIOSH’s mandate. 
IV. Action Items and Update 
Based upon the discussions at the July 2004 meeting, NIOSH took actions toward some 
epidemiologic studies or analyses that could be informative. 
A. Epidemiologic Studies 
Despite the limitations of epidemiologic research in this area, panel members had several 
suggestions for future studies or analyses. Below are some activities undertaken by 
NIOSH that can address the radiogenicity of CLL.  
i. Meta-Analysis  
It was suggested that a meta-analysis or a pooled analysis of previously published 
CLL studies might be useful in evaluating the radiogenicity of CLL. Since the July 
21, 2004 meeting, NIOSH researchers have investigated the feasibility of conducting 
a meta-analysis and found that it was not feasible.  This decision is based on the 
following observations: 
  
o There is a large amount of heterogeneity in exposures among the studies: 
occupational exposure (chronic low dose), medical exposure (acute dose), A-
bomb (acute high dose), and internal versus external radiation. 
o Much heterogeneity exists in the radiation-exposed populations available for 
study:  occupational cohorts (healthy worker effect), medical cohorts (possible 
increased susceptibility, failure to control for chemotherapy, short follow-up due 
to short survival), A- bomb (low background incidence of CLL). 
o The lack of reporting on CLL explicitly (many studies exclude CLL a priori, or 
report on leukemia and leukemia-CLL) left few non-overlapping study 
populations; this, coupled with differences among reporting measures did not 
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allow for synthesis of results (ERR, SMR, RR, categorical observed/expected 
ratio with trend test). 
o Requests for data sets from other medical studies were largely unsuccessful. 
 
Instead, a systematic review on the radiogenicity of CLL is currently underway. The 
review will focus on the available epidemiologic literature regarding the radiogenicity 
of CLL, derived from studies of medically exposed cohorts, as well as occupationally 
exposed populations. Results from the systematic review are anticipated to be 
published in a peer-reviewed journal in early 2006. 
ii. Pooled Analysis 
The IARC study, a 15-country, 400,000-person study of mortality among nuclear 
workers, has been underway for several years. The overall study findings were 
reported in June 2005 (http://www.cdc.gov/niosh/pdfs/IARCabstract2.pdf). The June 
2005 publication did not provide specifics on CLL but NIOSH has commissioned the 
IARC researchers to conduct such a pooled analysis including dose-response analysis 
on the individual and combined U.S. cohorts from Hanford, Idaho National 
Engineering and Environmental Laboratory, and Oak Ridge National Laboratory. 
Consistent with the research gaps identified in the public meeting, various lags up to 
20 years are being used. Uncertainties in the dose estimates will also be included in 
the full statistical model. We expect the publication to be completed and released in 
early 2006.  
iii. CLL Research Studies 
o INEEL Study 
This study includes 63,561 workers, and over 10,000 deaths. Of the 73 underlying 
and non-underlying leukemia deaths among radiation-monitored workers, 21 were 
due to CLL. This study was completed in 2005 
(http://www.cdc.gov/niosh/docs/2005-131/pdfs/2005-131.pdf). No association 
was found between external radiation and CLL risk when all underlying and non-
underlying causes of death were considered. 
 
o Portsmouth Naval Shipyard Study 
This leukemia case-control study of the Portsmouth Naval Shipyard workers, 
conducted by NIOSH, included 115 leukemia cases, of which 14 were CLLs. 
Only 3 of the CLL cases received radiation exposure; their collective dose was 
only 50 mSv. Analysis of leukemia and leukemia excluding CLL showed no 
change is the odds ratio per 10 Sv upon exclusion of the CLL cases 
(http://www.cdc.gov/niosh/docs/2005-104/pdfs/2005-104.pdf). 
 
o Multisite Leukemia Case-Control Study  
This NIOSH case-control study has gathered leukemia cases from six cohorts 
comprised of approximately 95,000 workers. Five of these cohorts are from the 
Department of Energy (DOE) complex and one from a naval shipyard. A total of 
257 leukemia cases have been identified, which includes 43 known CLL cases. 
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NIOSH has accelerated efforts pertaining to CLL analyses to expedite 
communication of CLL results. The study is nearing completion and the results 
are anticipated in early 2006.  
iv. Other Studies 
o NIOSH will continue to evaluate the relationship between ionizing radiation 
exposures and CLL in radiation-exposed cohorts that are studied in the future. 
 
o Based on funding and current work projections, the epidemiologic data system for 
radiation-exposed cohorts at NIOSH is anticipated to be fully functional and 
populated in about 2 years. This system provides a centralized data bank of 
epidemiologic data pertaining to occupational cohorts studied by NIOSH and 
others.  The system will increase the efficiency of examining causes of death such 
as CLL across the DOE cohorts.  
B. Molecular Studies 
The cellular and molecular changes associated with the onset of CLL are being 
intensively investigated by research organizations around the world. Recent discoveries 
indicate that even B-cell CLL is likely not a single disease. For example, multiple B-cell 
genetic markers help differentiate familial and aggressive subtypes of the disease in 
tissues collected from CLL patients. Strategies for the analysis of the relationship 
between ionizing radiation and the genetic markers associated with CLL could follow 
several lines of investigation. The relationships among CLL subsets, MM, and NHL will 
be better understood when the underlying genetics and cellular markers for these diseases 
have been identified. Molecular research could also identify possible sources of genetic 
susceptibility for CLL and estimate its prevalence in populations. The specific locations 
on the gene where ionizing radiation may alter the structure and change genetic 
expression might also be identified. Stored tissue samples from CLL patients could be 
used to follow the time course of mutations and cellular expressions. 
 
Although the line of inquiry could ultimately be informative, the course of the research 
would likely require many years to develop, as several experts commented. On the other 
hand, the epidemiologic studies such as the NIOSH multi-site study and the IARC multi-
national study were very close to completion and thus received the earmarked resources 
needed for completion. NIOSH will continue its focus on epidemiologic research but will 
also examine ways to promote the continuation of molecular studies. 
C. Animal Studies 
None of the panel members considered current animal models to be a promising approach 
for elucidating the relationship between radiation and CLL. However, it is recognized 
that the panel expertise was not primarily in animal research. 
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V. Summary of NIOSH Focus 
The CLL public meeting was very useful in assisting NIOSH to identify avenues of research 
to examine CLL radiogenicity. NIOSH will continue its focus on completion of 
epidemiologic projects to assess CLL radiogenicity. In concordance with the panel, NIOSH 
will pursue pooled analyses, with examination of alternate lag assumptions, in both the 
IARC-commissioned CLL analyses and the multi-site leukemia case-control study. The 
findings of these research activities should be available soon and will provide more 
information on the radiogenicity of CLL.  
VI. Appendices 
A. Overview of Chronic Lymphocytic Leukemia (Microsoft® Office PowerPoint® 
presentation) 
B. Annotated bibliography 
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Appendix A 
Overview of Chronic Lymphocytic Leukemia 
(Microsoft® Office PowerPoint® presentation) 
Overview of Chronic 
Lymphocytic Leukemia
Current knowledge and NIOSH research activities
National Institute for Occupational Safety and Health
Division of Surveillance, Hazard Evaluations, and Field Studies
Health-Related Energy Research Branch
October 2005
TM
Chronic lymphocytic leukemia*
Diagnosis:
– Automated instrumentation & diagnostic algorithm  
greatly increased pre-clinical diagnosis of CLL
– Now routinely diagnosed as elevated lymphocyte count 
in CBC
Prognosis:
– “Watchful waiting” given way to increased 
treatment as infectious & autoimmune 
complications recognized
– Current estimates: 50% of early-stage CLL will 
progress to advanced stage & death
*Shanafelt et al. Mayo Clin Proc 2004; 79:388-398
Leukemia subtypes (ICD-9)
Lymphoid
– Acute lymphocytic (204.0); excludes acute 
exacerbation of chronic)
– Chronic lymphocytic (204.1)
– Subacute lymphocytic (204.2)
– Other (204.9) 
Myeloid [aka myelogenous, granulocytic] (205)
Monocytic (206)
Other specified (207)
Unspecified (208)
CLL subtypes
B-lymphocyte CLL (approximately 95%)
– Characterized by accumulation of B-cells 
through impeded apoptosis
– Identified by expression of CD-5 cell surface 
receptor
– p53 suppression also has been indicated; 
– susceptibility may have an inherited 
component
T-lymphocyte CLL (5%)
Incidence & prevalence of CLL 
(SEER 2003)
Prevalence:
– In 2001, 58,574 cases in US (0-11 years post-diagnosis), 
compared to 33,017 for myeloid & monocytic
– More common among whites, males
Incidence:
– No clear secular trends 
– Adult lifetime probability of developing any leukemia (WM 
age 20-95+) is 1.51%. By subtype:
CLL = 0.56%, ALL = 0.06%
CML= 0.20%, AML = 0.46%
– Especially low among Asian- and Native-Americans
– Increases greatly with age
Crude CLL incidence rates 
1992-2001 (SEER 2003)
Etiology of CLL: 
epidemiologic evidence
Ionizing radiation:
– No medically-exposed, occupationally-
exposed or environmentally-exposed 
populations have shown significantly 
increased risks of CLL
Other exposures:
– Some evidence of linkage to risk factors for 
non-Hodgkin’s lymphoma; e.g., Agent Orange 
defoliant (IOM 2003, pp. 372-375)
Limitations of existing evidence
Comparability of studied populations 
(e.g., Japanese A-bomb survivors) to 
U.S. workers
Comparability of exposures (acute 
external low-LET) to U.S. workers
Studies with primarily internal, high-LET 
exposure are inconclusive
Limitations inherent in death certificate-
based studies of CLL
Current NIOSH studies
Multi-site Leukemia Case-Control Study (late 2005)
– ~260 cases, >40 CLLs
– Underlying cause of death only
– Bone marrow doses for γ, x-ray, neutron & Pu
– Adjustment for benzene & carbon tetrachloride
Cohort mortality studies
– Contract with IARC to estimate γ risk for CLL, including 
non-underlying causes (Nov. 2004)
– INEEL cohort mortality study (21 cases; Sept 2004)
Current NIOSH studies, cont.
Meta-analysis of existing radiation-
exposed studies
– Using published and unpublished data 
(depending on co-operation of other 
researchers)
– Will conduct analysis separately for externally 
and internally-exposed populations
Possible future NIOSH studies
Possible extramural research 
If merited, additional epidemiologic 
analysis of occupational or radiotherapy 
cohorts
Inclusion of non-underlying cause of death
or incidence studies
DOE-wide exposure-based cohort studies
– Internal exposures (e.g., Pu, U)
– Neutron exposures 
Other research needed
Additional occupationally-exposed cohorts?
Basic radiobiological research on CLL?
Biomarkers (or other pre-clinical disease 
markers) for CLL?
Other non-radiological etiologic studies?
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Appendix B 
Chronic Lymphocytic Leukemia  
Annotated Bibliography 
July 21, 2004 
 
Preface 
This annotated bibliography was compiled from the available scientific literature and presented 
at the Public Meeting to Seek Input on Gaps in Chronic Lymphocytic Leukemia (CLL) 
Radiogenicity Research held in Washington, DC on July 21, 2004. It is intended to inform 
interested parties on the types and breadth of research that has been conducted on the 
radiogenicity of CLL and some related issues. This bibliography should not be considered a 
complete review of all scientific research on these topics. Statements in this document should not 
be interpreted as official policy from the National Institute for Occupational Safety and Health 
and the Centers for Disease Control and Prevention. 
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Acronyms and Abbreviations 
 
ABCC Atomic Bomb Casualty Commission 
ALL acute lymphocytic leukemia 
AML acute myelogenous leukemia 
AMPS acute myeloproliferative syndrome  
ANL/ANNL acute non-lymphocytic leukemia 
AT ataxia telangiectasia 
ATB at the time of the (atomic) bomb 
ATL adult T-cell leukemia 
ATM  ataxia telangiectasia mutated 
BCML B-cell monoclonal lymphocytosis  
BCLL B-cell chronic lymphocytic leukemia  
BGD benign gynecological disorders 
BNHL B-cell non-Hodgkin’s lymphoma 
BPLL B-cell prolymphocytic leukemia 
cCLLa common chronic lymphocytic leukemia antigen 
CGL chronic granulocytic leukemia 
cGy centigray 
CLL chronic lymphocytic leukemia 
CML chronic myelogenous leukemia 
DOE Department of Energy 
DS1986 dose system 1986 
EAR excess absolute risk  
EBV Epstein-Barr virus 
EMF electro-magnetic field 
ERR excess relative risk  
EMC essential mixed cryoglobulinemia 
FAB French-American-British (leukemia classification system) 
Gy gray (unit of radiation dose) 
HARDTACK nuclear test 
HCL hairy cell leukemia 
HCV hepatitis C virus 
HLA  human leukocyte antigens  
HTLV-1 human T-cell lymphotropic virus-1 
HTLV-2  human T-cell lymphotropic virus-2 
IARC International Agency for Research on Cancer 
ICD International Classification of Disease 
IL-4  interleukin-4 
K25 DOE’s Oak Ridge K25 facility 
LET low-energy transfer 
LL lymphocytic leukemia, lymphatic leukemia, lymphoblastic leukemia or 
lymphoid leukemia 
LLNL Lawrence Livermore National Laboratory 
LOH loss of heterozygosity  
LPT lymphocyte phenotype 
LSS Life Span Study 
MGUS monoclonal gammopathy of unknown significance  
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mGy milligray 
MHC  major histocompatibility complex  
MM multiple myeloma 
mSv millisievert 
nCi nanocurie 
NHL non-Hodgkin’s lymphoma 
NIOSH National Institute for Occupational Safety and Health 
NRPP  Nuclear Reactor Propulsion Program 
O/E ratio of observed to expected cases 
ORNL DOE’s Oak Ridge National Laboratory (X-10) 
OR odds ratio 
PCR polymerase chain reaction 
PHA phytohemagglutinin 
PL/PLL prolymphocytic leukemia 
PMR proportionate mortality ratio 
PNS Portsmouth Naval Shipyard 
PPBL persistent polyclonal B-cell lymphocytosis 
ppm parts per million 
PY person years 
PYR person-years per rad 
RA rheumatoid arthritis 
RB  retinoblastoma 
RBE relative biological effect 
RES reticulo-endothelial system  
RR relative risk  
RT radiation treatment or radiotherapy 
SEER Surveillance, Epidemiology, and End Results program 
SES socio-economic status 
SIR standardized incidence ratio 
SL small lymphocytic lymphoma 
SMOKY nuclear test in 1957 as part of operation PLUMBOB 
SMR standardized mortality ratio 
SRR standardized rate ratio 
Sv sievert  
TBI total body irradiation 
TCLL  T-cell chronic lymphocytic leukemia 
TPLL  T-cell prolymphocytic leukemia 
UK United Kingdom 
UKAEA United Kingdom Atomic Energy Authority  
US United States 
USPHS United States Public Health Service 
µT microtesla 
WLM working-level months 
X-10 DOE’s Oak Ridge X-10 facility 
Y-12 DOE’s Oak Ridge Y-10 facility 
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I. Occupational Radiation Exposure 
a. Ionizing Radiation 
i. Nuclear Industry Workers 
Muirhead CR, Goodill AA, Haylock RGE, et al. [1999]. Occupational 
radiation exposure and mortality: second analysis of the National Registry for 
Radiation Workers. J Radiol Prot 19: 3-26. 
 
This update of the cohort mortality study of the National Registry for Radiation 
Workers included 124,743 workers with follow-up through 1992. The unlagged 
standard mortality ratios (SMRs) for leukemia, leukemia excluding chronic 
lymphocytic leukemia (CLL), and non-Hodgkin’s lymphoma (NHL) were 0.91 
(95% CI=0.75-1.10), 0.94 (95% CI=0.75-1.15), and 1.00 (95% CI=0.81-1.21), 
respectively. Two year lags were employed for leukemia; the SMR for leukemia 
was 0.95 (95% CI=0.78-1.15) and the SMR for leukemia excluding CLL was 0.98 
(95% CI=0.79-1.20). The SMR for NHL using a 10 year lag was 1.05 (95% 
CI=0.83-1.30). Internal analysis by dose level revealed borderline significant 
results for leukemia and leukemia excluding CLL, with p values of 0.18 and 0.061, 
respectively. There was no evidence of a positive trend for NHL (10 year lag). 
Estimated excess relative risks (ERR) per sievert (Sv) for leukemia, leukemia 
excluding CLL, and NHL were 1.20 (90% CI=-0.68-4.61), 2.55 (90% CI=-0.03-
7.16), and 0.03 (90% CI=-1.33-3.06), respectively.  
 
Dupree Ellis E, Watkins JP, Ingle JN, Phillips JA [1998]. External radiation 
exposure and mortality among a cohort of uranium processing workers: Final 
Report. Oak Ridge Associated Universities, Oak Ridge, TN. Unpublished. 26 pgs. 
 
The mortality experience through 1993 of uranium processing workers employed 
at Mallinckrodt Chemical Works between 1942 and 1966 was evaluated in this 
study. Among this cohort of 2,514 workers, 13 cases of leukemia occurred, one of 
which was a CLL. This case of CLL was categorized in the 20-40 millisievert 
(mSv) cumulative external exposure group. Dose response analysis was 
performed, where the observed to expect (O/E) ratio was calculated for the 
following exposure categories, in mSv: 0-5, 5-10, 10-20, 20-40, 40-80, 80-160, 
and 160+. For leukemia, the ratios for the aforementioned categories were as 
follows: 3/4.05, 3/1.34, 1/2.79, 2/1.55, 0/0.71, 3/0.81, 0/0.75. For leukemia 
excluding CLL, the ratios were: 3/3.81, 3/1.25, 1/1.60, 1/1.39, 0/1.58, 3/0.70, 
0/0.67. There was no evidence of a dose-response relation as the p values for the 
trend test were 0.74 and 0.79 for leukemia and leukemia excluding CLL, 
respectively.  
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Frome EL, Cragle DL, Watkins JP, et al [1997]. A mortality study of 
employees of the nuclear industry in Oak Ridge, Tennessee. Radiat Res 148: 
64-80. 
  
SMR analysis of this cohort of 106,020 Oak Ridge workers employed at least 30 
days between 1943 and 1985 demonstrated a deficit of leukemia deaths compared 
to the United States (US) population, with the exception of non-white males, 
where the SMR was 1.11. No association was seen between leukemia deaths and 
radiation dose using a 2 year lag. No CLL specific results were presented. It was 
found that the leukemia mortality differed by Oak Ridge facility, “except for those 
born after 1930, leukemia mortality rates at X-10 were higher than those for US 
white males and higher than those for similar Y-12 and multiple-facility workers.”  
 
Fry SA, Dupree EA, Sipe DL, et al. [1996]. A study of the mortality and 
morbidity among persons occupationally exposed to ≥ 50 mSv in a year: 
Phase 1, mortality through 1984. Appl Occup Environ Hyg 11:334-343, 1996. 
 
A mortality analysis was conducted of white male workers, who were ever 
employed between 1943 and 1978 at Department of Energy (DOE) or US Navy’s 
Nuclear Reactor Propulsion Program (NRPP) facilities, and who had at least one 
annual dose that exceeded 50 mSv. The SMR for leukemia, using the general US 
population as the comparison group, was below expectation, at 0.47 (95% 
CI=0.05-1.68). The categories including NHL demonstrated non-significant 
elevations; the SMR for lymphosarcoma was 2.26 (95% CI=0.72-5.27) and the 
SMR for other lymphatic cancers was 1.46 (95% CI=0.47-3.42). 
  
Cardis E, Gilbert ES, Carpenter L, et al [1995]. Effects of low doses and low 
dose rates of external ionizing radiation: cancer mortality among nuclear 
industry workers in three countries. Radiat Res 142:117-132. 
 
The International Agency for Research on Cancer (IARC) performed a 
multinational study of nuclear radiation workers, combining cohorts from the US, 
United Kingdom (UK) and Canada. The combined cohort included 95,673 workers 
contributing 2,124,526 person years at risk; the purpose of such a large study 
population was to increase power to detect differences in mortality and to increase 
the precision of risk estimates. There were 15,825 total deaths (16.5 % of the 
cohort), including 147 leukemia deaths, where 27 were from CLL. O/E deaths of 
CLL per dose category are as follows: 0-10 mSv: 12/13.7, 10-20 mSv: 4/4.0, 20-
50 mSv: 6/4.4, 50-100 mSv: 4/2.2, 100-200 mSv: 1/1.5, 200-400 mSv: 0/0.9, 400+ 
mSv: 0/0.3, showing a non-significant negative trend of -0.74 (p=0.771). Using 
Poisson regression and controlling for age, sex, socio-economic status (SES), 
calendar time, and facility, the relative risk (RR) per Sv took the form 1+βz, where 
z is the cumulative dose in Sv. A 2 year lag was employed for leukemia. For CLL, 
the ERR per Sv was estimated to be -0.95 (90% CI <0, 9.4). The RR of CLL 
comparing 100 mSv to 0 mSv was 0.91, indicating no increased risk of CLL as a 
result of radiation dose. Leukemia excluding CLL was significantly associated 
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with cumulative radiation, presenting a trend of 1.85 (p =0.046). Modeling 
demonstrated an RR of 1.22 comparing 100 mSv to 0 mSv. The authors note that 
as most of the workers in this cohort are still young, and only 16.5% have died, 
additional follow-up studies are needed to increase the precision in risk estimates. 
 
Swift M [1995]. Cancer mortality and low doses of ionizing radiation. Lancet 
345:253. 
 
In a comment to the Lancet regarding the IARC study, by Cardis et al. (1994), 
Swift points out that “leukemia is unique among radiogenic cancers in that the 
latency after exposure is typically 1-5 years. Almost all the excess risk of leukemia 
is dissipated within 5-10 years after that exposure. There is no reason to expect a 
cumulative effect on leukemia mortality from non-leukemogenic doses over 
several or many years. None was found.” 
 
Cardis E, Gilbert ES, Carpenter L, et al. [1994]. Direct estimates of cancer 
mortality due to low doses of ionizing radiation: an international study. 
Lancet 344:1039-1043. 
 
A combined analysis of seven cohorts from 3 countries was performed to assess 
leukemia risk resulting from radiation. The ERR per Sv for leukemia excluding 
CLL was 2.2 (90% CI=0.1-5.7). No estimates were given for all leukemia or for 
CLL separately. 
 
Carpenter L, Higgins C, Douglas A, et al [1994]. Combined analysis of 
mortality in three United Kingdom nuclear industry workforces, 1946-1988. 
Radiat Res 138: 224-238. 
 
A combined cohort mortality study was carried out on workers from the United 
Kingdom Atomic Energy Authority (UKAEA), Sellafield, and British Nuclear 
Fuels. Over 75,000 workers (40,761 monitored for radiation) were followed 
through 1988. The SMR analysis for leukemia revealed no excess in leukemia 
deaths in either group of workers, compared to the population of England and 
Wales. The rate ratio comparing monitored workers to non-monitored workers for 
all leukemia was 1.03 (95% CI=0.67-1.59), the point estimate for the rate ratio 
increased with exclusion of CLL cases (RR=1.20, 95% CI=0.73-1.97). According 
to the stratified analysis by dose level, there was evidence of increasing leukemia 
deaths with increasing dose level. This relationship strengthened with the 
exclusion of CLL cases. The ERR per Sv for leukemia excluding CLL, using a 2 
year lag, was estimated to be 4.18 (95% CI=0.4-13.4). The SMR for NHL among 
monitored workers was 1.10, whereas the SMR for NHL for non-monitored 
workers was 0.76. The rate ratio for NHL for monitored workers relative to non-
monitored workers was 1.37 (95% CI=0.81-2.31). 
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Douglas AJ, Omar RZ, Smith PG [1994]. Cancer mortality and morbidity 
among workers at the Sellafield plant of British Nuclear Fuels. Brit J Cancer 
70: 1232-1243. 
 
This cohort study of 14,282 Sellafield workers employed 1947-1975 included 
follow-up through 1988. SMR analyses were performed using the general 
population of England and Wales as the comparison group. The SMRs for 
leukemia for radiation and non-radiation workers were 0.81 and 0.30 (p<0.05), 
respectively. Leukemia and leukemia excluding CLL (there was only 1 observed 
case of CLL) did demonstrate evidence of positive trend which was significant at 
the 1% level, even after a 2 year lag was employed. The ERR estimate, per Sv, for 
leukemia excluding CLL (2 year lag) was 13.92 (90% CI=1.94-70.52). The SMR 
for NHL among the radiation workers was 1.07, whereas the SMR among the non-
radiation workers was 0.44. Stratified analysis by dose level did not reveal 
evidence of increasing NHL mortality with increasing dose.  
 
Fraser P, Carpenter L, Maconochie N, et al. [1993]. Cancer mortality and 
morbidity in employees of the United Kingdom Atomic Energy Authority, 
1946-1986. Brit J Cancer 67:615-624. 
 
This mortality study update included additional follow-up of 34,869 employees of 
the UKAEA cohort. The UKAEA cohort consists of workers from weapons 
facilities in Harwell, London, Culham, Dounreay and Winfrith, in the UK. The 
SMRs, adjusting for age, sex, calendar period, establishment and social class, were 
calculated based on death rates in England and Wales. The SMRs for leukemia 
among radiation workers and non-radiation workers were 1.10 (31 observed 
deaths) and 1.30 (29 observed deaths). The rate ratio comparing radiation workers 
to non-radiation workers with 0 lag was 0.97 (95% CI=0.53-1.78) for leukemia 
and 1.11 (95% CI=0.56-2.20) for leukemia excluding CLL, respectively. With a 2 
year lag, the rate ratios were estimated at 1.09 (95% CI=0.59-2.01) for leukemia 
and 1.28 (95% CI=0.65-2.53) for leukemia excluding CLL. For NHL, the SMRs 
among radiation workers and non-radiation workers were 1.35 (7 observed deaths) 
and 0.75 (11 observed deaths), respectively. The rate ratio for NHL comparing 
radiation workers to non-radiation workers was 1.57 (95% CI=0.71-3.50) for a 0 
lag and 1.74 (95% CI=0.80-3.79) for a 10 year lag. There was no evidence of a 
dose response relationship for radiation with leukemia or NHL. The ERR per Sv 
for leukemia, based on a 2 year lag, was -4.2 (95% CI=-5.7-2.6). 
 
Gilbert ES, Omohundro E, Buchanan JA, Holter NA [1993]. Mortality of 
workers at the Hanford site: 1945-1986. Health Phys 64:577-590. 
 
This update of the Hanford cohort mortality study included 44,154 workers first 
employed at the site from 1944-1978 with follow-up through 1986. O/E estimates 
(expected deaths were calculated based on the experience of all workers in the 
study population, controlling for age, calendar year, gender, number of years 
monitored and SES), by dose category, did not indicate a radiation dose response 
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relationship with CLL. For the dose category 0-<10 mSv: O/E=6/5.6=1.07, 10-<50 
mSv: O/E=1/2.1=0.48, 50-<100 mSv: O/E=2/0.6=3.33, no cases were observed in 
the highest two dose categories of 100-<200 mSv and over 200 mSv. The trend 
test statistic was -0.45 for a 2 year lag. For NHL the O/E ratios for the exposure 
levels defined above were 37/39.1, 17/13.7, 3/2.6, 1/1.8, and 1/1.8. The trend test 
statistic was -0.85 with a 10 year lag. Other analyses were performed to 
specifically examine leukemia risk, excluding CLL (2 year lag, ERR estimate=-
1.1% (90% CI=<0-1.9%, 95% CI=<0-3.0%)). 
 
Gilbert ES, Cragle DL, Wiggs LD [1993]. Updated analysis of combined 
mortality data for workers at the Hanford site, Oak Ridge National 
Laboratory, and Rocky Flats weapons plant. Radiat Res 136: 408-421. 
 
An update of the 1989 cohort mortality study of Hanford, Oak Ridge National 
Laboratory (ORNL), and Rocky Flats workers, this study included additional years 
of follow-up. An internal stratified analysis by dose was conducted for specific 
cancers, adjusting for age, calendar year, sex, years monitored, and SES. For CLL 
the O/E ratios for the dose categories were: 8/9.1 (0-<10 mSv), 5/3.9 (10-<50 
mSv), 2/1.0 (50-<100 mSv), 0/0.5 (100-<200 mSv), 0/0.3 (200-<400 mSv), and 
0/0.1 (400+ mSv); the trend test statistic was negative and non-significant (-0.37). 
The ratios for leukemia excluding CLL, using the aforementioned dose categories, 
were 41/41.0, 20/17.6, 1/3.5, 3/2.5, 1/2.0, and 1/0.5; the test statistic for the trend 
test was non-significant at 0.47. The results for the NHL-specific analysis were as 
follows for the same dose categories: 44/47.4, 22/16.9, 3/3.3, 2/2.3, 1/1.7, and 
0/0.4, with a non-significant test statistic of -0.90. The combined ERR estimate per 
Sv for leukemia excluding CLL was -1.0 (90%CI=<0-2.2). No ERR estimate was 
reported for CLL.  
 
Gribbin MA, Weeks JL, Howe GR [1993]. Cancer mortality (1956-1985) 
among male employees of Atomic Energy of Canada limited with respect to 
occupational exposure to external low-linear-energy-transfer ionizing 
radiation. Radiat Res 133: 375-380. 
 
Workers in the Canadian nuclear industry were studied to assess the relationship 
between external radiation and mortality. Of the 8,977 workers studied, 227 
developed cancer. The SMR for NHL, based on Canadian national rates, was 0.84 
(95% CI=0.34-1.73). The SMRs for leukemia and leukemia excluding CLL were 
0.60 (95% CI=0.22-1.30) and 0.45 (95% CI=0.12-1.16), respectively. SMRs by 
dose category were calculated, as was a corresponding test of trend. The p value 
for the test of trend for all leukemia was 0.11. This analysis was based only 6 total 
cases of leukemia (2 CLL). Excluding the 2 cases of CLL, both of which were 
unexposed to radiation, strengthened the observed positive trend between leukemia 
and increasing dose (p=0.058). Using a linear excess risk model and a 2 year lag, 
the excess relative risk % per 10 mSv for leukemia and leukemia excluding CLL 
were 7 (95% CI=-0.54-47.4) and 19 (95% CI=0.14-113), respectively. 
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Kendall GM, Muirhead CR, MacGibbon BH, et al. [1992]. Mortality and 
occupational exposure to radiation: first analysis of the National Registry for 
Radiation Workers. BMJ 304: 220-225. 
 
The National Registry for Radiation Workers was established in 1976 for British 
workers. This analysis included approximately 95,000 workers with a collective 
dose of 3,200 man Sv, followed through 12/31/1988. Sixty-two percent of the 
cohort accumulated a lifetime dose of less than 10 mSv, whereas only 9% had a 
dose greater than 100 mSv (approximately 50% of the latter worked at Sellafield). 
SMR analyses, adjusting for age, calendar year, and sex, were performed where 
the external comparison group was the general population of England and Wales. 
The SMR for leukemia was 0.87 (no lag) and 0.91 (2 year lag). SMRs were also 
calculated for leukemia excluding CLL, these SMRs were 0.88 (no lag) and 0.93 
(2 year lag). Internal analyses were also executed to examine whether increasing 
dose was related to cancer mortality. For all leukemia (59 cases), the O/E estimates 
for each dose category were as follows: <10 mSv: 0.95 (O=24), 10-<20mSv: 0.87 
(O=6), 20-<50 mSv: 0.89 (O=8), 50-<100 mSv: 0.96 (O=6), 100-<200 mSv: 1.30 
(O=7), 200-<400 mSv: 1.06 (O=4), 400+ mSv: 1.63 (O=4). The p value for the 
one-tailed trend test was 0.10 and the ERR per Sv was estimated as 2.286 (90% 
CI=-0.322, 8.367). All leukemia excluding CLL was also analyzed with the 
following O/E ratios for the same dose categories listed above: 0.93 (O=20), 0.75 
(O=4), 1.07 (O=7), 0.66 (O=3), 1.21 (O=5), 1.37 (O=4), and 1.97 (O=4). The one-
tailed test of trend was determined to be significant, with a p value of 0.03. The 
ERR per Sv was 4.277 (95% CI=0.396, 13.58). The authors note as a limitation 
that the study could not control for internal radiation or chemical exposure. 
 
Wiggs LD, Cox-DeVore CA, Wilkinson GS, et al [1991]. Mortality among 
workers exposed to external ionizing radiation at a nuclear facility in Ohio. 
Journal of Occupational Medicine 33:632-637. 
 
A retrospective cohort study was conducted to evaluate the mortality experience of 
workers at the Mound nuclear weapons facility. In this cohort of 4,182 white males 
ever employed between 1947 and 1979, 593 deaths occurred, yielding an overall 
SMR below expectation (SMR=0.89, 95% CI=0.82-0.97). SMRs for cause specific 
cancers were not significantly elevated. Internal analysis was also performed in 
order to further assess the role of radiation and cancer. This analysis was restricted 
to the 3,229 members of the cohort who were monitored for external ionizing 
radiation (mean cumulative dose=29.7 mSv, median dose=5.8 mSv). The overall 
SMR for this population was 0.79 (95%CI=0.70-0.88), consistent with a strong 
healthy worker effect. An elevated SMR was observed for leukemia among these 
workers, though it was not significant as it was based on only 4 cases (SMR=1.24, 
95% CI=0.34-3.16). Maximum likelihood estimates of the rate ratio were 
generated comparing those with ≥ 10 mSv to those with an exposure of less than 
10 mSv. The rate ratio for lymphatic leukemia (LL), using a 10 year lag, was 7.04 
(0.20-191.71). Standard rate ratio (SRR) analyses, breaking dose into 3 categories, 
were also performed. For LL, the SRR for the highest dose category (>50 mSv) 
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compared to the referent category (<10 mSv) was 31.65 (95% CI=1.98-506.35). 
The SRR analysis also indicated a significant positive trend; however, the analysis 
was based on only 2 LL cases. Of the 2 lymphatic cases, at least 1 was a CLL. This 
case occurred in the highest exposure category of >50 mSv.  
 
Wilkinson GS, Dreyer NA [1991]. Leukemia among nuclear workers with 
protracted exposure to low-dose ionizing radiation. Epidemiology 2:305-309.  
 
A pooled analysis was performed to calculate an overall RR for leukemia for 
nuclear workers, using data from seven published studies. The pooled RR 
comparing workers exposed to >10 mSv to workers exposed to <10 mSv, with an 
external adjustment for age and calendar time, was determined to be 1.5. RRs for 
workers exposed to 10-50 mSv and >50 mSv, compared to workers exposed to 
<10 mSv, were 1.8 and 1.2, respectively. No results by leukemia subtype were 
given.  
 
Wing S, Shy CM, Wood JL, et al. [1991]. Mortality among workers at Oak 
Ridge National Laboratory. JAMA 265:1397-1402.  
 
Workers employed at ORNL from 1943-1972 were followed until 1984 to assess 
mortality trends. Of the 8,318 white male workers considered in the analysis, 
1,524 were identified as decreased prior to 1984. The SMR, comparing mortality 
among ORNL workers to that of the US white male population, was significantly 
elevated for leukemia (SMR=1.63, 95% CI=1.08-2.35). The SMR was also 
significantly elevated for the subcohort of workers monitored for internal 
radiation, at 2.23 (95% CI=1.27-3.62). Lymphosarcoma and reticulosarcoma 
SMRs were above 1 for all workers and for the internally monitored workers, 
however the SMRs were not statistically significant. The category “other 
lymphatic”, including International Classification of Disease (ICD)-8 codes 202 
and 203, demonstrated deficits in all workers and in all internally monitored 
workers; the SMRs were 0.41 (95% CI=0.13-0.95) and 0.19 (95% CI=0.00-1.06), 
respectively. Modeling of the leukemia deaths (excluding CLL), adjusting for age, 
cohort, and age by cohort, gave a % increase per 10 mSv of 6.88 for a 5 year lag 
and 9.15 for a 10 year lag. “The standard errors were larger than the parameter 
estimates and the chi square values indicate that the linear term for radiation dose 
did not contribute to the goodness of fit of the model. Analyses repeated with 
chronic lymphocytic deaths that were excluded from the leukemia category 
showed similar results.” 
 
National Academy of Sciences/National Research Council (NAS/NRC) [1990]. 
Health Effects of Low Levels of Ionizing Radiation (BEIR V). National 
Academy Press, Washington, DC. 
 
The model proposed by the BEIR V committee to predict leukemia risk from 
radiation dose was derived from leukemia data excluding CLL. The BEIR V report 
cites three major studies of radiation and leukemia where no excess of CLL was 
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observed: Preston et al. (1987) which found no excess of CLL in the LSS cohort of 
atomic bomb survivors, Darby et al. (1987) where only 2 cases of CLL arose in a 
cohort of 14,106 patients treated with x-ray for ankylosing spondylitis (2.38 
expected), and Boice et al. (1987 and 1988) where among 30,000 women treated 
with fractionated doses of radiation for cervical cancer, no excess of CLL 
occurred. 
 
Gilbert ES, Peterson GR, Buchanan JA [1989]. Mortality of workers at the 
Hanford site: 1945-1981. Health Phys 56:11-25. 
 
Gilbert et al. performed an update of the mortality experience of the Hanford 
workers to include additional years of follow-up. Again, no increased risk was 
seen for leukemia. The ERR of leukemia was estimated to be -2 per million 
person-years per 10 mSv (95% limits=-2, 8). A lagged analysis (2 years and 10 
years) was conducted on the monitored workers. Observed and expected deaths 
(“expected deaths may be interpreted as the number of cases expected in the 
category if exposure to radiation were unrelated to the cause of death and should 
not be confused with expected deaths calculated from US mortality rates”) were 
calculated by level of exposure and a trend test was performed. For CLL, 8 deaths 
occurred between 1955 and 1981, all of which occurred in the lowest exposure 
category of 0-19 mSv; this was slightly higher than the expected number of 6.7.  
 
Gilbert ES, Fry SA, Wiggs LD, et al [1989]. Analyses of combined mortality 
data on workers at the Hanford site, Oak Ridge National Laboratory, and 
Rocky Flats nuclear weapons plant. Radiat Res 120:19-35.  
 
A combined mortality study examined cancer deaths among white male workers 
who were monitored for external radiation at Hanford, ORNL, and Rocky Flats. 
Data analysis by cumulative dose, lagged 2 years, demonstrated no significant 
excess in deaths from CLL (0-10 mSv: O/E=6/5.3, 10-50 mSv: O/E=3/2, 50-100 
mSv: O/E=0/0.5, 100-200 mSv: O/E=0/0.3, >200 mSv: O/E=0/0.3). The combined 
(all-site) trend test statistic (-0.76) for CLL was non-significant, based on 9 cases. 
A positive, though non-significant, trend was seen at ORNL only. Lymphoma also 
showed no evidence of a dose relation (trend test statistic=-0.17, based on 49 
cases). 
 
Beral V, Fraser P, Carpenter L, et al [1988]. Mortality of employees of the 
Atomic Weapons Establishment: 1951-1982. BMJ 297:757-770. 
  
This cohort mortality study involved 22,522 workers ever employed at the atomic 
weapons establishments of Aldermaston, Fort Halstead, Orfordness, Foulness, and 
Woolrich Common from 1951-1982. Follow-up was completed through 1983. Of 
the 3,115 deaths occurring in this cohort, 865 were due to cancer. Among the 
radiation monitored workers, leukemia and NHL deaths amounted to 4 and 3, 
respectively. Stratified analysis by dose level was conducted, adjusting for age, 
sex, calendar period and social class. The expected numbers were based on rates in 
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all subjects with a radiation record. For leukemia, all 4 cases among radiation 
workers occurred in the <10 mSv category, yielding an O/E of 1.21. None of the 5 
CLL cases that arose in the cohort occurred in radiation workers. The rate ratio for 
employees with a radiation record compared with other employees was 0.42 (95% 
CI=0.15-7.47) for leukemia and 0.53 for leukemia excluding CLL (p>0.05). For 
NHL, the O/E ratio (10 year lag) was 0.75 for workers with a dose <10 mSv and 
5.55 for workers with a dose of 10-19 mSv. The rate ratio for NHL comparing 
monitored workers to non-monitored workers was 0.53 (95% CI=0.10-5.03) with 
no lag and 0.90 (95% CI=0.16-12.43) with a 10 year lag.  
 
Checkoway H, Pearce N, Crawford-Brown DJ, Cragle DL [1988]. Radiation 
doses and cause-specific mortality among workers at a nuclear materials 
fabrication plant. Am J Epidemiol 127:255-266. 
   
The study included 6,781 Y-12 white male workers ever employed during the 
period 1947-1979. The SMR for leukemia, with a referent population of US white 
males, was lower than expectation (SMR=0.50, 95% CI=0.14-1.28, 4 observed 
cases). Leukemia subtypes were not specified. SMRs for the categories containing 
cases of NHL were 0.62 (95% CI=0.13-1.81) for lymphosarcoma (ICD-8 200) and 
1.86 (95% CI=0.85-3.53) for other lymphatic cancers (ICD-8 202, 203, and 208). 
Dose response analyses for alpha and gamma radiation were performed for lung 
cancer only.  
 
Cragle DL, McLain RW, Qualters JR, et al. [1988]. Mortality among workers 
at a nuclear fuels production facility. Am J Ind Med 14:379-401. 
 
Duration of employment was used as a proxy for exposure in this cohort mortality 
study of workers employed at the Savannah River Plant. The study population was 
restricted to white males employed at least 90 days between 1952 and 1974, 
yielding a cohort of 9,860 individuals. The cohort was followed for vital status 
until the end of 1980. SMRs were calculated for subcohorts stratified by SES 
(hourly, salaried, or combined) and employment period (pre-1955, post 1955). The 
SMRs, based on US population rates, for leukemia for hourly and salaried workers 
were 1.63 and 1.05, respectively. The SMRs for hourly workers employed before 
1955, by duration of employment, were as follows: 1.24 (<5 years), 2.75 (5-15 
years), and 1.57 (>15 years). The finding of an SMR of 2.75 for the workers 
employed 5-15 years was significant at the 5% level. There were 4 cases of CLL 
among the 13 leukemias observed in hourly employees. (Note: the year of death, 
age of death, length of employment, cumulative dose, and ever exposure to 
internal radiation were presented in tabular format for each salaried leukemia 
case.)  
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Reynolds P, Austin DF [1985]. Cancer incidence among employees of the 
Lawrence Livermore National Laboratory, 1969-1980. Western J Med 
142:214-218. 
 
Cancer incidence was studied among workers of the Lawrence Livermore National 
Laboratory (LLNL), a high-energy physics research center in Alameda County, 
California. The cohort was restricted to employees aged 20-69 years, who resided 
in the San Francisco metropolitan area. The Resource for Cancer Epidemiology 
database was used to identify incident cancer cases. Cases were excluded if their 
cancer diagnosis was not concurrent with active employment at LLNL. Three 
leukemias (none of which were CLL) and 6 NHLs were observed among the male 
workers, yielding SMRs of 0.90 and 1.08, respectively, where the comparison 
group was the San Francisco metropolitan general population.  
 
Gilbert ES [1983]. An evaluation of several methods for assessing the effects 
of occupational exposure to radiation. Biometrics 39:161-171. 
 
Power curves were generated from data on 15,375 Hanford radiation-monitored 
workers to evaluate the ability of different analytical methods to detect significant 
differences for the outcome of leukemia. The results are summarized as follows; 
“it is found that the introduction of an external control can increase power, 
although not when an overall adjustment factor must be estimated from the data or 
when death rates for the study population are substantially lower that those for the 
control population. It is also found that little power is lost if exposures are 
grouped. Finally the power calculations indicate, as expected, that in the analyses 
of occupationally exposed populations, such as the Hanford workers, there is very 
little chance of detecting radiation effects at the levels of our current estimates. 
However, power is reasonably good for detecting effects that are 10 to 15 times 
larger.” 
 
Tolley HD, Marks S, Buchanan JA, Gilbert ES [1983] A further update of the 
analysis of mortality of workers in a nuclear facility. Radiat Res 95:211-213. 
 
Tolley et al. report on the mortality experience of 15, 992 white male Hanford 
workers first employed before 1965 with follow-up for vital status through 1978. 
Trend analysis showed no evidence of a relation between “other leukemia” (ICD 
204, 206, 207) and increasing cumulative radiation dose. There were only 5 cases 
of “other leukemia”; none of these cases was exposed to a cumulative radiation 
dose >2 rem. The distribution of leukemia subtype within this category is not 
given.  
 
Rinsky RA, Zumwalde RD, Waxweiler RJ, et al. [1981] Cancer mortality at a 
naval nuclear shipyard. Lancet 8214:231-235. 
 
Rinsky et al. conducted a cohort mortality study of workers at the Portsmouth 
Naval Shipyard (PNS) to confirm the finding of a 5-fold increase in proportionate 
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mortality from leukemia among radiation workers at PNS, reported by Najarian et 
al. in 1978. The study population of the current study included 24,545 workers 
employed between 1952 and 1977. The cohort was further divided into subcohorts 
according to radiation monitoring status, where subcohort I included all exposed 
radiation workers (monitored workers with measurable dose reading), subcohort II 
consisted of non-radiation workers (not monitored), and subcohort III included 
unexposed radiation workers (workers who were monitored but had a 0 dose). The 
SMR for the full cohort, as standardized by the US white male population, was 
0.94 (95% CI=0.67-1.28) for leukemia, based on 39 cases. The SMRs for leukemia 
by subcohort were 0.84 (95% CI=0.34-1.74) for subcohort I, 1.06 (95% CI=0.72-
1.51) for subcohort 2, and 0.43 (no CI given, only 1 death observed, 2.3 expected). 
Internal SMR analyses were also conducted using subcohort II to derive the 
number of deaths expected to occur in subcohort I (radiation exposed workers). 
The SMR for subcohort I was 0.70 (non-significant), based on 7 leukemia deaths, 
of which 2 were characterized as “lymphatic”. Further analysis of subcohort I 
stratifying by dose category did not reveal a dose response trend. In summary, the 
authors found no excess of leukemia in radiation exposed workers at PNS, 
contradicting the results found by Najarian et al. The authors do acknowledge that 
the internal comparison group used in their analysis (subcohort II) “did not 
account for the possible selection of particularly healthy individuals for radiation 
work.” No analysis of subcohort I was presented using subcohort III, a cohort of 
individuals qualified for radiation work, as the internal comparison group. 
 
Gilbert ES, Marks S [1979]. An analysis of the mortality of workers in a 
nuclear facility. Radiat Res 79:122-148. 
 
Unlike the prior studies of the Hanford facility, this study utilized data on both 
deceased and living workers in order to determine whether excess mortality 
occurred in this population due to radiation exposure. Workers hired after 1965 
were excluded, leaving 20,842 white male employees who were followed until 
4/1/1974. At Hanford, radiation exposure was primarily for whole-body, 
penetrating gamma radiation. In terms of internal radiation, only 450 plutonium 
deposition cases were documented. Since only 3 died of cancer (brain, buccal and 
lung), such radiation exposure was not further considered. An SMR analysis was 
conducted, stratifying on duration of employment. The SMR for leukemia was not 
elevated in either employment group (<2 years SMR=0.56, ≥ 2 years SMR=0.46). 
The SMR for lymphosarcoma and reticulosarcoma (ICD-8 200) was below 
expectation in the short term worker category (SMR=0.71), whereas among the 
longer term workers the SMR was 1.05. Other neoplasms of the lymphatic and 
hematopoietic tissue (ICD-8 202, 203, 208, and 209) showed an SMR for short 
term workers of 0.78 and an SMR for longer term workers of 1.18. Restricting 
SMR analysis to deaths occurring during or after 1965, in order to examine rates 
by leukemia subtype, did not reveal a significant excess of leukemia deaths for any 
subtype. The SMRs for LL were 0.42 among the short term workers and 0.29 
among the long term workers. Only multiple myeloma (MM) showed a greater 
number of deaths than was expected, with SMRs for short term and long term 
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workers of 1.60 and 1.32, respectively. Additional analyses by dose for the group 
employed greater than 2 years showed no evidence of a trend by level of exposure, 
except for MM. With a 10 year lag, the trend for MM remained positive, and the p 
value for the test of trend by dose for lymphosarcoma and reticulum cell sarcoma 
was 0.15. Again, there was no evidence for an increasing risk of leukemia with 
increasing exposure level. This study did not find an excess of deaths due to 
myeloid leukemia, which was associated with radiation in several other studies, 
but did find evidence of radiation-induced MM. The authors offer a possible 
explanation that “chronic exposure to radiation manifests itself differently from 
acute exposure.” The authors also caution the reader that the results for MM were 
based on small numbers. 
 
Hutchinson GB, MacMahon B, Jablon S, Land CE [1979]. Review of report 
by Mancuso, Stewart and Kneale of radiation exposure to Hanford workers. 
Health Phys 37:207-220. 
 
Hutchinson et al. performed new proportionate mortality ratio (PMR) analyses 
standardized by age and year, for the Mancuso data on 24,939 male Hanford 
facility workers employed between 1943 and 1971 and followed until 1972. PMRs 
were presented by dose interval, with a test of trend. For haemopoietic and 
lymphopoietic cancers (ICD 200-209), the PMRs were as follows: 0.01-0.24 rads 
O/E=1.02, 0.25-0.64 rads O/E=1.16, 0.65-1.04 rads O/E=0.52, 1.05-4.04 rads 
O/E=0.72, 4.05-10.04 rads O/E=0.80, 10.05+ rads O/E=2.0. For lymphomas, 
(same dose categories as above) the PMRs were 0.67, 1.32, 0.59, 1.41, 1.43, and 
NA (0 observed cases). Exposed LL cases existed in only the first two dose 
categories, with PMRs of 1.43 and 2, respectively. The cumulative dose of the 2 
exposed LLs was 0.29 rads and the cumulative dose including the unexposed case 
of lymphatic leukemia was 0.19 rads. Myeloma, in contrast to the aforementioned 
cancers, did present evidence of a significant trend. Based on this new analysis, 
Hutchison et al. states “there is no evidence of radiation relationship for lymphatic 
and haemopoietic cancers other than myeloma.”  
 
Anderson TW [1978]. Radiation exposures of Hanford workers: a critique of 
the Mancuso, Stewart and Kneale report. Health Phys 35:743-750. 
 
Anderson criticizes the SMR results contained in Mancuso et al. (1977) tables 4 
and 17, which are not age-adjusted. Furthermore, he notes these SMRs were 
calculated using observed deaths classified in ICD-8, but expected deaths 
classified in ICD-7. As there were differences in ICD-7 and 8 for reticulo-
endothelial system (RES) cancers, he notes this may have affected RES SMR 
results. Anderson presents age-adjusted excess deaths and compares these to 
excess deaths derived by Mancuso. For LL, the excess number of deaths, with age 
adjustment, was -4.6, whereas the Mancuso unadjusted number of excess deaths 
was -6.4. Lymphoma excess deaths decreased following age adjustment, from 6.3 
excess deaths to -0.8 excess deaths. RES deaths decreased as well, from -6.8 to -
9.0, after adjustment for age. 
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Mancuso TF, Stewart A, Kneale G [1977]. Radiation exposures of Hanford 
workers dying from cancers and other causes. Health Phys 33: 369-385. 
 
The 3,250 pre1973 deaths occurring in white, male, Hanford workers were 
investigated in this study to examine the relation between radiation and cancer. In 
a case-control analysis, the mean radiation dose among cancer deaths (cases) was 
compared to the mean radiation dose among non-cancer cases (controls). The 
mean cumulative radiation dose for workers dying of cancer was 138 centirads 
(13.8 milligray (mGy)), whereas the mean cumulative radiation dose for workers 
dying of non-cancers was 99 centirads. The researchers also compared mean 
cumulative radiation dose by cancer type to the mean cumulative dose of all the 
deceased workers (107 centirads). Mean dose greater than 107 centirads was seen 
among those dying from myeloma (775 centirads), myeloid leukemia (122 
centirads) and lymphomas (119 centirads). LL deaths and other RES neoplasms 
had cumulative mean doses less than 107 centirads, with doses of 19 and 12 
centirads, respectively. The O/E ratio for LL, as derived from death rates among 
white males in the year 1960, was 0.32 based on 3 cases. This ratio is not age-
adjusted. No further analyses of LL were performed; rather “all RES” analyses 
were conducted. Comparing deaths in the Hanford cohort to the expected number 
of deaths based death rates from the US white male population in 1960, an SMR of 
1.58 was observed for RES. Comparisons of mean cumulative dose among RES 
deaths compared to non-cancer deaths, stratified by pre-death interval, though not 
age-adjusted, showed significantly higher mean cumulative doses from 0-18 years 
before death. No difference in dose, by pre-death interval, was found among the 
non-cancer group. The authors also performed calculations to estimate the 
doubling dose, or the dose needed to double the normal risk of dying from any 
form of cancer, for cancer and RES. These doubling doses were determined to be 
12.2 and 2.5 rads, respectively, which the researchers note are lower than estimates 
based on atomic bomb data. Another analysis was performed by age to identify 
any significant difference in cumulative mean dose among RES cancers compared 
to non-cancers, by age group. Ages 55-71 among the RES group had a higher 
cumulative mean dose than non-cancers. 
 
ii. Radiologic Technologists and Radiologists 
 
Doody MM, Mandel JS, Lubin JH, Boice Jr JD [1998]. Mortality among 
United States radiologic technologists, 1926-1990. Cancer Cause Control 9:67-75. 
 
Radiologic workers certified for at least 2 years by the American Registry of 
Radiologic Technologists during 1926-1982 were followed until 1990 to assess 
excess mortality in this population. Unlike other studies to date, the majority of the 
cohort consisted of women (73%). The SMRs for leukemia and lymphosarcoma, 
based on age, sex, and calendar year adjusted US mortality rates, were 0.93 (95% 
CI=0.76-1.13) and 1.03 (95% CI=0.72-1.38), respectively. No significant trend 
was observed for leukemia by increasing number of years certified nor by calendar 
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year of certification. Of the 103 leukemia deaths observed in this cohort, 18 were 
due to CLL. Age, gender and calendar year adjusted RRs were calculated where 
the referent group was defined as radiologic technologists certified after 1940 for 
less than 10 years. For radiologic technologists certified after 1940, the RRs for 
the years certified categories of <10, 10-<20, 20-<30 and 30+ were as follows: 1.0 
(referent) 0.5, 1.5, and 1.0. For workers certified before 1940, the RRs for the 
aforementioned categories were 5.0, NA, 2.5, and 3.0, respectively. No significant 
increase of CLL was found. The authors comment that the similar pattern observed 
for leukemia excluding CLL and CLL, “is noteworthy since CLL has never been 
linked to radiation in any study.” 
 
Yoshinaga S, Aoyama T, Yoshimoto Y, Sugahara T [1998]. Cancer mortality 
among radiological technologists in Japan: updated analysis of follow-up data 
from 1969-1993. Journal of Epidemiology 9:61-72.  
 
A study of 12,195 male Japanese radiological technologists born before 1951 was 
carried out to determine whether an increase of cancer deaths occurred in this 
population compared to the general Japanese population. The analysis also 
considered 2 subcohorts, workers born before 1934 (cohort 1) and workers born in 
1934 or after (cohort 2), in order to account for the institution of the Radiation 
Hazard Prevention Act of 1958. It was thought that cohort 1 may have experienced 
greater exposure to radiation than cohort 2. Of the 20 leukemia deaths observed in 
the entire cohort, 14 occurred in cohort 1 (including 1 CLL death), and 6 leukemia 
deaths occurred in cohort 2. The SMRs for leukemia and lymphoma in the full 
cohort were 1.31 (95% CI=0.80-2.02) and 1.24 (95% CI=0.72-1.99), respectively. 
The SMRs for leukemia and lymphoma for cohort 1 were 1.55 (95% CI=0.85-
2.60) and 1.48 (95% CI=0.83-2.44), respectively. For cohort 2 the SMR for 
leukemia was 0.95 (95% CI=0.35-2.08) and the SMR for lymphoma was 0.56 
(95% CI=0.08-2.04). The SMRs for leukemia achieved significance when a 
comparison population of Japanese professional and technical workers was used to 
derive the expected number of leukemia deaths (age and calendar year adjusted). 
The SMR for cohort 1 was 1.82 (95% CI=1.00-3.06).  
 
Wang J, Inskip PD, Boice JD, et al. [1990]. Cancer incidence among medical 
diagnostic x-ray workers in China, 1950-1985. Int J Cancer 45:889-895. 
 
To assess the relationship between diagnostic x-ray exposure and cancer risk, 
27,011 x-ray workers in China were compared to 25,782 physicians without work-
related x-ray exposure. The RR for lymphatic leukemia was found to be 4.3, which 
was significant at the 5% level (one-sided). This RR was based on 8 cases of LL, 
only 1 of which was of the CLL subtype. The study also found, for all leukemia, a 
difference in the RR for males and females; the RR for males was 3.0, whereas the 
RR for females was 1.1. 
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Smith PG, Doll R [1981]. Mortality from cancer and all causes among British 
radiologists. Brit J Radiol 54:187-194.  
 
Radiologists ever belonging to a British radiological society from 1897 to 1954 
were studied to determine if excess cancer deaths occurred in this group compared 
to men of the same social class (social class 1) residing in England and Wales. 
Follow-up for mortality was completed though January 1, 1977. Within this cohort 
of 1,338 men, 8 leukemia deaths were identified, 3 of which were of the CLL 
subtype. SMR analysis (age and calendar year adjusted) was performed, stratifying 
by date of entry in the cohort (before or after 1921). Since radiation regulations 
were not imposed prior to1921, it was suspected that the group entering the cohort 
before 1921 had a greater exposure to radiation. The SMR for all leukemia for the 
pre1921 cohort, based on 4 cases, was 6.15 (one-sided p<0.01); one of these 
leukemia cases was a CLL (0.2 expected CLL cases). Where the date of entry in 
the cohort was after 1920, 4 additional leukemias were observed, 2 of which were 
of the CLL subtype (0.7 expected CLL cases). The O/E for CLL for the full cohort 
was 3.45 (3 observed CLL cases), which was almost significant at the 5% level 
(p=0.06). 
 
Matanoski GM, Seltser R, Sartwell PE, et al [1975]. The current mortality 
rates of radiologists and other physician specialists: specific causes of death. 
Am J Epidemiol 101:199-210.  
 
Mortality patterns of members of the Radiological Society of North America 
during 1920-1969 were examined in this study. The SMRs for leukemia, stratified 
by date of entry into the society, were as follows: 1920-1929 (all ages) 3.01 
(p<0.05), 1930-1939 (through age 74) 4.06 (p<0.05) and 1940-1949 (up to age 64) 
0.58 (p<0.05). Expected values were derived from 1960 US white male mortality 
rates. The SMRs for the radiologists were higher than the SMRs observed for 
physicians of other specialties.  
 
iii. Nuclear Test Workers 
  
Dalager NA, Kang HK, Mahan CM [2000]. Cancer mortality among the 
highest exposed US atmospheric nuclear test participants. JOEM 42:798-805.  
 
This study assessed the effect of radiation exposure from nuclear fallout by 
comparing the mortality experience of 1,010 nuclear test participants exposed to ≥ 
5 rem, to the mortality experience of the HARDTACK cohort, a group of nuclear 
test participants exposed to ≤ 0.25 rem. Cox regression yielded a leukemia RR, 
adjusted for age, rank at participation, and length of follow-up, of 1.51 (95% 
CI=0.23-9.69).  
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Bross ID, Bross NS [1987]. Do atomic veterans have excess cancer? New results 
correcting for the healthy soldier bias. Am J Epidemiol 126:1042-1050. 
 
A study in 1985 by Robinette et al. confirmed the finding of increased leukemia in 
the SMOKY cohort of nuclear test participants reported by Caldwell et al. (1980). 
Robinette et al. (1985) concluded, in their examination of 5 nuclear test series, that 
there was “no consistent or significant evidence for an increase in leukemia or 
other malignant disease in nuclear test participants.” Bross and Bross (1987) 
critiqued the findings of Robinette, since their SMRs, calculated based on rates in 
U.S. white males, did not account for the “healthy soldier effect.” Bross et al., 
reanalyzed the Robinette data, dividing the reported leukemia SMRs by a chosen 
“referent” SMR (cardiovascular disease among the lowest dose category) in order 
to alleviate the “healthy soldier effect”. This methodology, coupled with the 
exclusion of the lymphatic cancer (4 cases of 24), led Bross and Bross to believe 
there was evidence of an excess of radiogenic cancers among these nuclear 
participants. No CLL results are reported.  
 
Raman S, Dulberg CS, Spasoff RA, Scott T [1987]. Mortality among 
Canadian military personnel exposed to low-dose radiation. Candian Medical 
Association Journal 136:1051-1056. 
 
A study was executed to assess the relationship between radiation and cancer 
among Canadian military personnel exposed to nuclear tests. The mortality 
experience of 954 nuclear test participants was compared to the mortality 
experience of an unexposed cohort of military personnel. The referent population 
was compiled by selecting 2 unexposed, age-matched military controls per each 
exposed individual. One case of leukemia arose among the exposed group and 5 
cases of leukemia arose among the controls (leukemia subtype not specified). The 
RR for leukemia was 0.40. A leukemia SMR was also calculated based on death 
rates for Canadian males. The SMR was below expectation at 0.68.  
 
Caldwell GG, Kelley DB, Heath CW. [1980]. Leukemia among participants in 
military maneuvers at a nuclear bomb test site. JAMA 244:1575-1578. 
 
Nine of 3,224 men who participated in the SMOKY nuclear bomb test in Nevada 
held on August 8, 1957 have developed leukemia (4 acute myelogenous leukemia 
(AML), 3 chronic myelogenous leukemia (CML), 1 hairy cell leukemia (HCL), 
and 1 acute lymphocytic leukemia (ALL)). This was a significant excess of 
leukemia, as only 3.5 cases were expected to occur. No cases of CLL have yet 
been observed among these test participants; however, follow-up of the cohort has 
only reached 76% completion.  
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iv. Radionuclides, including Plutonium Exposure 
  
Omar RZ, Barber JA, Smith PG [1999]. Cancer mortality and morbidity 
among plutonium workers at the Sellafield plant of British Nuclear Fuels. 
Brit J Cancer 79:1288-1301. 
 
The 14,319 Sellafield workers ever employed between 1947 and 1976, and with 
known date of birth, were followed until 1993 to assess patterns of mortality in 
relation to internal (plutonium) and external radiation exposure. The SMRs for 
leukemia, comparing mortality rates among the Sellafield workers to mortality 
rates among the general population of England and Wales, were 0.71 for 
plutonium workers, 0.88 for other radiation workers, and 0.49 (p<0.05) for non-
radiation workers. The SMRs for NHL were found to be 1.47 among the 
plutonium workers, 0.98 among other radiation workers, and 0.33 (p<0.05) among 
non-radiation workers. Rate ratios were derived from maximum likelihood 
estimates; the rate ratio for leukemia for plutonium workers compared to other 
radiation workers was 0.79 and the rate ratio for radiation workers compared to 
non-radiation workers was 1.27. The rate ratio for NHL for plutonium workers 
compared to other radiation workers was 1.39 and the rate ratio for NHL 
comparing radiation workers to non-radiation workers was 2.83. No confidence 
limits were given around these estimates. Trend analysis was conducted to 
determine if increasing radiation dose led to increased mortality. Unlagged 
analysis of leukemia by external dose did demonstrate a significant trend, as did 
leukemia excluding CLL. The observed positive trend between leukemia 
excluding CLL and radiation dose was still significant after a 2 year lag. There was 
no evidence of trend for leukemia or NHL by plutonium dose.  
 
Carpenter LM, Higgins CD, Douglas AJ, et al [1998]. Cancer mortality in 
relation to monitoring for radionuclide exposure in three UK nuclear 
industry workforces. Brit J Cancer 78:1224-1232. 
 
The 40,761 employees who were monitored for external radiation were analyzed 
in terms of internal exposure to tritium, plutonium, or other radionuclides. For 
leukemia the SMRs for each group were below expectation, except for the group 
of workers not monitored for internal radiation, where the SMR was 1.17. Non-
significant rate ratios below 1 were observed upon comparing the different groups 
of internally monitored workers to workers not monitored for internal dose. A 
trend analysis by cumulative dose was performed for workers ever monitored for 
internal radiation, as well as for workers never monitored for internal radiation. 
For leukemia excluding CLL the strength of association of the positive trend 
differed little between the two groups. Analysis of NHL revealed elevated SMRs 
for each internal exposure group. The rate ratios for NHL comparing workers 
monitored for internal radiation to workers not monitored for internal radiation 
were 1.90 (95% CI=0.74-4.30) for tritium, 1.48 (95% CI=0.76-2.83) for 
plutonium, and 0.90 (95% CI=0.43-1.81) for other radionuclides.  
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Voelz GL, Lawrence JNP, Johnson ER [1997]. Fifty years of plutonium 
exposure to the Manhattan project plutonium workers: an update. Health 
Phys 73:611-619. 
 
Twenty-six white male workers exposed to plutonium through work on the 
Manhattan Project have been evaluated periodically over the past 50 years to 
identify any health consequences resulting from their radiation exposure. As of 
1994, 7 deaths have occurred among these workers; 18 deaths were expected to 
occur based on US rates. There have been no leukemia diagnoses in these workers. 
 
Wiggs LD, Johnson ER, Cox-DeVore CA, Voelz GL [1994]. Mortality 
through 1990 among white male workers at the Los Alamos National 
Laboratory: considering exposures to plutonium and external ionizing 
radiation. Health Phys 67:577-588. 
 
Examination of the mortality of a cohort of 15,727 white male workers ever 
employed at Los Alamos National Laboratory from 1943-1977, and followed for 
vital status until 1990, revealed SMRs for leukemia, lymphosarcoma, and other 
lymphatic malignancies of 1.01, 0.94, and 0.77, respectively. The results of the 
dose response analysis for LL (4 cases, all CLL) were as follows: 0-9 mSv: 
RR=1.0 (3 cases), 100+ mSv: RR=4.00 (1 case); the trend statistic was 1.33. No 
cases were observed in the dose categories of 10-49.9 mSv and 50-99.9 mSv. This 
trend became significant (test statistic=1.73) when the dose response analysis was 
limited to non-plutonium workers, as none of the CLL cases were plutonium 
workers.  
 
Wiggs LD, Cox-DeVore CA, Voelz GL [1991]. Mortality among workers 
monitored for 210Po exposure: 1944-1972. Health Phys 61:71-76. 
 
The mortality experience of 2,181 workers monitored for polonium-210 at the 
Mound facility from 1944-1972 was evaluated in this study. Two cases of CLL 
were observed in this cohort, one of the cases had a polonium-210 dose < 10 mSv, 
whereas the other cases had an exposure >1000 mSv. Employing a 2 year lag, the 
RR for CLL comparing the risk in the highest exposure category (>1000 mSv) to 
the risk in the referent category (<10 mSv) was 2.55. This RR rose slightly to 2.58 
using a 10 year lag. 
  
Wilkinson GS, Tietjen GL, Wiggs LD, et al. [1987]. Mortality among 
plutonium and other radiation workers at a plutonium weapons facility. Am J 
Epidemiol 125:231-250. 
 
Plutonium workers at Rocky Flats were studied with respect to their mortality 
experience. Among the 5,413 white male workers employed at least 2 years, only 
4 leukemia deaths occurred. The SMR for leukemia, where expected deaths were 
derived from US rates, was 0.75 (90% CI=0.26-1.71). Analysis was completed 
comparing risk of lymphopoietic cancer among those exposed to ≥ 2 nanocurie 
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(nCi) to those exposed to <2 nCi for various lag periods. Leukemia was not 
considered alone in the RR analysis for plutonium. For a lag period of 2 years, the 
RR for all lymphopoietic cancer (ICD 200-209) was 7.69 (90% CI=0.99-72.93). 
The 4 cases of plutonium exposed workers were due to reticulum cell sarcoma, 
NHL, MM, and myeloid leukemia. With a 5 year lag the RR increased to 9.86 
(90% CI=1.26-94.03); a non-significant RR of 5.22 was observed when a lag of 10 
years was employed. Analysis by external radiation exposure revealed no increase 
in risk of lymphopoietic cancer comparing those exposed to ≥1 rem to those 
exposed to <1 rem (RR=0.84, 90% CI=0.12-3.95). The RR for leukemia in the 
analysis of external radiation was 1.01 (90% CI=0.80-9.12) 
 
Voelz GL, Hempelmann LH, Lawrence JNP, Moss WD [1979]. A 32-year 
medical follow-up of Manhattan Project plutonium workers. Health Phys 
37:445-485.  
 
Twenty-six male workers exposed to high levels of plutonium were selected for 
medical follow-up. The workers had exposure to inhaled plutonium during 1944-
1945, during their work for the Manhattan Project. For the follow-up period of 
1975-1978, there were no cancer cases other than skin cancer. Medical 
surveillance revealed normal hematology. 
 
 v. Uranium 
 
Ritz, B [1999]. Radiation exposure and cancer mortality in uranium 
processing workers. Epidemiology 10:531-538. 
 
A mortality study was conducted of 4,014 white male uranium workers employed 
during 1951-1989 at the Fernald plant in Ohio. The SMR for leukemia was 1.16 
(95% CI=0.62-1.98), which included 1 case of CLL out of 38 total leukemia and 
aleukemia cases. Further analyses excluded CLL.  
 
Roscoe RJ [1997]. An update of mortality from all causes among white 
uranium miners from the Colorado Plateau study group. Am J Ind Med 
31:211-222. 
 
The study population of this cohort mortality study was derived from white male 
uranium miners who mined the Colorado Plateau for at least one month prior to 
1964 and who also participated in the United States Public Health Service 
(USPHS) health surveys. The resultant 3,238 workers were followed until 1990 for 
vital status. It has been previously demonstrated that decay products of uranium 
are related to lung cancer, and associations between leukemia and NHL with radon 
have also been suggested. In this study, the SMR for leukemia and aleukemia 
(unlagged) was elevated, though not significantly (SMR=1.6, 95% CI=0.8-2.7). 
The SMR for NHL was below expectation at 0.8 (95% CI=0.3-1.7). SRR analysis 
revealed no evidence of trend with increasing exposure to radon progeny for 
neither leukemia nor NHL. Leukemia subtype was not specified. 
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Cragle DL, Watkins JP, Ingle JN, Robertson-Demers K, Tankersley WG, 
West CM [1995].  Mortality among a cohort of white male workers at a 
uranium processing plant: Fernald feed materials production center, 1951-
1989. Oak Ridge, TN: Center for Epidemiologic Research, Oak Ridge 
Institute for Science and Education. Unpublished. 29 pg.  
 
Cragle et al. studied 4,014 white male workers employed at the Fernald plant from 
1951-1981. Workers were followed for vital status until 1989. Leukemia deaths 
were not in significant excess (SMR for salaried workers=1.59, 95% CI=0.51-
3.71; SMR for hourly workers=1.07, 95% CI=0.48-2.11). There was no evidence 
of increasing risk for leukemia excluding CLL (test of trend statistic =0.04) or for 
CLL (test of trend statistic=0.02) with increasing cumulative internal radiation 
exposure. There were only two CLL deaths observed in this cohort; the two cases 
were assigned to the 20-40 mGy and the 40-80 mGy categories, respectively. 
 
Darby SC, Whitley E, Howe GR, et al. [1995]. Radon and cancers other than 
lung cancer in underground miners: a collaborative analysis of 11 studies. J 
Natl Cancer I 87:378-384.  
 
Combination of data from 11 studies allowed for the examination of cancer 
mortality among 64,209 uranium miners. The O/E ratios for leukemia, leukemia 
excluding CLL, and NHL were as follows: 1.16, 1.11, and 0.80. O/Es were also 
calculated stratifying on time since first employment. Among workers whose time 
since first employment was less than 10 years, the O/E for leukemia was 
significantly elevated (1.93, 95% CI=1.19-2.95, based on 21 cases). The O/E for 
leukemia excluding CLL was increased, though not significantly (1.28, 95% 
CI=0.51-2.64, based on 7 cases). The SMR for NHL was below expectation at 
0.81 (95% CI=0.30-1.77). For workers whose time since first employment was 
greater than 10 years, the O/E ratios for leukemia, leukemia excluding CLL, and 
NHL were 0.99, 1.08 and 0.79, respectively; these estimates were not significant at 
the 5% level. Analysis by cumulative radon exposure demonstrated no evident 
trend for increasing leukemia risk with increasing radon dose. For leukemia there 
were 14 cases (16.3 expected) in the lowest exposure category of <50 working-
level months (WLM), 3 cases (2.4 expected) in the 50-<100 WLM category and 5 
cases (2.8 expected) in the 100-<500 WLM category. There were no cases 
observed in the remaining 3 exposure categories (500-<1000 WLM, 1000-<1500 
WLM, and 1500+ WLM). The distribution of cases of leukemia excluding CLL, 
by dose, was as follows: 5 cases (6.3 expected) in the lowest exposure group, and 
2 cases (0.4 expected) in the 50-<100 WLM group.  
 
Roscoe RJ, Deddens JA, Salvan A, Schnorr TM [1995]. Mortality among 
Navajo uranium miners. Am J Public Health 85:535-540. 
 
A retrospective cohort study of 757 Navajo uranium miners was undertaken to 
assess mortality in this cohort compared to non-whites in New Mexico and 
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Arizona. Eligibility criteria included mining the Colorado Plateau for at least one 
month prior to 1964 and participation in the USPHS health surveys. No excess of 
leukemia was observed in the study cohort, as there were no observed cases 
(SMR=0.0, 95% CI=0-2.8). The SMR for NHL was also below expectation 
(SMR=0.6, 95% CI=0.01-3.3). 
 
Polednak AP, Frome EL [1981]. Mortality among men employed between 
1943 and 1947 at a uranium-processing plant. JOM 23:169-178.  
 
In a cohort mortality study examining the relationship between uranium exposure 
and cancer, workers employed at the Oak RidgeY-12 facility from 1943-1947 
were followed for vital status until 1974. SMRs for specific causes of death were 
calculated for these workers, where expected numbers were derived from age and 
calendar period adjusted death rates among US white males. With the exception of 
respiratory cancer, the cause-specific SMRs were all below expectation, indicating 
a healthy worker effect. The SMR for leukemia was 0.92, based on 40 cases (data 
on subtype not provided). SMRs for lymphosarcoma and other lymphatic 
malignancies were 0.67 and 0.57, respectively. Internal analysis was also 
performed, classifying workers by department: alpha and beta chemistry, all alpha 
and beta departments, electrical workers, and all other. The alpha and beta 
chemistry, all alpha beta departments, and electrical worker groups were thought 
to have exposure to uranium dust, whereas the “all other” group was considered 
unexposed. “SMRs” were calculated for each exposure group, where the expected 
numbers were derived from mortality rates in the “all other” category. The SMRs 
for leukemia by department subgroup were all below expectation.  
 
vi. Cosmic Radiation 
 
Gundestrup M, Storm HH [1999]. Radiation-induced acute myeloid 
leukaemia and other cancers in commercial jet cockpit crew: a population-
based cohort study. Lancet 354:2029-2031.  
 
Risk of cancer from exposure to cosmic radiation among airline crews was 
investigated in this study. Cosmic radiation consists of neutron and gamma 
radiation; the dose received by flight crews is estimated to be 3-6 mSv/year. The 
dose of cosmic radiation received is dependent on flight hours, flight altitude and 
latitude, and solar activity. 3,877 individuals with Danish cock-pit crew licenses 
were identified for follow-up. The standardized incidence ratio (SIR) for CLL, 
using Denmark incidence rates, was 1.3 (95% CI=0-7.2) for jet crews, based on 1 
case. There were no cases of CLL among non-jet crews. SIRs by flight hours 
showed that the CLL case occurred in the highest exposure category of ≥ 5,000 
flight hours (SIR=1.3). Small numbers of cases limited the ability to detect any 
significant effect of cosmic radiation.  
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Band PR, Le ND, Fang R, et al. [1996]. Cohort study of Air Canada pilots: 
mortality, cancer incidence, and leukemia risk. Am J Epidemiol 143:137-143.  
 
In this cohort study, 2,740 Air Canada pilots, employed at least 1 year after 1950, 
were followed until 1992. SMRs and SIRs were calculated for leukemia, using 
mortality and incidence rates of the Canadian male population to obtain expected 
numbers. The SMR for all leukemia was below expectation (0.86, 3 cases), 
whereas the SMR for myeloid leukemia was higher than expected, at 1.32 (2 
cases), though not significantly. SIRs for leukemia were elevated: the SIR for all 
leukemia was 1.65 (90% CI=0.86-2.88, 9 cases), the SIR for leukemia excluding 
CLL was 1.88 (90% CI=0.80-3.53, 7 cases), the SIR for CLL was 1.15 (90% 
CI=0.20-3.61, 2 cases), and the SIR for myeloid leukemia was 2.93 (90% CI=1.37-
5.50, 7 cases). 
 
b. Non-Ionizing Radiation 
i. EMF 
Floderus B, Persson T, Stenlund C, et al. [1993]. Occupational exposure to 
electromagnetic fields in relation to leukemia and brain tumors: a case-
control study in Sweden. Cancer Cause Control 4: 465-476. 
 
A case-control study design was used to evaluate the relationship between 
occupational exposure to electro-magnetic fields (EMF) and the outcomes of 
leukemia and brain cancer. Eligible cases and controls were chosen from the study 
base of all men who were ages 20-64, employed, and living in mid-Sweden, in the 
year 1980. From this cohort, cases of leukemia and brain cancer occurring between 
1983 and 1987 were eligible for inclusion in the study. 850 such cases (250 
leukemias, 112 CLL) were identified (using the Cancer Registry) and 2 controls 
per case were selected matching on age. A questionnaire to obtain data on work 
history, area of residence, smoking status, and exposure to benzene, ionizing 
radiation, and solvents, was administered to the study subjects. The workplace of 
the task held the longest during the 10 years prior to diagnosis of the case (primary 
exposure) was identified from the questionnaire, enabling the researchers directly 
measure the EMF of the identified workplaces with a dosimeter. EMF exposure 
was divided into quartiles in the analysis. The CLL risk increased with increasing 
EMF exposure upon comparing the referent quartile (Q1) to the exposed quartiles, 
though no test of trend was reported (Q2/Q1 odds ratio (OR)=1.1(95% CI=0.5-
2.3), Q3/Q1 OR=2.2 (95% CI=1.1-4.3), Q4/Q1 OR=3.0 (95% CI=1.6-5.8), 90th 
percentile (P90) OR=3.7 (95 %CI=1.8-7.7)). By stratifying singly by the potential 
confounders, the authors concluded that “the results were not changed when 
controlling for the confounding factors considered.”  
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Gilman PA, Ames RG, McCawley MA [1985[. Leukemia risk among US white 
male coal miners. J Occup Med 27:669-671. 
 
A case-control study was undertaken to assess the relationship between 
occupational EMF exposure and leukemia. Coal miners were studied, as this group 
works around high voltage power distribution lines, step-down transformers and 
converters, and electronic trolleys. Study subjects were identified from four 
National Institute for Occupational Safety and Health (NIOSH) cohorts of coal 
miners, where all subjects were deceased. Forty cases of leukemia were identified 
from this cohort; 4 controls (coal miners dying from a cause other than cancer or 
accident) were selected for each case, matching on birth year and age at death. A 
dichotomous exposure scheme was used, where greater than or equal to 25 years 
employment as a coal miner was considered exposed and less than 25 years 
employment as a coal miner was considered unexposed. A significant increase in 
leukemia risk was observed for all leukemia (OR=2.53). The OR for CLL was 
6.33 (p<0.05) comparing long term coal mining workers to those with <25 years 
employment. Analysis by smoking status and analysis by pneumoconiosis revealed 
no significant difference in exposure between cases and controls, thus the authors 
concluded “the increased risk observed for ‘all leukemia’ cannot be related to 
cigarette smoking (OR=1.02 not significant) or to coal workers’ pneumoconiosis 
(OR=0.15, not significant).” The researchers do acknowledge that exposure to 
chemicals, like benzene, could account for the observed increase in leukemia.  
II. Environmental Radiation Exposure 
a. Atomic Bomb Survivors 
Little MP, Weiss HA, Boice Jr JD, et al. [1999]. Risks of leukemia in Japanese 
atomic bomb survivors, in women treated for cervical cancer, and in patients 
treated for ankylosing spondylitis. Radiat Res 152:280-292.  
 
In a pooled analysis of three cohorts (283,139 individuals) including atomic bomb 
survivors, women treated for cervical cancer, and patients treated for ankylosing 
spondylitis, 383 leukemias were observed. Models were fit separately and combined 
by leukemia subtype (AML, ALL, and CML). “The most parsimonious dose-response 
model fitted to the three datasets had a purely quadratic term combined with an 
exponential cell sterilization term, together with adjustments to the RR for time after 
exposure and attained age.” CLL was excluded from the analysis as there was no 
excess risk from this leukemia subtype in the atomic bomb studies, nor in the studies 
of medical exposures; the RR for CLL comparing irradiated patients to non-irradiated 
patients was 1.03 (90% CI=0.3-3.9) in the cervical cancer study and 1.44 (95% 
CI=0.62-2.79) in the ankylosing spondylitis study. The authors comment that “the 
absence of risk of CLL suggests a marked heterogeneity in the radiation risk for 
various subtypes of leukemia, which is further reinforced by the finding of significant 
heterogeneity in the optimal model parameters in our analysis of three main radiogenic 
subtypes (AML, ALL, CML).” 
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Hoel DG, Li P [1998]. Threshold models in radiation carcinogenesis. Health Phys 
75: 241-250.  
 
The authors fitted the total leukemia model devised by Preston et al. (linear quadratic 
in form) to the A-Bomb Life Span Study (LSS) data to determine whether the model 
was effective in predicting leukemia risk at low doses of radiation. The researchers 
found that the model over-predicted leukemia incidence in the lowest dose group; the 
predicted values were 30-60% greater than the observed values. This suggests that the 
dose-response may not be linear at low doses. Upon adding a term to the model to 
account for a threshold effect, it was found that this model provided a better fit to the 
data. The authors report that the estimated threshold values for leukemia appear to be 
in the range of 0.05-0.10 Sv.  
 
Little MP, Muirhead CR [1998]. Curvature in the cancer mortality dose response 
in Japanese atomic bomb survivors: absence of evidence of threshold. Int J 
Radiat Biol 74:471-480.  
 
The authors fitted the atomic bomb survivor LSS data to various models to determine 
the best fitting model to describe leukemia incidence. The linear-threshold model, 
(where dose response is assumed to be linear above the threshold) estimates a 
threshold value of 0.16, which was found to be significantly different from zero (value 
for no-threshold effect). But upon adding a quadratic term to the linear-threshold 
model, the threshold estimate was found to be non-significant, whereas the quadratic 
term improved model fit. Therefore the authors concluded that “the most parsimonious 
description of the leukemia dose response is provided by a linear-quadratic function of 
dose.” 
 
Akiyama M [1995]. Late effects of radiation on the human immune system: an 
overview of immune response among the atomic-bomb survivors. Int J Radiat 
Biol 68:497-508. 
 
An update is provided on the late effects of radiation on the immune systems of 
atomic bomb survivors. T-cell abnormalities were noted among survivors exposed to 1 
gray (Gy) and greater. Such abnormalities included a decreased proportion of CD3+ 
T-cells in the periphery and an increased number of CD4- CD8- (double negative) αβ+ 
T-cells (observation period 1987-91). A defective T-cell response to mitogens and 
alloantigens was noted in the observation period of 1974-85. B-cell abnormalities 
were also present in atomic bomb survivors, including increased numbers in the 
periphery (1987-91), increased serum immunoglobulin (Ig) A in females (1987-89) 
and increased IgM and rheumatoid factor in both males and females, and an increased 
level of anti-Epstein Barr virus (EBV) antibody (1987-90). 
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Preston DL, Kusumi S, Tomonaga M, et al. [1994]. Cancer incidence in atomic 
bomb survivors part III: leukemia, lymphoma and multiple myeloma, 1950-1987. 
Radiat Res 137:S68-S97. 
 
Of 339 leukemias occurring in the LSS cohort of atomic bomb survivors, 261 cases 
were eligible for analysis. Nonresident cases, second primary cases, and cases with 
diagnosis dates outside the follow-up period (diagnosis <1950 or >1987) were 
excluded from analysis. Analysis was further restricted to cohort members with a Dose 
System 1986 (DS1986) dose estimates between 0-4 Gy; thereby excluding 24 cases 
with unknown dose and 6 cases with dose >4 Gy. There were 17 leukemias in 
Hiroshima residents characterized as “other”, 15 were included in the analysis (4 CLL, 
7 acute leukemia unspecified, 2 HCL, and 2 myelodysplastic syndrome). “As a result 
of the Leukemia Registry-FAB [French-American-British] reclassification, most of the 
cases previously classified as CLL or ‘lymphosarcoma leukemia’, including many of 
the cases in the earlier report by Finch and Hoshino, are now classified as ATL [adult 
T-cell leukemia].” For the “other” leukemia grouping, the authors report a significant 
linear dose response for the Hiroshima data (p<0.004). The risk for “other” leukemia 
was consistent across age at exposure and time since exposure categories. Only 0.03 
excess “other” leukemia cases occurred among those exposed to less than 0.01 Gy; 
however 5.54 excess cases were observed among those exposed to 0.01-4 Gy. Also, 
there were significant risk differences by sex for “other” leukemia; females had an 
excess absolute risk (EAR) of 0.44 per 104 person-year (PY) Sv (95% CI=0.14-0.92), 
whereas males showed a negative EAR estimate (upper 95% bound=0.20). For NHL, 
the EARs for men and women were 0.56 (95% CI=0.08-1.39) and 0.00 (upper 95% 
bound=0.28) cases per 104 PY Sv, respectively.  
 
Kato H [1988]. Radiation-induced cancer and its modifying factor among A-
bomb survivors. Unusual Occurrences as Clues to Cancer Etiology. R.W. Miller 
et al, Japan Sci Soc Press, Tokyo/Taylor & Francis, LTD., pp 117-124. 
 
This study described temporal patterns in relation to leukemia risk. An increase in 
leukemia risk emerged in both Hiroshima and Nagasaki about 3 years after the bombs 
were dropped, where the peak incidence occurred in 1951-1952. Incidence of 
leukemia has since declined, however an elevation of leukemia in Hiroshima was 
found to be present in the most recent atomic bomb study update (1981-1985). The 
author observed that the “younger the age ATB [at the time of the bomb], the greater 
the risk of leukemia during the early period, and the more rapid the decline thereafter. 
Moreover, the length of the latency period seems to decrease with dose.” The article 
also evaluated the appropriateness of the absolute risk model versus the relative risk 
model in predicting leukemia risk. In an absolute risk model the excess deaths are 
assumed to be constant by age at death. The relative risk model assumes that the 
relative risk is constant by age at death throughout life, but that the excess deaths 
increase with age at death in proportion to age-specific mortality rates of the control 
population. By examining relative risk by ATB cohort and age at death, it was found 
that the relative risk remained essentially constant. By computing excess deaths by age 
ATB and age at death, it was found the excess deaths were not constant across age at 
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death categories, rather in each age ATB cohort excess deaths increased with age at 
death. This analysis suggests that the relative risk model is more appropriate in 
predicting leukemia risk in the atomic bomb survivors than is the absolute risk model. 
 
Tanaka K, Kamada N [1985]. Leukemogenesis and chromosome aberrations: de 
novo leukemia in humans with special reference to atomic bomb survivors. Acta 
Haematol Jpn 48:1830-1842. 
 
Chromosome aberrations were found in 10-30% of bone marrow and peripheral 
lymphocytes of apparently healthy atomic bomb survivors who were within 1 
kilometer of the hypocenter of the bombing. In these heavily exposed survivors, a non-
random distribution of chromosome breakage was observed. There were 50 bands that 
demonstrated a significant increase in breakage frequency, including 11q22, 11q23, 
13q14, and 14q32.  
 
Ichimaru M, Ishimaru T, Belsky JL [1978]. Incidence of leukemia in atomic 
bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950-
1971. Radiat Res 19:262-282.  
 
This study examined the 136 cases of leukemia occurring between 1950 and 1971 in 
the leukemia registry cohort of 109,000 atomic bomb survivors. This report 
demonstrated that the “leukemogenic effect of atomic radiation, which has been 
declining since the peak was reached in 1951-1952, was still evident in the period 
1965-1971, especially among Hiroshima survivors.” Only 1 case of CLL was reported 
in the Leukemia Registry; the age ATB was 37 and the age of onset of CLL was 58. 
The individual was a Nagasaki survivor with a reported dose of “0” for both gamma 
and neutron exposure.  
 
Ishimaru T, Otake M, Ichimaru M [1978]. Incidence of leukemia among atomic 
bomb survivors in relation to neutron and gamma dose, Hiroshima and Nagasaki, 
1950-1971. Radiation Effects Research Foundation Technical Report 14-77. 
 
Models describing the dose curve of the effects of radiation on leukemia were 
evaluated using data from the atomic bomb Leukemia Registry, from 1950-1971. The 
first model considered a linear dose response for both gamma and neutron radiation, 
whereas the second model had a linear term for neutron exposure and a squared term 
for gamma exposure. Risk estimates by kerma dose from model 1 and model 2 for all 
leukemia for gamma radiation were calculated to be 1.08 cases per million person-
years per rad (PYR) and 0.00364 cases per million PYR2. For neutron related 
leukemia risk, the estimates from models 1 and 2 were 6.13 and 7.37 cases per million 
PYR, respectively. The authors concluded that “data on leukemia in Hiroshima and 
Nagasaki for the period 1950-1971 do not point clearly to a dose response model 
which is linear or one which is quadratic with respect to gamma radiation.” The data 
did suggest a difference in chronic granulocytic leukemia (CGL) risk with respect to 
type of radiation exposure; “the incidence of CGL appears to depend principally upon 
the neutron dose.” 
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Finch SC, Hoshino T, Itoga T, et al. [1969]. Chronic lymphocytic leukemia in 
Hiroshima and Nagasaki, Japan. Blood 33:79-86. 
 
In Japan, CLL comprises 2-3% of all leukemia, whereas it the US this figure is about 
30%. The authors estimated the incidence rate of CLL in Japan to be 0.8 per million 
per year. In the US the incidence rate is 20-fold higher, with an estimated rate of 15 
per million per year. Six CLL cases were identified in Nagasaki residents from 1946-
1965, yielding a Nagasaki-specific incidence rate of 0.88 per million per year. Five of 
these residents were within the city limits ATB, but all were more than 3,000 meters 
from the hypocenter (estimated dose <1 rad). The mean year of diagnosis of these 5 
cases was 1961 (range=1959-1965), with an average age of onset of 56 years 
(range=51-61). Where the surrounding areas of Nagasaki were included, 6 more cases 
of CLL were identified in 1946-1965 (no incidence rate given). In Hiroshima there 
were no cases of CLL reported among residents during 1946-1965; however when 
surrounding areas were included, 2 cases of CLL were found. The authors state that 
“reports from the ABCC [Atomic Bomb Casualty Commission] have failed to 
demonstrate an excessive leukemia incidence beyond 1,600 meters from the 
hypocenter. If exposure to ionizing radiation had been an important factor, one would 
have expected chronic lymphocytic leukemia to have developed more frequently in the 
proximally exposed populations of both cities. This has not been observed.” The study 
thus concluded that there is no evidence to suggest that the bombings increased risk of 
development of CLL in Hiroshima and Nagasaki. 
 
b. Nuclear Test Fallout 
  
Boice JD, Lubin JH [1997]. Occupational and environmental radiation and 
cancer. Cancer Cause Control 8:309-322. 
 
In this review the authors discuss research which has explored the relationship 
between exposure to nuclear fallout and risk of cancer. The authors describe the 
1990 study by Stevens et al.: “a more recent case-control study of 1,000 
individuals who died of leukemia in southwest Utah …found a weak, but non-
significant, association between estimated bone marrow dose and all 
leukemia…While acute leukemia following childhood exposure was increased, 
similar levels of risk for chronic lymphocytic leukemia (CLL), a tumor not shown 
to be elevated after irradiation, tempers the causal interpretation.” 
 
Stevens W, Thomas DC, Lyon JL, et al. [1990]. Leukemia in Utah and 
radioactive fallout from the Nevada Test Site. JAMA 264:585-591. 
 
Dose from nuclear fallout from the Nevada test site was estimated to assess 
leukemia risk in this population-based case-control study. Eligibility criteria 
included residing in Utah at time of death (with death between 1/1/1952 and 
1/31/1981), birth before 11/1/1958, and membership in the Church of Jesus Christ 
of Latter-day Saints during 1950-58 (these records were used to determine 
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residence prior to fallout exposure). Cases had to have mention of leukemia 
somewhere on their death certificate, except for CLL, where CLL had to be cited 
as the underlying cause of death. 1,177 leukemia cases and 5,330 controls were 
identified and assigned dose categories of low (0-2.9 mGy), intermediate (3-5.9 
mGy), and high (6-30.0 mGy). Analysis was performed by leukemia subtype. The 
OR for CLL for the intermediate and high groups, using the low category as the 
referent group, were 1.06 (95% CI=0.76-1.50) and 1.70 (95% CI=0.61-4.73), 
respectively. The trend test for CLL was not significant (p>0.10). Analyses for 
ALL and for leukemia excluding CLL showed increased RRs over dose groups, 
where the tests of trend were significant at the 10% level (ALL p=0.068, leukemia 
excluding CLL p=0.084). 
 
III. Radiotherapy and Risk of CLL as a Secondary Cancer 
 
dos Santo Silva I, Malveiro F, Jones ME, Swerdlow AJ [2003]. Mortality after 
radiological investigation with radioactive Thorotrast: a follow-up study of up to 
fifty years in Portugal. Radiat Res 159:521-534. 
 
Portuguese patients who were administered Thorotrast during 1928-1959 and a 
comparison group of patients who received non-radioactive contrast agents were followed 
until 1996. An effort was made to frequency-match the control group to the Thorotrast 
group on sex, age, calendar period and underlying condition for treatment. The author’s 
note this effort was not fully achieved as Thorotrast was the most common radiographic 
contrast agent administered before 1940. Of the 1,096 patients who were administered 
Thorotrast systemically, 6 developed leukemia. One case of leukemia occurred among the 
1,014 controls. As there were no cases of the CLL subtype, analysis was specific for 
leukemia excluding CLL. The SMR for leukemia excluding CLL for those systematically 
exposed was 8.17 (p<0.001), whereas the SMR for leukemia excluding CLL for the 
control group was 0.80. The RR for leukemia excluding CLL, comparing the Thorotrast 
exposed group to the unexposed group, was significant at 10.2, though the confidence 
interval was wide (95% CI=1.24-471). For hematologic disorders other than leukemia, the 
SMR for the Thorotrast group was 10.3 (95% CI=3.80-22.5), based on 4 cases of NHL, 1 
case of Hodgkin’s disease and 1 case of MM. No cases of other hematologic disorders 
were observed in the comparison group. 
 
Fowble B, Hanlon A, Freedman G, et al. [2001]. Second cancers after conservative 
surgery and radiation for stages I-II breast cancer: identifying a subset of women at 
increased risk. Int J Radiation Oncology Biol Phys 51:679-290. 
 
The study included 1,253 breast cancer patients who were treated with conservative 
surgery and radiation between 1978 and 1994 at the Fox Chase Cancer Center or the 
University of Pennsylvania. 167 patients developed a second cancer. A total of 3 
leukemias were observed in the cohort, yielding a 10 year cumulative incidence for 
leukemia of 0.2%. Two of the 3 leukemias were of the CLL subtype. One of these CLLs 
received adjuvant therapy with tamoxifen in addition to their surgery and radiation 
treatment. Four cases of NHL arose in the cohort (cumulative incidence not given). 
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Neugut AI, Ahsan H, Robinson E, et al. [1997]. Bladder carcinoma and other second 
malignancies after radiotherapy for prostate carcinoma. Cancer 79:1600-1604. 
 
This retrospective cohort study investigated the relationship between radiation treatment 
(RT) for prostate cancer and the development of a second primary cancer. A cohort of 
141,761 prostate cancer patients was identified from the Surveillance, Epidemiology, and 
End Results program (SEER) data. 34,889 of the patients in this cohort received RT. As 
RT for prostate cancer is focused in the pelvic area, second cancers considered in the 
analysis included bladder, rectal and acute non-lymphocytic leukemia (ANL). CLL, which 
has not been demonstrated to be associated with radiation exposure, was analyzed as a 
negative control. SIRs were calculated to estimate relative risk. “The ratio of the observed 
to the expected number of cases gives an estimate of the relative risk for developing a 
second primary cancer for patients with primary prostate carcinoma compared with people 
without a prior primary tumor.” Bladder cancer was significantly elevated for the RT 
group diagnosed more than 8 years following RT (RR=1.5, 95% CI=1.1-2.0), but not for 
the non-RT group (RR=1.0, 95% CI=0.7-1.2) The authors also reported a non-significant 
increased risk of CLL more than 8 years after RT for prostate cancer (RR=1.3, 95% 
CI=0.5-2.9, 6 observed cases). 
 
Chao CKS, Lai PP, Michalski JM, et al. [1995]. Secondary malignancy among 
seminoma patients treated with adjuvant radiation therapy. Int J Radiation 
Oncology Biol Phys 33:831-835. 
 
This study examined 128 patients with seminoma of the testis, who had undergone RT, to 
determine if the development of secondary cancer was increased in this study group 
compared to the general population. The median age of the study population was 37 years 
with a median follow-up time of 11.7 years. Expected numbers of secondary cancers were 
estimated from the SEER data based on the Connecticut tumor registry. Nine cases of 
secondary cancer arose in the study population, yielding an elevated, but non-significant, 
SIR of 2.09 (95% CI=0.39-3.35). A significantly increased SIR was observed when 
stratifying by latency period, where the 11-15 year latency group showed an SIR of 4.54 
(95% CI=1.22-11.63). Of the 9 secondary cancers, one was a case of CLL. The CLL case 
was 50 years old at the age of diagnosis for seminoma and developed CLL 2 years after 
RT. As there were so few cases of secondary cancer, the effect of RT on CLL could not be 
isolated. Furthermore, the authors acknowledge that it cannot be determined whether the 
increase in secondary cancers was a result of RT or rather a result of a biological 
disposition to developing secondary cancers. 
 
Holowaty EJ, Darlington GA, Gajalakshmi CK, et al. [1995]. Leukemia after 
irradiation for endometrial cancer in Ontario. Cancer 76:644-649.  
  
A nested case-control study investigated the relationship between RT and leukemia risk 
among endometrial cancer patients. 13,843 women who were diagnosed with endometrial 
cancer during 1964-1987, and who had survived at least one year following diagnosis, 
were identified via the Ontario Cancer Registry. Leukemia was subsequently diagnosed 
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among 47 of these women (15 CLL, 20 acute non-lymphocytic leukemias (ANLL), 2 
ALL, and 10 CML). Controls were matched to cases on age and calendar year of 
endometrial cancer diagnosis (4 controls per case for ANLL, ALL, and CML; 2 controls 
per case for CLL). In this study, CLL was “retained for the purpose of detecting a 
significant ascertainment bias.” The authors report that the “association between 
radiotherapy and CLL approached unity” (data not shown).  
 
Curtis RE, Boice Jr JD, Stovall M, et al. [1994]. Relationship of leukemia risk to 
radiation dose following cancer of the uterine corpus. J Natl Cancer I 86:1315-1324. 
 
A case-control study was performed to evaluate the relationship between RT and the 
development of leukemia. 218 cases of leukemia (57 CLL) were observed in a cohort of 
110,000 women with cancer of the uterine corpus. The mean age of the cohort was 62 
years, enabling the researches to study older populations. A 1:4 case to control ratio was 
employed in this study to maximize power, yielding 775 controls matched on age at 
diagnosis and race. Among the CLL cases, 35 of 54 received RT for cancer of the uterine 
corpus, whereas 84 of 127 matched controls received RT for cancer of the uterine corpus 
(matched RR=0.90, 95% CI=0.4-1.9). Subsequent analyses excluded CLL; no results were 
presented for CLL by dose category. A significant risk was observed for leukemia 
excluding CLL (RR=1.92, 95% CI=1.3-2.9). Regarding a dose response relationship 
between radiation and leukemia (excluding CLL), the authors concluded that “overall the 
pattern of risk in relation to dose was erratic and was most consistent with a constant 
increased risk across the entire dose range.” The authors also explored linear models and 
linear-exponential models for dose; both models yielded almost identical results. Risk did 
not appear to drop off at high doses, as the exponential “cell-killing” term did not 
contribute meaningfully to the model. Upon examination of age at exposure, the RRs for 
leukemia excluding CLL were found to be relatively constant across age groups.  
 
Griem ML, Kleinerman RA, Boice Jr JD, et al. [1994]. Cancer following 
radiotherapy for peptic ulcer. J Natl Cancer I 86:842-849.  
 
Patients treated for peptic ulcer at the University of Chicago during 1937-1965 were 
identified and categorized by RT status. 1,831 of the patients received RT, whereas 1,778 
did not. The RR for leukemia and aleukemia (ICD-8 204-207), adjusting for sex, age, 
smoking, calendar year and time since entry in the cohort, was 3.28 (95% CI=1.0-10.6). 
For NHL, the RR comparing the RT exposed group to the non-RT group was 1.88 (95% 
CI=0.07-5.0). RT was found to increase the risk of all cancers by 50%. The RR (1.53) 
remained constant when stratifying by time since irradiation, suggesting that “radiation 
damage persists for many years.” The authors did note that the “patients treated with 
radiotherapy appeared to be less fit than those treated by other means, and they were less 
likely to be candidates for surgery”, which may have contributed to the observed 
relationship between RT and cancer. 
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Andersson M, Carstensen B, Visfeld J, et al. [1993]. Leukemia and other related 
hematological disorders among Danish patients exposed to thorotrast. Radiat Res 
134:224-233.  
 
Of 1,003 Danish patients who were treated with thorotrast during 1935-1947 and followed 
until 1992, 37 developed leukemia. There were 2 cases of CLL where the age at injection 
of thorotrast was 42 and 48, respectively. The age at diagnosis of both cases was over 70 
years, and the diagnosis of the cases occurred 22 and 34 years after injection (mean 
dose=1.68 Gy). CLL was excluded from all analysis.  
 
Inskip PD, Kleinerman RA, Stovall M, et al. [1993]. Leukemia, lymphoma and multiple 
myeloma after pelvic radiotherapy for benign disease. Radiat Res 135:108-124. 
 
A multi-center retrospective cohort study was undertaken in New England to assess the 
relationship between RT and cancers of the blood or lymph. 12, 955 women treated for 
benign gynecological disorders (BGD) between 1925 and 1965 were eligible for inclusion 
in the study. Of these subjects, 9,770 received RT, whereas 3,185 did not. CLL and 
lymphocytic leukemia (LL) were grouped together in the SMR analyses. Mortality due to 
CLL and LL for RT BGD patients was found to be significantly higher than that of the US 
population (SMR=1.8); a similar SMR (1.6), though non-significant, was also observed 
among the non-RT BGD patients. An internal comparison of patients receiving RT 
compared to those not receiving RT showed a non-significant RR of 1.1 for CLL and LL 
(90% CI=0.5-3.0). The RR for NHL (0.90, 90% CI=0.6-1.6) also did not show any 
significant effects of radiation. Further SMR analyses for CLL and LL by latency were 
performed, demonstrating SMRs that “fluctuated erratically over time after treatment for 
BGD.” The SMRs for both the RT group and the non-RT group showed excesses of CLL 
and LL deaths compared to the US population (time since treatment 0-5 years: RT 
SMR=2.3, non-RT SMR=5.2; 5-10 years: RT SMR=0 (no cases), non-RT SMR=0 (no 
cases); 10-20 years: RT SMR=2.9, non-RT SMR=3.2; 20-30 years: RT SMR=1.0, non-RT 
SMR=0 (no cases); >30 years: RT SMR=2.2, non-RT SMR=1.5). RRs comparing the RT 
group to the non-RT group by time since first treatment were not provided. Additional 
analyses revealed “no evidence of a monotonic trend in the SMR with mean marrow dose 
for any of the lymphoreticular cancers” and that “all of the excess mortality due to CLL 
and LL among radium-treated patients occurred among women whose mean marrow dose 
exceeded 50 cGy [centigray], but the association between SMR and dose ≥ 0 was not 
significant (p>0.09).” The authors observed little evidence of an association between 
CLL, Hodgkin’s disease, NHL, or MM and RT; however, the researchers’ findings did 
support an association between RT and acute myelocytic or monocytic leukemia. 
 
Hellbardt A, Mirimanoff RE, Obradovic M, et al. [1990]. The risk of second cancer (SC) 
in patients treated for testicular seminoma. Int J Oncology Biol Phys 18:1327-1331. 
 
A study of patients treated at the Geneva University Cantonal Hospital during 1951-1986 
for testicular seminoma was conducted to assess the relationship between RT and second 
cancer. The study cohort included 116 patients treated with RT for testicular seminoma, of 
which 11 developed a second cancer. None of the second cancers had prior chemotherapy 
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treatment. The distribution of the second cancers was as follows: 8 solid tumors, 2 NHL 
and 2 leukemias (1 CLL, 1 AML). The O/E for leukemia, where the expected numbers 
were derived from the leukemia incidence of a similar age group of Danish males, was 
13.37 (p=0.006). However, when the leukemias were considered separately, the 
associations were not significant (data not shown). The NHL cases were not found to be in 
excess.  
 
Inskip PD, Monson RR, Wagoner JK, et al. [1990]. Leukemia following radiotherapy 
for uterine bleeding. Radiat Res 122:107-119. 
 
The association of RT and cancer was examined in this study of women treated with RT 
for BGD. Eligible cases (4,483) included women diagnosed with BGD from 1925-1965 in 
selected hospitals in Massachusetts and Rhode Island. Follow-up was through 1/1/1985, 
except for 515 women whose records were destroyed in a flood and did not allow 
additional tracing after 1967. The overall mortality rate for the BGD cohort did not differ 
from that of the general population (SMR=1.0, 95% CI=1.0-1.1); however the SMR for 
cancer was significantly increased (SMR=1.3, 95% CI=1.2-1.4). The BGD group 
experienced a 2-fold excess of leukemia deaths compared to the general female 
population. The SMR for CLL and LL was also found to be significantly elevated in this 
study (SMR=2.1, 95% CI=1.96-8.14). This SMR was based on 9 cases (6 CLL, 3 LL) all 
of whom received an estimated dose greater than 50 cGy. CLL and LL could not be 
separated in the analyses as individual rates were not available. The authors speculate that 
women with BGD were under closer medical surveillance than the US population, and 
that “CLL, as an indolent malignancy, was detected more frequently.” The authors state 
that “in view of the low case fatality rate and the fact that it is predominantly a disease of 
old age, there is clearly room for differential misclassification error to have occurred.” 
 
Curtis RE, Boice JD, Stovall M, et al. [1989]. Leukemia risk following radiotherapy 
for breast cancer. J Clin Oncol 7:21-29. 
 
A nested case-control study was undertaken to examine risk of leukemia following RT for 
breast cancer. From a cohort of 22,753 women diagnosed with breast cancer between 
1935 and 1972 in Connecticut, 48 leukemias were identified via the Connecticut Tumor 
Registry. Ten of these leukemias were of the CLL subtype. Controls were matched to 
leukemia cases 2:1 on age and calendar year of diagnosis of breast cancer. The matched 
RR describing the association between RT and development of CLL was elevated, though 
not significantly (RR=1.84, 90% CI=0.5, 6.7). For leukemia excluding CLL, the RR 
approached unity at 1.02 (95% CI=0.5-2.1). The authors limited further analyses by dose 
and time since diagnosis to leukemia excluding CLL. 
 
Boice Jr JD, Engholm G, Kleinerman RA, et al. [1988]. Radiation dose and second 
cancer risk in patients treated for cancer of the cervix. Radiat Res 116:3-55. 
 
From a multinational cohort of 150,000 cervical cancer patients, 4,188 second cancers 
arose. A matched case-control study was undertaken to evaluate the risk of second cancer 
following RT, where 6,880 controls were selected. The matched RR for CLL was 1.03 
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(90% CI=0.3-3.9), whereas the matched RR for leukemia excluding CLL was 
significantly elevated (RR=2.02, 90% CI=1.0-4.2). In this study, the risk of developing 
NHL among those receiving RT was 2.5 times that of those not receiving RT (90% 
CI=0.8-7.6). Risk estimates by dose were calculated for 1 year survivors of cervical 
cancer. For CLL and leukemia excluding CLL the excess absolute risks were 0.00 (90% 
CI=0.00-0.17) and 0.10 (90% CI=0.00-0.31), respectively. The authors acknowledge that 
the small number of unexposed cases, due to receipt of RT by the majority of the cervical 
cancer patients, was a statistical limitation of the study. 
 
Boice Jr JD, Blettner M, Kleinerman RA, et al. [1987]. Radiation dose and leukemia 
risk in patients treated for cancer of the cervix. J Natl Cancer I 79:1295-1311. 
 
A case-control study was performed to assess the risk of leukemia following RT among 
patients treated for cervical cancer. The study utilized data from 17 cancer registries and 
16 oncologic clinics from Canada, Europe, and the US to identify cases and select 
controls. 195 cases of leukemia were identified, including 52 CLL. Controls were matched 
4:1 to cases on cervical cancer diagnosis age and year. The matched RR for CLL 
comparing the frequency of RT among cases and controls was 1.03 (90% CI=0.3-3.9). 
Further analyses excluded CLL.  
 
Holm LE, Wiklund KE, Lundell GE, et al. [1989]. Cancer risk in population 
examined with diagnostic doses of 131I. J Natl Cancer I 81:302-306. 
 
35,074 people treated with radioactive iodine in Sweden, between 1951 and 1969, were 
followed though 1984 to assess whether radioactive iodine treatment induced cancer. The 
Swedish Cancer Registry was used to determine incidences of cancer following 131I 
treatment, excluding cancers developing less than 5 years after the treatment. The overall 
SIR of 1.01 (95% CI=0.98-1.04) indicated that the incidence of cancer among the study 
cohort was not significantly different than expected based on US cancer incidence rates. 
Leukemia incidence, however, was elevated. Separating CLL from non-CLL revealed 
significant elevations for both leukemia groups with SIRs of 1.30 (36 cases) and 1.38 (83 
cases), respectively. Further SIR analyses by number of years of follow-up demonstrated a 
significant risk for leukemia only in the group followed 15-19 years (SIR=1.60, 95% 
CI=1.12-2.22). With respect to this result the authors state that, “radiogenic 
leukemia…would be expected to be highest within 5-9 years and then decrease; this 
pattern is not consistent with our finding the highest risk 15-19 years after exposure”. 
Results by years of follow-up were not presented for CLL and non-CLL leukemia 
subgroups. The researchers speculate that closer medical surveillance of the study 
population may account for the observed findings and that “without the 131I examination, 
the indolent tumors detected would not otherwise have led to clinically apparent disease.” 
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Boice JD, Day NE, Anderson A, et al. [1985]. Second cancers following radiation 
treatment for cervical cancer: an international collaboration among cancer 
registries. J Natl Cancer I 74:955-975. 
 
A study of second cancers following treatment of cervical cancer was performed using  
data from 15 cancer registries in 8 countries. From the cohort of 182, 040 cervical cancer 
patients, 22 were subsequently diagnosed with CLL. The O/E ratios for CLL, where the 
expected numbers were based on rates from the general population, were 0.70 (16 cases) 
for patients receiving RT and 2.00 (6 cases) for those not receiving RT. Restricting the 
data to follow-up greater than 10 years gave an O/E for CLL among those receiving RT of 
0.90, based on 9 observed cases. No cases of CLL were seen among the non-RT group 
followed for greater than 10 years, though 1.2 cases were expected based on the age and 
calendar period specific rates for the general female population. An excess of NHL was 
seen among the cervical cancer patients followed for more than 10 years who received RT 
(O/E=1.3), but a deficit was observed for the women not treated with RT (O/E=0.3). 
Neither CLL nor NHL demonstrated a significant trend when analyzed by time since first 
RT treatment (CLL: p=0.141, NHL: p=0.416).  
 
Harvey EB, Brinton LA [1985]. Second cancer following cancer of the breast in 
Connecticut, 1935-1982. Natl Cancer Inst Monogr 68:99-112. 
 
Examination of 41,109 women diagnosed with breast cancer in Connecticut between 1935 
and 1982 revealed that 3,984 of the women had been diagnosed with a subsequent cancer. 
The authors report that the risk for CLL, among women with breast cancer, was below 
expectation, with an RR of 0.5 (95% CI=0.2-1.0). The RR for NHL was also below the 
null value (RR=0.90). The RRs restricted to patients receiving RT were 1.2 and 1.7 for 
CLL and NHL, respectively. The RRs were lower among women not receiving RT (CLL: 
RR=0.4, NHL: RR=0.7).  
 
IV. Diagnostic X-Rays and Risk of CLL 
 
Boice JD, Morin MM, Glass AG, et al. [1991]. Diagnostic x-ray procedures and risk 
of leukemia, lymphoma and multiple myeloma. JAMA 265:1290-1294. 
 
A case-control study of members of two health plans was conducted to assess the 
relationship between RT and leukemia, lymphoma, and MM. Diagnoses were available 
between 1959 and 1979 for the Portland, Oregon health plan and between 1956 and 1982 
for the northern California plan. Eligibility was restricted to subjects who had not received 
RT or chemotherapy for a prior malignancy. A 2:1 and 1:1 control to case match was 
performed for Portland members and California members, respectively, where subjects 
were matched on sex, age, plan, years in plan, and year membership began. Dose was 
estimated upon examination of each subject’s x-rays and an exposure score was assigned 
from 0-4. The RRs for CLL comparing ever exposed to never exposed, for various lags, 
were 0.66 (95% CI=0.4-1.2, 3 month lag), 0.56 (95% CI=0.56, 2 year lag), 0.67 (95% 
CI=0.4-1.3, 4 year lag) and 0.51 (95% CI=0.30-0.90, 5 year lag). The authors speculate 
this protective effect could be due to chance or ascertainment bias. The study did find that 
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NHL cases were more frequently exposed to x-rays than controls (RR=1.32, 3 month lag); 
however, the association disappeared after a 2 year lag was employed (RR=0.99). The 
study demonstrated some evidence that risk of MM increased concordant with diagnostic 
x-ray exposure level, as significant trends at the 10% level were seen irrespective of lag. 
 
Darby SC, Doll R, Gill SK, Smith PG [1987]. Long term mortality after a single 
treatment course with x-rays in patients treated for ankylosing spondylitis. Brit J 
Cancer 55:179-190. 
 
Of 14,106 patients treated with x-ray for ankylosing spondylitis in Great Britain and 
Northern Ireland between 1935 and 1954, 39 cases of leukemia were observed. The O/E 
based on age, sex, and calendar year specific mortality rates in England and Wales was 
3.17 for leukemia (p<0.001). A significant increased risk persisted 15 years after 
treatment (RR=1.87). No trend by age at exposure was observed in the leukemia data. 
Analysis of leukemia by subtype yielded an O/E ratio for CLL of 1.09 in the ≥ 15 years 
since exposure stratum, based on 2 cases. The CLL cases occurred 26 and 31 years after 
exposure, respectively, and both cases were treated between the ages of 25-34. The author 
acknowledges that these results are constrained because 1/3 of the leukemia deaths were 
not specified by subtype, including 6 cases of unspecified lymphatic.  
 
Gibson R, Graham S, Lilienfeld A, et al. [1972]. Irradiation in the epidemiology of 
leukemia among adults. J Natl Cancer Inst 48:301-311. 
 
A case-control study was undertaken to examine the relationship between diagnostic x-ray 
exposure and leukemia risk. The study consisted of 1,414 cases identified in the areas of 
upstate New York, Baltimore, and Minneapolis and 1,370 population controls from these 
areas. The age-adjusted RR demonstrated that male CLL cases (n=304) were more 
frequently exposed to diagnostic x-rays to the trunk than were controls (all RRs were 
below 1 for x-rays to all sites). When male exposure status was defined as 11+ x-rays to 
the trunk the RR was 1.03 (p=0.89), and when exposure status was defined as 16+ x-rays 
to the trunk the RR was 1.25 (p=0.56). A significant difference was observed between 
male cases and controls when exposure was defined as 21+ x-rays to the trunk. The RR 
was found to be 2.03 (p=0.02). Female CLL cases (n=170) had similar exposure to x-rays 
as did the controls. The only excess was for self-respondents with 21+ x-rays for all sites 
combined (RR=1.02, p=0.57). No categorical trend analysis was performed to determine 
whether increasing number of x-rays corresponded to increasing leukemia risk.  
 
V. CLL and Solvent Exposure 
 
Adengoke OJ, Blair A, Shu XO, et al. [2003]. Occupational history and exposure and 
the risk of adult leukemia in Shanghai. AEP 13:485-494.  
 
A case-control study of leukemias reported to the Shanghai Cancer Registry from 
6/1/1987-8/31/1989 was performed to identify risk factors for leukemia. There were 21 
cases of CLL, 81 ALL, 236 AML, and 79 CML. A questionnaire was distributed to the 
cases (or next of kin) and the 502 controls selected from the general population, to obtain 
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information on demographics, occupation, lifestyle factors, family history, education, and 
exposure to chemicals, radiation, and diagnostic x-rays. Results were presented by 
subtype of leukemia with the exception of CLL.  
  
Glass DC, Gray CN, Jolley DJ, et al. [2003]. Leukemia risk associated with low-level 
benzene exposure. Epidemiology 14:569-577. 
 
This study utilized a nested case-control design to examine the relationship between 
benzene exposure and lympho-hematopoietic cancer in a cohort of Australian male 
petroleum workers. From the conditional logistic regression analysis, the ORs for CLL 
were increased among the exposure groups compared to the referent category, though not 
significantly (referent ≤ 4 cumulative lifetime parts per million (ppm) years OR=1, 4-8 
ppm years OR=2.76 (95% CI=0.42-18.1), >8 ppm years OR=4.52 (95% CI=0.89-22.9)). 
This analysis was based on only 11 cases of CLL, thereby limiting the ability to detect a 
significant effect. 
 
Huebner WW, Schnatter AR, Nicolich MJ et al. [1997]. Mortality experience of a 
young petrochemical industry cohort: 1979-1992 follow-up study of US-based 
employees. JOEM 39:970-982. 
 
A retrospective cohort study of 81,746 former and current petrochemical workers was 
performed to determine whether these workers had increased mortality rates compared to 
the general US population. The cohort was relatively young, as only approximately 4% of 
the cohort had died. Cause-specific SMRs were calculated, stratified by race and sex, for 
the entire cohort and by job subtype. Overall, the cohort exhibited SMRs below 
expectation, indicative of a strong healthy worker effect. However, a non-significant 
elevation in mortality was seen for CLL across the entire cohort, where the SMR was 1.60 
(95% CI=0.85-2.73, 13 deaths). Of the 13 cases of CLL, 11 of these workers began 
employment between 1934 and 1955, worked at least 30 years, had greater than 35 years 
latency, and died between the ages of 56-76. The stratum specific SMR for CLL among 
white males employed prior to 1960 was 1.81 (95% CI=0.90-3.24). Nine of these 11 
workers had “some plant, field or laboratory experience, at least early in their careers. 
However, no patterns or consistencies were seen with regard to jobs, units, or specific 
chemical exposures.”  
  
Ireland B, Collins JJ, Buckley CF, Riordan SG [1997]. Cancer mortality among 
workers with benzene exposure. Epidemiology 8:318-320. 
 
4,172 male hourly workers beginning employment between 1940 and 1977 at the 
Monsanto Company plant in Sauget, Illinois were followed though 1991 to assess 
mortality associated with benzene exposure. The O/E ratios for CLL, based on Illinois 
rates, were presented for production workers by benzene exposure categories. Among 
those without benzene exposure, the O/E was 1.00 (95% CI=0.0-5.5), based on only one 
case. The <12 ppm-months category showed as O/E of 5.9 (95% CI=0.1-32.6), again 
based on 1 case. There were no cases in the 12-72 ppm-months category, consistent with 
an expected number of 0.15 cases. In the highest exposure group, ≥ 72 ppm-months, 1 
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CLL case was observed, yielding an O/E of 6.7 (95% CI=0.2-37.7). No deaths of NHL 
were seen among the exposed workers. 
 
Nordlinder R, Jarvholm B [1997]. Environmental exposure to gasoline and leukemia 
in children and young adults—an ecology study. Int Arch Occup Environ Health 
70:57-60.  
 
Benzene exposure from gasoline and car exhaust has been implicated as a risk factor for 
childhood leukemia. This study categorized 277 areas in Sweden into 4 groups according 
to car density, which served as a surrogate for childhood benzene exposure. Incidence 
rates for leukemias during the study period of 1975-1985 were collected via the National 
Swedish Cancer Register for children and young adults aged 0-24 years. As only 3 cases 
of CLL were reported in this age group in the 10 years time, this leukemia was not 
analyzed. The study did have adequate numbers, however, to separately analyze NHL, 
ALL, AML, and CML. The only significant finding of the study occurred upon comparing 
AML incidence in the highest car density category to the lowest car density category 
(RR=1.62, p=0.05). The authors acknowledge that as an ecological study there was a lack 
of control for confounding; the observed relationship may have been due to another factor 
that is associated with both AML and living in areas of high car density. 
 
Savitz DA, Andrews KW [1997]. Review of epidemiologic evidence on benzene and 
lymphatic and hematopoietic cancers. Am J Ind Med 31:287-295. 
 
In a review of benzene and lymphatic and hematopoietic cancer, Savitz et al. cites studies 
that investigated the relationship between benzene and CLL. Linet et al. (1987a) reported 
an RR for CLL of 0.9 (95% CI=0.5-1.5) and 1.5 (95% CI=0.9-2.5), using two versions of 
a job exposure matrix to estimate benzene exposure. An RR of 1.1 (95% CI=0.6-2.0) was 
observed by Malone et al. (1989) for risk of CLL following benzene exposure.  
 
Landrigan PJ [1996]. Benzene and blood: one hundred years of evidence. Am J Ind 
Med 29:225-226. 
 
This editorial speaks to the effects of benzene in relation to blood disorders. The author 
cites the findings of Yin et al. (1996), where a significant excess of leukemia was found 
among benzene exposed workers. Yin observed elevations for CML, AML, and LL; 
though AML was the only significant association at the 5% level. The author also 
emphasizes that the observed dose-response relationship, where increasing benzene levels 
lead to decreasing absolute lymphocyte levels, adds to the biologic plausibility of an 
association between benzene and leukemia.  
 
Paxton MB [1996]. Leukemia risk associated with benzene exposure in the Pliofilm 
cohort. Environ Health Persp 104 (Suppl 6):1431-1436. 
 
A mortality update through 1987 of the Pliofilm cohort revealed 22 leukemia cases among 
the benzene-exposed population of non-salaried Goodyear rubber workers. No CLL cases 
were reported. 
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Yin SN, Hayes RB, Linet MS et al. [1996]. A cohort study of cancer among benzene-
exposed workers in China: overall results. Am J Ind Med 29:227-235. 
 
In a cohort study involving 74,828 benzene-exposed factory workers (as determined by 
job title and department) and 35, 805 unexposed workers, a significant elevation in 
leukemia mortality was observed among the exposed population (RR=2.3, 95% CI=1.1-
5.0). By subtype, AML mortality occurred significantly more frequently among the 
benzene exposed (RR=3.1, 95% CI=1.2-10.7). The RRs for CML and LL were also 
elevated, though not significantly. All lymphatic leukemia among the exposed were due to 
AML; there were no cases of CLL among the exposed. The investigators do note, 
however, that CLL is rare in Asian populations.  
 
Austin H, Delzell E, Cole P [1988]. Benzene and leukemia: a review of the literature 
and a risk assessment. Am J Epidemiol 127:419-439. 
 
This review article cites CLL specific results from several benzene studies. Girard et al. 
(1970), in a hospital based case-control study, found an RR for benzene and toluene 
exposure of 4.1 (95% CI=1.4-12.0) for CLL. Linos et al. (1980) assessed the risk of 
leukemia following benzene exposure via a case-control study; the RR for leukemia was 
3.3 (95% CI=0.6-28.0), where 3 of the 4 exposed cases were CLLs. In a cohort mortality 
study, Decoufle et al. (1983) observed 3 leukemia deaths among chemical workers (1 
CLL); only 0.44 deaths were expected (SMR=682, 95% CI=141-1992). An RR of 2.5 for 
LL risk was reported by Checkoway et al. (1984) among benzene exposed workers.  
 
Wilcosky TC, Checkoway H, Marchall EG, et al. [1984]. Cancer mortality and 
solvent exposures in the rubber industry. Am Ind Hyg Assoc J 45:809-811.  
 
A study of the carcinogenic effects of solvent exposure was performed on a cohort of 
6,678 male rubber workers, followed for vital status until 1974. Solvent exposure among 
those members of the cohort dying of stomach cancer, respiratory cancer, prostate cancer, 
lymphosarcoma, and leukemia was compared to a 20% age-stratified random sample of 
the cohort. Exposure to a solvent was defined as working in an area where the solvent was 
authorized for use. Ten cases of LL and 9 cases of lymphosarcoma occurred in this cohort 
of rubber workers. The proportion of CLL cases in the LL category was not provided. The 
OR comparing the carbon tetrachloride exposure of cases to controls was 15.3 (p<0.001) 
and 4.2 (p<0.05) for LL and lymphosarcoma, respectively. Significantly elevated ORs at 
the 1% level were observed for exposure to carbon disulfide; the OR for LL was 8.9 and 
the OR for lymphosarcoma was 5.6. Both LL and lymphosarcoma exhibited an OR of 4.0 
for hexane exposure, significant at the 5% level. Ethyl acetate (OR=5.3) and acetone 
exposure (OR=6.8) occurred significantly more frequently among the LL cases than the 
controls. There was evidence of increased risk of lymphosarcoma following xylene 
exposure (OR=3.7, p<0.05). The authors note that the results of this study may “reflect a 
single causative agent that is correlated with several of the solvents” since “different 
solvents were used simultaneously in a given process area”.  
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VI. CLL and Farming 
 
Lee E, Burnett CA, Lalich N, et al. [2002]. Proportionate mortality of crop and 
livestock farmers in the United States, 1984-1993. Am J Ind Med 42:410-420.  
 
This study investigated the mortality trends of crop farmers and livestock farmers, with 
cause-specific PMRs calculated for each group of farmers. CLL was significantly elevated 
in both groups; the PMRs for white, male crop farmers and white, male livestock farmers 
were 1.14 (95% CI= 1.04-1.25) and 1.28 (95% CI= 1.06-1.53), respectively. These results 
suggest that both types of farmers, crop and livestock, undergo a common exposure to 
carcinogens, such as pesticides or chemicals, leading to their increased risk for CLL. The 
authors also report a significant increase of LL and MM among both farming groups. Only 
the livestock workers had a significant excess of deaths due to NHL, ALL, and myeloid 
leukemia. 
 
Gonzalez CA, Agudo A [1999]. Occupational cancer in Spain. Environ Health Persp 
107:273-277. 
 
In a review of occupational cancer in Spain the author cites the 1991 study by Lopez-
Abente where a statistically significant increase of stomach cancer, brain cancer, CLL, 
MM and NHL was observed among the agricultural occupations. The case-control study 
utilized death certificates from the region of Castilla-Leon. 
 
Brandt L [1985]. Environmental factors and leukaemia. Med Oncol & Tumor 
Pharmacother 2:7-10.  
 
In this review of the literature regarding environmental exposures and leukemia, the 
author considers farming as an environmental exposure for CLL. Brandt cites Milham 
(1971), who reported CLL as a common death among farmers, and Donham et al. (1980), 
who suggested that bovine leukosis may be transmitted to humans. The relationship 
between bovine leukosis and leukemia was examined in a study by Kvarnfors et al. 
(1975); leukemia was not found to be increased in an area where bovine leukosis was 
prevalent. 
 
Thomas TL, Krekel S, Heid M [1985]. Proportionate mortality among male corn 
wet-milling workers. Int J Epidemiol 14:432-437. 
 
Corn wet-milling workers are exposed to a variety of potentially hazardous agents 
including: grain dusts, pesticides and fumigants, acids, solvents, sulphur dioxide, and 
other chemicals involved in the production of oil, starch, syrup, and animal feed. 
Proportionate mortality analysis was conducted on 748 male corn wet-milling workers 
who died between January 1947 and June 1981. Significant excesses of proportionate 
deaths were observed among whites for the outcomes of leukemia and other lymphoma, 
with PMRs of 2.21 and 3.10, respectively. Calculation of PMRs by work type 
demonstrated that 4 of the 8 leukemia deaths occurred in white maintenance workers. The 
PMR for leukemia (1 case of lymphatic) among the maintenance workers was 3.08. 
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 VII. Other Risk Factors for CLL 
 
Adami J, Gridely G, Nyrén O, et al. [1999]. Sunlight and non-Hodgkin’s lymphoma: 
a population-based cohort study in Sweden. Int J Cancer 80:641-645. 
 
The study was undertaken to evaluate the relationship between ultra-violet light exposure 
and NHL and CLL cancer incidence. The eligible study population included all Swedish 
residents who were gainfully employed according to either the 1960 or 1970 census, 
resulting in 4,171,175 study subjects followed from 1/1/1971 until cancer diagnosis, 
death, or the end of study date, 12/31/1989. Cancer incidence data were obtained by 
record linkage to the Swedish Cancer Registry. Sunlight exposure was measured by place 
of residence according to the census data, where residence was grouped into one of 4 
latitude categories. The census also provided occupational data, allowing the researchers 
to analyze occupational exposure to sunlight and occupational exposure to pesticides and 
chemicals. Poisson regression was used to model the effects of the exposure variables 
(latitude and occupation) controlling for potential confounding by age, residence in a large 
city or not, SES, number of hours worked per week, and exposure to pesticides/solvents. 
The final model, adjusted for age, showed a significant increase in NHL among the 2 
southernmost regions compared to the referent upper north category. The risk ratios for 
CLL, however, did not demonstrate any relationship with latitude, as the rates for the 3 
southernmost latitude exposure groups were not significantly different than that of the 
northernmost latitude group; furthermore, all point estimates for the RRs were less than 1 
in comparison to the referent latitude category.  
 
Miligi L, Seniori Constantini A, Crosignani P, et al. [1999]. Occupational, 
environmental, and life-style factors associated with the risk of hematolymphopoietic 
malignancies in women. Am J Ind Med 36:60-69. 
 
This case-control study attempted to identify risk factors for hematolymphopoietic cancers 
among women living in Italy, where NHL and CLL were considered together in the 
analysis. Twelve areas were selected for study: 2 industrialized areas, 6 agricultural areas 
and 4 mixed areas. From these areas, 1,183 female cases of hematolymphopoietic cancers 
(reflecting a 9.4% nonresponse rate), were included in the study, as were 828 female 
controls (reflecting a 19.8% nonresponse rate). A 1:1 case to control ratio was used for the 
611 combined NHL and CLL cases, with a greater case to control ratio employed for the 
other cancer types. The authors singly considered various risk factors, including 
occupation, hair dye use, education level, and smoking status, in logistic regression 
analyses adjusting for age. Borderline significant elevations in NHL/CLL were observed 
among smokers (OR=1.2, 95% CI=1.0-1.5) and teachers (OR=1.7, 95% CI=1.0-2.7). Non-
significant elevations of NHL/CLL were found among medical, dental and veterinary 
workers (OR=1.4), clerical workers (OR=1.1), textile workers (OR=1.1), rubber and 
plastic workers (OR=1.5), production workers not elsewhere classified (OR=2.4), 
bleachers, dyers and textile product finishers (OR=2.1) and housewives (OR=1.2).  
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Adami H, Tsaih S, Lambe M, et al. [1997]. Pregnancy and risk of non-Hodgkin’s 
lymphoma: a prospective study. Int J Cancer 70:155-158. 
 
As the etiology of NHL and CLL is likely related to immune function, and since 
pregnancy affects the immune system, the relationship between pregnancy and risk of 
NHL and CLL was investigated in this study. Incidence data from the Swedish Cancer 
Registry was linked with exposure data from the Swedish Fertility Register. 1,546 cases 
of NHL and 198 cases of CLL were identified among women aged 15 and older born 
during the period 1925-1972. Using 5 age-matched controls per case, conditional logistic 
regression was performed adjusting for age at first birth. The ORs for NHL and CLL 
comparing ever parous women to never parous women were 0.96 (95% CI=0.82-1.12) and 
0.92 (95% CI=0.60-1.40), respectively. Examination of the relationship between NHL and 
CLL with number of births revealed non-significant negative trends. For CLL, the ORs 
for 3, 4 and 5 births were 0.76 (95% CI=0.44-1.30), 0.76 (95% CI=0.37-1.55) and 0.62 
(95% CI=0.22-1.75) respectively, yielding a test of trend p value of 0.18. These results 
suggest that pregnancy may be protective against development of NHL and CLL.  
 
Verkasalo PK [1996]. Magnetic fields and leukemia—risk for adults living close to 
power lines. Scand J Work Environ Health 22 (Suppl 2):1-56.  
 
Eligibility criteria for this study of magnetic fields and leukemia included residing in 
Finland within 500 meters of 110, 220, and 400 kilovolt overhead power lines with a 
magnetic field ≥ 0.01 µT during 1970-1989, and age >20 years. 383,700 people were 
included in the cohort study. The SIR for CLL was 1.03 (95% CI=0.80-1.29). No other 
leukemia subtype showed an elevation of disease incidence compared to the general 
Finish population. A nested case-control study was also performed, where 10 controls 
were matched on age and sex to each of the 196 leukemia cases. Again, only CLL 
demonstrated evidence of increased risk due to exposure to magnetic field, though the risk 
estimates were based on small numbers. When stratifying on time since first exposure, a 
significant increase in CLL risk was observed for those exposed to ≥ 0.40 µT, at least 10 
years prior to diagnosis of CLL (RR=4.62, 95% CI=1.41-15.1). Also, among subjects who 
were exposed to ≥ 0.10 µT, those exposed for a duration of at least 12 years had an almost 
5-fold increase in risk compared to those exposed less than 12 years (RR=4.86, 95% 
CI=1.54-15.4). As noted by the authors, these results suggest that a latency period greater 
than 10 years should be considered for future studies of CLL. 
 
Markovic-Denic LJ, Jankovic S, Marinkovic J, et al. [1995]. Brick mortar exposure 
and chronic lymphocytic leukemia. Neoplasma 42:79-81. 
 
A case-control study consisting of 130 CLL cases and 130 controls, matched on hospital, 
sex, age, residence area and type, and income was performed. The risk factors examined 
were occupation category, work in hazardous industry (category appears not to include 
radiation work), family history of leukemia and other malignancies, tonsillectomy, and 
exposure to pesticides, manure, organic solvents, dyes, oil, acids, brick mortar, hair dye, 
farming, and electromagnetic radiation. Data on exposure were obtained through 
interview of cases and controls. Conditional logistic regression analysis revealed 5 
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significant risk factors at the 10% level for CLL: family history of leukemia (OR=2.40, 
95% CI=1.10-5.23), hair dye use (OR=1.97, 95% CI=1.08-3.59), brick mortar exposure 
(OR=1.79, 95% CI=0.96-3.26), work in hazardous industry (OR=1.55, 95% CI=1.01-
2.39), and exposure to electromagnetic radiation (OR=1.25, 95% CI=0.97-1.63). 
 
Linet MS, Cartwright RA [1988]. Chronic lymphocytic leukemia: epidemiology and 
etiologic findings. Nouv Rev Hematol 30:353-357. 
 
The results of 2 case-control studies are presented in this report: a study in Baltimore, 
Maryland and a sister study in Yorkshire, England. In Baltimore, 342 cases of CLL were 
diagnosed between 1975 and 1982. Hospital controls (non-cancer patients) were selected 
using a 1:1 match on age, sex, race, and year of diagnosis. The Yorkshire study included 
330 CLL cases diagnosed from 1979-1984, where controls were matched (1:1.7) on the 
same criteria as listed above. A questionnaire was given over the phone to cases (or next 
of kin) and controls inquiring about SES, family history, mediation use, lifetime 
occupational history, occupational and environmental exposures, and use of cigarettes and 
alcohol. The authors report an increased OR for leukemia and lymphoma among close 
relatives of CLL patients compared to controls (Baltimore: OR for siblings=2.2 (95% 
CI=0.9-5.1), OR for parents=7.5 (95% CI=2.1-26.2); Yorkshire: OR for any blood 
relative=1.8 (95% CI=0.9-3.3)). For the Baltimore study, no association was observed 
between prior history of subacute or chronic bacterial infection and CLL. In the Yorkshire 
study, however, the odds of a having a prior diagnosis of scarlet fever were found to be 
3.2 (95% CI=1.2-8.3) times higher among cases than controls. The OR comparing CLL 
cases to matched controls also revealed significant differences in prior exposure to chronic 
ear infections (OR=1.9) and bronchitis (OR=2.2). Furthermore, the Yorkshire study 
demonstrated that the cases more frequently reported migraine, hypertension, myocardial 
infarction, skin cancer, RT for skin cancer and history of prior malignancy than did 
controls. The Baltimore study showed that cases reported allergy-related disorders more 
than did controls. Both studies demonstrated that cases were less likely to have an 
appendectomy. The authors conclude that their results are consistent with a genetic 
predisposition to CLL, “although it is probable that environmental determinants are 
important in the etiology, given the substantial sporadic occurrence of CLL within 
families. Several of the findings also provide support for an association of CLL with 
preceding immune perturbation.” The researchers do not report their findings regarding 
the relationship between occupational exposure and CLL.  
 
VIII. CLL and Risk of Second Primary Malignancies 
  
Potti A, Kishor Ganti A, Koch M, et al. [2001]. Identification of HER-2/neu  
overexpression and the clinical course of lung carcinoma in non-smokers with 
chronic lymphocytic leukemia. Lung Cancer 34:227-232. 
 
Previous studies have demonstrated that CLL patients have an increased risk for 
developing second primary cancers. Travis et al. (1992) reported the RR for lung cancer 
among CLL patients to be 1.90. The purpose of this study was to evaluate the role of 
HER-2/neu in the development of lung cancer in CLL patients. HER-2/neu codes for a 
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receptor tyrosine kinase which can act in several signal transduction pathways; 
furthermore, overexpression of HER-2/neu has been observed in several types of cancers. 
To eliminate smoking as a confounder, the study was restricted to nonsmokers who were 
diagnosed with lung cancer at least 6 months after being diagnosed with CLL. Of 417 
patients with CLL, 14 patients met the study criteria. In 9 of the 14 cases (64%), HER-
2/neu overexpression was observed. Nine of 10 patients with advanced stage lung cancer 
showed overexpression of HER-2/neu; whereas in the 4 patients with localized 
malignancies, HER-2/neu expression was not seen. The authors suggest that 
overexpression of HER-2/neu “may play a role in the development of secondary 
malignancies, that appear to be more advanced at the time of diagnosis; probably 
secondary to accelerated tumor growth.” The study also suggests that HER-2/neu may be 
associated with a worse than expected prognosis in patients. In light of these findings, 
increased surveillance for lung cancer among CLL patients is recommended by the 
authors. 
 
Nanjangud GJ, Saikia TK, Chopra H, et al. [1996]. Development of PH positive 
chronic myeloid leukemia in a patient with chronic lymphocytic leukemia treated 
with total body irradiation: a rare association. Leukemia Lymphoma 22:355-359. 
 
In this case report, a patient diagnosed with CLL in 1984 received total body irradiation 
(TBI) as treatment. He later developed CML about 73 months after the first course of TBI 
treatment, while the morphologic evidence of CLL disappeared. The authors recommend 
careful follow up of patients receiving TBI, or avoidance of TBI in favor of newer 
treatments that may become available in the future. 
 
Schmidt HH, Sill H, Beham-Schmid C, et al. [1995]. Hodgkin’s disease developing after 
spontaneous remission of chronic lymphocytic leukemia. Ann Hematol 71:247-252. 
  
The authors present a case of a woman diagnosed with CLL in 1967. In 1984, treatment 
was required due to disease progression; hence, a single course of chemotherapy was 
administered. The following year, spontaneous remission of the CLL was observed until 
1993. Spontaneous remission is a rare event, occurring in about 1% of cases. 
Chemotherapy, radiation, and viral infections have been reported to precede spontaneous 
remission. The authors argue that the chemotherapy dose was “not sufficient to produce 
such a complete and long-lasting normalization of the WBC.” This case is also unique in 
that the patient went on to develop Hodgkin’s disease in 1993. The researchers performed 
a literature review of all documented cases of spontaneous remission of CLL and found 
that about 40% of spontaneous remission cases developed secondary neoplasms with 
follow-up of greater than 2 years; the authors did not speculate about the of role radiation 
treatment in the development of these cancers. Also of note in this CLL case is the finding 
of an inversion of chromosome 9 upon karyotyping. It is unclear whether this abnormality 
was related to the pathogenesis of CLL in this patient.  
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Travis LB, Curtis RE, Hankey BF, et al. [1992]. Second cancers in patients with 
chronic lymphocytic leukemia. J Natl Cancer I 84:1422-1427. 
 
An investigation into the relationship between CLL and development of secondary cancer 
was carried out using the SEER cancer registry. The registry was used to identify all cases 
of CLL diagnosed during 1973-1988. Additionally, the registry provided data on 
demographics, vital status, tumor histology, type of initial treatment, and occurrence of 
second cancers. Of the 9,456 CLL cases identified, 840 (9%) went on to develop a second 
cancer. The number of observed cases (840) was significantly greater than the number of 
cases expected to occur in the general population (658), yielding a O/E ratio of 1.28 (95% 
CI=1.19-1.37). Among men, but not women, an excess of brain cancer was observed 
(O/E=2.84, 95% CI=1.46-4.96); 7 of the 13 observed brain cancers were reported in Iowa. 
Lung cancer (O/E=1.90, 95% CI=1.65-2.17), intraocular melanoma (O/E=3.97, 95% 
CI=1.07-10.16), malignant melanoma (O/E=2.79, 95% CI=1.85-4.03) and Hodgkin’s 
disease (O/E=7.69, 95% CI=4.09-13.14) were significantly elevated in the CLL cohort 
compared to the general population. There appeared to be a reduction in risk for breast 
cancer and cancer of the uterine cervix and corpus which the authors note has also been 
reported for women with NHL. The excesses of secondary lung cancer and cutaneous 
melanoma seen in this study have also been reported in NHL patients. Unlike what has 
been observed with past NHL reports, where “sharp increases in risk over time suggested 
a treatment-related effect”, the elevations of secondary cancer among the CLL patients 
remained relatively constant across follow-up periods and treatment groups. 
 
Greene MH, Wilson J [1985]. Second cancer following lymphatic and hematopoietic 
cancers in Connecticut, 1935-1982. National Cancer Institute Monographs 68:191-217. 
 
The risk of developing a second cancer following cancer of the lymphatic and 
hematopoietic system was evaluated, using data from Connecticut Tumor Registry for the 
years 1935-1982. 1,875 CLL patients were identified. The mean age of disease diagnosis 
was 67 and 17.5% of CLL patients received RT. 165 of these CLL patients developed a 
second cancer (RR=1.3, 95% CI=1.1-1.5). There were 6,734 NHL patients diagnosed 
during the interval studied; the average age of diagnosis among these patients was 58 and 
51% received RT for NHL. A second cancer was diagnosed in 319 of the NHL patients 
(RR=1.24, 95% CI=1.11-1.39). The “pattern of increased risk for malignant melanoma, 
soft tissue carcinoma, and lung cancer that was seen in this series [of NHL patients] 
resembles that reported among patients with CLL, a neoplasm closely related to NHL.” 
This pattern was first reported for CLL in data from the National Cancer End Results 
Program, by Green et al. (1978), where “the pattern of excesses of malignant melanoma, 
soft tissue sarcomas, and lung cancers…suggested a role for leukemia-related 
immunosuppression rather than leukemia therapy in the genesis of these subsequent 
cancers.”  
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O’Donnell JF, Brereton HD, Greco FA, et al. [1979]. Acute nonlymphocytic leukemia 
and acute myeloproliferative syndrome following radiation therapy for non-
Hodgkin’s lymphoma and chronic lymphocytic leukemia: clinical studies. Cancer 
44:1930-1938.  
 
At the National Cancer Institute, 113 patients with advanced NHL and 75 patients with 
CLL were treated with RT from 1965-1975. Among this cohort, 7 patients developed 
ANLL secondarily, and 1 developed acute myeloproliferative syndrome (AMPS). Only 
one of the CLL cases developed a second leukemia. The authors state that, “the hallmark 
of our eight patients who developed ANLL or AMPS was repeated courses of radiation, 
and each received multiple techniques. No leukemia has been seen to date in patients who 
received a single induction course of radiation.” 
 
Whang-Peng J, Knutsen T, O’Donnell JF, Brereton HD [1979]. Acute non-
lymphocytic leukemia and acute myeloproliferative syndrome following radiation 
therapy for non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: 
cytogenetic studies. Cancer 44:1592-1600. 
 
One case of secondary ANLL was identified among 76 cases of CLL patients treated with 
RT at the National Cancer Institute’s Clinical Center, as reported by O’Donnell et al. 
(1979). Cytogenetic analysis of this patient, an 82 year old woman, revealed the presence 
of multiple chromosome abnormalities. Seven cases of ANLL secondary to NHL were 
also examined for chromosome abnormalities. The CLL patient demonstrated a more 
complex pattern of chromosomal aberrations than did the NHL patients; furthermore, the 
authors state that “she exhibited…the most extensive and complex chromosome 
involvement…that has been observed in our laboratory to date.” 
 
Greene MH, Hoover RN, Fraumeni JF [1978]. Subsequent cancer in patients with 
chronic lymphocytic leukemia—a possible immunologic mechanism. J Natl Cancer I 
61:337-340.  
 
According to data from the National Cancer Institute’s End Results Program, 4,869 cases 
of CLL were diagnosed between 1935 and 1971. 234 of these CLL cases developed a 
second primary cancer, representing a 10% excess of cancer (RR=1.1, 95% CI=1.0-1.3). 
This excess was mainly due to malignant melanoma, soft tissue sarcoma, and lung cancer. 
The elevation in these cancers was apparently independent of sex, treatment group, and 
follow-up period.  
 
Rosner F, Grunwald H [1975]. Hodgkin’s disease and acute leukemia. Am J Med 
58:339-353.  
 
This article includes a review of 37 cases of co-disease with CLL and Hodgkin’s disease. 
In 29 of the 37 patients, the CLL diagnosis preceded the Hodgkin’s disease diagnosis. In 
19 of these patients the diagnosis of Hodgkin’s disease was made at autopsy. The period 
between diagnosis of CLL and the subsequent diagnosis of Hodgkin’s disease was less 
than 1 year in 9 patients.  
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IX. Descriptive Epidemiology and Literature Reviews of CLL   
  
Call TG, Phyliky RL, Noel P, et al. [1994]. Incidence of chronic lymphocytic 
leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on 
changes in initial stage at diagnosis. Mayo Clin Proc 69:323-328. 
 
Patterns of incidence and stage of diagnosis were assessed over the time frame of 1935-
1989 in Olmsted County, Minnesota. 148 cases of CLL were diagnosed in Olmsted 
residents during this period. Examination of these cases revealed that the incidence rate of 
CLL has increased over the 55 year study period among persons older than age 50. The 
rates of CLL for those younger than age 50, however, remained essentially constant. The 
researchers found that the sex ratio (male: female) for CLL decreased with advancing age 
(<50 years of age 2.3:1, 50-74 years of age 1.8:1, and >75 years of age 1.1:1). In addition, 
an increase in the proportion of cases diagnosed as stage Rai stage 0 (lymphocytosis only), 
the stage of CLL associated with the least risk, was observed in this cohort; however, 
survival time of the patients was lower than that reported in other studies. The authors 
offer a possible explanation for this phenomenon, that CLL may be “diagnosed 
incidentally in an increasing number of older patients seeking medical care for other 
chronic disease.” They further speculate that the observed trend of increasing CLL in this 
study may not reflect an actual increase in the incidence of the disease, but rather 
increased detection of CLL due to improved diagnostic tools and increased diagnosis of 
asymptomatic cases. 
 
Erlanson M, Osterman B, Jonsson H, et al. [1994]. Chronic lymphocytic leukemia: a 
retrospective study of 122 cases. Eur J Haematol 52:108-114. 
 
A retrospective study of 122 cases of CLL from the three northernmost counties of 
Sweden, diagnosed between 1978 and 1982 and followed until 1989, was performed to 
examine trends in survival. The researchers found that most of the cases of CLL were 
diagnosed incidentally; that is, CLL was detected during a check-up for another condition. 
At the time of diagnosis, only 55 of the 122 patients consulted their doctor because of 
symptoms related to CLL. Crude survival analysis demonstrated no difference in survival 
according to stage of disease; however, when cause-specific survival analysis was 
performed, with CLL as underlying cause of death, stage of disease was a slight indicator 
of prognosis (median survival time stage A=102 months, B=80 months and C=63 
months). In an exercise of Cox regression model building, age, sex and stage were 
significant predictors for prognosis. The authors conclude that the crude survival results 
seen by disease stage reflect the fact that many of the CLL patients died from diseases 
other than CLL. 
  
Storm HH, Clemmensen IH [1993]. Lymphatic and hematopoietic tissues. APMIS 
33:183-213. 
 
Incidence and survival patterns of cancers of the lymphatic and hematopoietic tissues, 
diagnosed between 1943 and 1987, were reported in this Danish study. During 1983-1987, 
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NHL accounted for 2% of malignant neoplasms. The incidence of NHL increased during 
the period of 1983-1987; the rates for men and women were 7.6 and 5.5 per 100,000, 
respectively. Mortality remained stable at 4 and 2 deaths per 100,000 for men and women, 
respectively. A 14-16% increase in relative 5-year survival between the 1970s and 1987 
was observed, reflecting the implementation of chemotherapy for treatment of NHL. CLL 
represented 1.3% of all cancers among men and 0.7% of cancers among women during 
the period 1983-1987. Incidence of CLL remained stable at <4 cases per 100,000 for 
males and 2 per 100,000 for females. Total leukemia mortality was essentially constant 
over this period. Of the 4,521 CLL cases diagnosed between 1943 and 1987, fewer than 
10% were younger than 50 years of age. The majority of cases (over 50%) were older than 
70 years. Steady increases in survival rates for CLL were seen in the periods 1953-1957 
and 1983-1987. 
 
Finch SC, Linet MS [1992]. Chronic leukemias. Bailliere’s Clinical Hematology 5:27-56. 
 
Potential problems in CLL diagnosis were described in this review. Among B-cell CLL 
(B-CLL) cases, over 25% may be asymptomatic or indolent for years; thus underdiagnosis 
of CLL may be substantial. In addition to underdiagnosis, diagnosis may be complicated 
by occurrences of Richter’s syndrome (where B-CLL transforms terminally into NHL) or 
by instances where transformed lymphomas present as leukemias. In rare instances, MM 
has transformed into CLL. Furthermore, cases which are actually CLL may be ascribed to 
“infectious, autoimmune, benign hematological, or drug-induced disorders, or other 
hematopoietic malignancies.” Lack of specification of leukemia subtype on death 
certificates is also problematic.  
 
Also discussed in this review was the incidence of CLL by race, geographic area, and sex. 
CLL has been shown to exhibit the greatest variability among populations compared to 
other leukemia subtypes. In the US, the age-adjusted incidence rate of CLL is highest 
among whites, followed by blacks, then Hispanics and lastly Asians; there is a difference 
8-9-fold in rates between whites and Asians. In most western populations, CLL comprises 
30% of all leukemias, whereas in Asian populations CLL is responsible for only 3-5% of 
leukemia. CLL is seen more frequently in males that females; the sex ratio is estimated to 
be approximately1.5-2.5. The author also noted an unexplained peculiarity in the 
incidence of CLL over the past century; in the 1940s and 1950s mortality rates increased 
across several countries for males over the age of 45 and females over the age of 60.  
 
Etiology was reviewed by the authors, who noted that familial leukemia is seen more 
frequently among CLL than the other subtypes. Chromosome aberrations were also 
discussed; it was stated that 50% of B-CLL cases have been demonstrated to have an 
abnormality in chromosome 12 or 14. The authors concluded that the fact that “over half 
of the CLL patients have no abnormality of chromosome 12 suggests that a specific CLL 
gene is unlikely.”  
 
Another interesting issue raised by the authors is association of CLL with several 
autoimmune disorders. “It has been hypothesized that some of the apparent associations of 
autoimmune disorders with CLL may reflect underlying perturbations of immune 
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mechanisms common to both disorders. The association with rheumatoid arthritis [RA] 
may be real, since CLL patients with this autoimmune disorder have been found to have 
the unusual subtype T-γ lymphocyte leukemia.” 
 
X. General Etiology of CLL 
  
Marti GE, Carter P, Abbasi F, et al. [2003]. B-cell monoclonal lymphocytosis and B-
cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. 
Cytometry 52(B):1-12. 
 
This study proposes that B-cell monoclonal lymphocytosis (BCML) is a precursor state 
for the development B-CLL, much like the relationship identified between monoclonal 
gammopathy of unknown significance (MGUS) and MM. Nine pedigrees were examined 
in this study of familial B-CLL, consisting of 19 individuals affected with B-CLL and 33 
unaffected individuals. Flow cytometry and polymerase chain reaction (PCR) analysis 
were used to determine BCML status in the unaffected individuals, where BCML was 
defined as “a pattern of abnormalities suggestive of, but not fulfilling, the minimal criteria 
for the diagnosis of B-CLL.” Of the 33 screened individuals, 6 (18%) were determined to 
have BCML. Compared to the population prevalence estimate of 0.7% for BCML, 
reported by Marti et al. (1995), the finding of 18% was highly significant (p=5.7x10-9).  
 
Lynch HT, Weisenburger DD, Quinn-Laquer B, et al. [2002]. Hereditary chronic 
lymphocytic leukemia: an extended family study and literature review. Am J Med 
Genet 115:113-117. 
 
This paper describes a CLL family where the father and all his children (4 sons, 2 of 
whom are identical twins) are affected with the disease. “This finding of male-to-male 
transmission excludes sex-linked inheritance and is consistent with an autosomal 
dominant mode of genetic transmission of susceptibility to CLL. The occurrence of CLL 
in identical twins in the sibship adds to the likelihood of a primary hereditary etiology. 
These results are also in agreement with a strong nongenetic familial factor, such as a 
common environmental exposure, but interviews with family members have not found 
any plausible environmental factors beyond growing up on a farm.” Cytogenetic analysis 
was also performed, revealing an acquired (buccal cells were normal) monosomy of 
13q14 in all 4 brothers to varying degrees. The authors note this finding suggests a genetic 
etiology that predisposes to loss of 13q14, which they propose would facilitate the 
expression of an oncogene on the homologous chromosome and result in CLL, or, 
alternatively, “it is also possible that the hereditary factor is a deleterious mutation on 
13q14, for example, in a tumor suppressor gene, that is unmasked by the acquired deletion 
of the normal allele on 13q14.” 
 
Annotated Bibliography – Chronic Lymphocytic Leukemia – July 21, 2004  
 
 
 49
Mueller LP, Machulla HKG [2002]. Increased frequency of homozygosity for HLA 
class II loci in female patients with chronic lymphocytic leukemia. Leukemia 
Lymphoma 43:1013-1019. 
 
CLL is characterized by a clonal proliferation of mature-appearing lymphocytes, where 
95% of all cases are of B-cell origin. Since B-cell proliferation normally occurs in the 
adaptive immune response and can be initiated by major histocompatibility complex 
(MHC)-restricted T-cell activation, the frequency of human leukocyte antigens (HLA) 
was examined among CLL patients. This study is the first to investigate the distribution of 
HLAs with respect to gender and age of disease onset. To examine gender differences, the 
frequencies of HLA-A, -B, -Cw, -DRB 1/3/4/5, -DQB1, and -DPB1 loci were analyzed 
among male and female German CLL cases and compared to the frequencies of the alleles 
among the control group, which was derived from healthy Caucasian blood donors. An 
increased frequency of homozygosity was observed for the DRB and DQB1 loci among 
female patients compared to male patients; increased frequency of homozygosity was also 
observed upon comparing female patients to gender matched controls. These findings are 
consistent with the HLA-DR/DQ region within the MHC containing a recessive, gender-
specific susceptibility factor. With regard to age of onset, the authors found an increased 
frequency of HLA-Cw*06 among the early onset patients (<61 years of age) compared to 
controls and compared to the late onset patients (≥ 61 years of age), though these 
differences were not significant after applying a correction factor for multiple 
comparisons. Finally, the study supported the previously reported finding of an increased 
frequency of HLA-DRB4*103 among CLL patients regardless of gender and .age. 
  
Stankovic T, Stewart GS, Fegan C, et al. [2002]. Ataxia telangiectasia mutated-
deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and 
results in defective damage response and unrepaired chromosome damage. Blood 
99:300-309. 
 
It has been previously established that 1) B-cell CLL can be described by the stage of B-
cell differentiation in which the cells are transformed—in either pregerminal or post 
germinal centers and 2) ataxia telangiectasia mutated (ATM) gene mutations can occur in 
B-CLL, leading to a defect in the p53 pathway and affecting cell cycle regulation and 
apoptosis. This study examined 50 B-CLL tumors in an attempt to ascertain the role of 
ATM mutations in the pathogenesis of B-CLL. Of the 50 tumors screened for ATM and 
TP53 status, 16 were found to have ATM mutations, 6 had TP53 mutations, and 28 
expressed wild type ATM and TP53. ATM and TP53 mutations were found to be 
mutually exclusive. To determine pregerminal or post germinal center of origin of the 50 
B-CLLs, the V gene family sequences from the tumor cells were compared with germline 
sequences. Less than 2% sequence homology was indicative of an absence of somatic 
variable region hypermutation, proving a pregerminal center origin. All 16 ATM mutant 
B-CLL tumors were of a pregerminal center origin, as were 5/6 of the TP53 mutant B-
CLLs. All 28 wildtype ATM and TP53 tumors were of post germinal center origin, as the 
sequence comparisons showed the presence of somatic mutation in the VH region. The 
study also demonstrated that the ATM mutant tumors displayed a deficient p53 response 
following irradiation, followed by a lack of upregulation of TRAIL-2 (a downstream 
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target that links irradiation induced p53 response with apoptosis) and finally an inability 
to repair induced chromosome breaks. The authors hypothesize that “loss of ATM 
function during B-cell ontogeny drives B-CLL tumorigenesis in pregerminal B-cells by a 
dual defect in p53 response and repair of chromosome breaks.” 
 
Gharagozloo S, Khoshnoodi J, Shokri F [2001]. Hepatitis C virus infection in 
patients with essential mixed cryoglobulinemia, multiple myeloma and chronic 
lymphocytic leukemia. Pathology Oncology Research 7:135-139. 
 
It has been previously demonstrated that hepatitis C virus (HCV) can infect human 
lymphocytes, suggesting that HCV may play a role in the development of some 
lymphoproliferative disorders. In support of this theory, recent studies have shown HCV 
to be associated with essential mixed cryoglobulinemia (EMC), NHL, low grade mucosal 
associated lymphoid tissue lymphoma, and ALL. This study examined the prevalence of 
HCV in Iranian patients with EMC, MM, and CLL compared to a control group of 
patients with chronic RA. RA patients were selected as controls in an attempt to account 
for hospital-associated risk factors for blood-borne disease. The results of the study 
confirm the association between EMC and HCV. Furthermore, the study showed an 
increased prevalence of HCV in the MM patients (11%, p<0.06) compared to the RA 
controls where 0 of 30 patients were HCV positive. The finding of 11% prevalence was 
also considerably higher, though not significantly, than the prevalence of HCV among the 
normal Iranian population, which is estimated to be 0.3%. For CLL, of the 23 patients 
screened for HCV, 1 was found to be HCV positive (4.3%), a non-significant result. 
 
Machulla HKG, Muller LP, Schaaf A, et al. [2001]. Association of chronic 
lymphocytic leukemia with specific alleles of the HLA-DR4:DR53:DQ8 haplotype in 
German patients. Int J Cancer 92:203-207. 
 
Considering B-cell proliferation normally occurs in response to MHC-restricted T-cell 
activation, the involvement of HLAs in the pathogenesis of CLL warranted investigation. 
This study examined the frequency of HLA alleles in 101 Caucasian CLL patients 
compared to 157 healthy Caucasian controls. An increased frequency of the single alleles 
of HLA-DRB1*0401 (RR=2.13, p<0.035), HLA-DRB4*0103 (RR=2.74, p<0.0025), 
HLA-DQB1*0302 (RR=2.03, p<0.035), and HLA-DPB1*0301 (RR=2.15, p<0.04) was 
observed; however, the statistical significance of these findings was lost after adjustment 
for multiple comparisons. An increased frequency of homozygosity of the HLA-DQB1 in 
CLL patients (RR=2.62, p<0.025, prior to correction factor) was observed which could be 
explained by a recessive susceptibility factor within or near the HLA-DR:DQ MHC 
region, according to the authors. The results of the haplotype analysis suggested to the 
researchers an association between CLL and the HLA-DR4:DR53:DQ8 haplotype. This 
association has been also been observed in insulin-dependent diabetes mellitus and RA, 
which is consistent with a common etiology among these diseases. 
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Pekarsky Y, Hallas C, Croce CM [2001]. Molecular basis of mature T-cell leukemia. 
JAMA 286:2308-2314. 
  
T-cell chronic lymphocytic leukemia (T-CLL) and T-cell prolymphocytic leukemia (T-
PLL) both result from clonal proliferation of post-thymic immunocompetent lymphoid 
cells. It has not been resolved whether the two leukemias are in fact separate entities. 
Compared to T-PLL, T-CLL shows smaller, more mature lymphocytes, similar to B-CLL. 
Both T-CLL and T-PLL frequently demonstrate chromosome rearrangement of 14q32.1 at 
the TCL1 locus, leading to activation of the TCL1 gene. TCL1 is expressed in T-cells at 
an early stage, whereas mature T-cells do not normally express the gene. Several studies 
have reported activation of TCL1 in nearly 100% of sampled cases of T-CLL/T-PLL. This 
article proposes that Tcl1 (the protein product of the TCL1 gene) interacts with Akt to 
increase Akt kinase activity, which subsequently activates a prosurvival pathway. Akt is 
the human homolog of v-akt, a gene from the murine retrovirus AKT8 which causes T-cell 
lymphoma in mice. 
 
Reimer P, Weibinger F, Tony HP, et al. [2000]. Persistent polyclonal B-cell 
lymphocytosis—an important differential diagnosis of B-cell chronic lymphocytic 
leukemia. Ann Hematol 79:327-331. 
 
Often patients with persistent polyclonal B-cell lymphocytosis (PPBL), an apparently 
benign disorder, are misdiagnosed with CLL. PPBL is characterized by high lymphocyte 
counts, binucleated B-cells, HLA-DR7 expression, and polyclonal increase of serum IgM. 
Evidence exists that a genetic disposition factors into the development of PPBL, as the 
vast majority of the cases are women and the cases are more frequently of the HLA-DR7 
phenotype. Since most of the documented PPBL cases have been smokers, it is likely 
smoking may also contribute to the onset of this disorder. This study looked at 
interleukin-4 (IL-4) response, as measured by CD23 and HLA-DR expression, as a means 
to distinguish PPBL cells from normal B-cells and from B-CLL cells. The investigators 
found that PPBL cells showed no IL-4 response whereas normal peripheral B-cells and B-
CLL cells responded to IL-4 stimulation. These results indicate that PPBL cells undergo 
different activation and differentiation than normal B-cells and B-CLL cells. 
 
Bullrich F, Rasio D, Kitada S, et al. [1999]. ATM mutations in B-cell chronic 
lymphocytic leukemia. Cancer Res 59:24-27. 
 
Ataxia-telangiectasia (AT) is an autosomal recessive disorder arising from mutations in 
the ATM gene on the long arm of chromosome 11, at 11q22-23. AT has been implicated 
in the development of T-PLL/T-CLL. This research involved sequencing DNA from 5 
patients with loss of heterozygosity (LOH) at 11q22-23 and lack of ATM expression, and 
1 patient with undetermined LOH status, in order to identify mutations in the ATM gene. 
Four missense mutations were found among these patients. Two of the patients carried the 
mutation in their germline, “suggesting that ATM heterozygotes may be predisposed to B-
CLL.” The authors speculate the carrier rate (heterozygosity) to at least be 5.9%, as 2 
heterozygotes were found among the 4 samples of germ-line DNA tested (the germ-line 
DNA was examined for only 4 out of 34 sporadic B-CLL cases with LOH and ATM 
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mutations). A rate of 0.2-1% of AT heterozygotes among Caucasians has been reported 
previously (Easton et al. 1994, FitzGerald et al. 1997); the current finding of 5.9% is 
significantly different than the estimate of 1%, with a one-sided p=0.045. 
 
Caligaris-Cappio F, Hamblin TJ [1999]. B-cell chronic lymphocytic leukemia: a bird 
of a different feather. J Clin Oncol 17:399-408. 
 
The authors characterize the “distinctiveness” of B-CLL: 1) it is the only blood 
malignancy whose frequency was not increased among atomic bomb survivors 2) the 
etiology suggests a genetic element 3) the disease is typified by defects in induction of 
apoptosis 4) CLL patients are prone to autoimmune phenomena. The authors describe the 
immunophenotype of B-CLL as similar to that of lymphocytes of the mantle zone. B-CLL 
cells express the majority of the same membrane antigens as do normal mature B-cells; 
however B-CLL cells also express CD5 as well as very faint amounts of monoclonal 
surface immunoglobulins (sIgs). The sIgs frequently exhibit polyreactive autoantibody 
activity, and the low levels of sIgM characteristic of CLL are also seen in normal B 
lymphocytes that have been anergized by self-antigen (Ag). Taken together, this 
information suggests that “B-CLL is a malignancy of a mantle zone-based subpopulation 
of anergic self-reactive CD5+ B-cells that are devoted to the production of polyreactive 
autoAbs [autoantibodies].” The authors also speculate that “extended cell survival is 
further shielded by a kinetic refractoriness likely promoted by abnormalities of the B-cell 
receptor complex and favored by some cytokines that highlight a reciprocal dialog 
between malignant B and T-cells.” 
 
Bauer SR [1997]. B-cell differentiation and risks for neoplastic transformation. In: 
Marti GE, Vogt RF, Zenger VE editors. Proceedings of a USPHS workshop on 
laboratory approaches to determining the role of environmental exposures as risk 
factors for B-cell chronic lymphocytic leukemia and other B-cell proliferative 
disorders. Atlanta, GA p 51-60. 
 
B-cell differentiation and the risks of neoplastic transformation are discussed by Bauer:  
 “The B-cell’s inherent capacity to rearrange and mutate its 
immunoglobulin genes is critical for generation of specific antibody-
mediated immunity. However, this capacity also introduces risk since the 
process of immunoglobulin rearrangement or mutation can go awry, 
resulting in unintentional rearrangement or mutation of genes involved in 
control of cell growth. In addition to this high mutation risk, B-cells have 
an innate capability to undergo high rates of proliferation at various stages 
of differentiation or in response to antigen. Thus mutations which 
accumulate can be unintentionally selected when an altered B-cell is 
undergoing the high natural proliferation in response to antigen or during a 
normal phase of differentiation. This selection then sets the stage for 
further accumulation of mutation and consequent B-cell neoplasia.” 
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Faguet GB [1997]. The common chronic lymphocytic leukemia antigen (cCLLa). In: 
Marti GE, Vogt RF, Zenger VE editors. Proceedings of the USPHS workshop on 
laboratory approaches to determining the role of environmental exposures as risk 
factors for B-cell chronic lymphocytic leukemia and other B-cell lymphproliferative 
disorders. Atlanta, GA, pp 103-105. 
 
Common chronic lymphocytic leukemia antigen (cCLLa), a 69 kilodalton surface 
glycoprotein, is expressed in B-CLL, prolymphocytic leukemia (PLL), and HCL. The 
expression is universal: the antigen is expressed in all clonal cells in all patients with these 
diseases. Furthermore, the antigen is not expressed by normal B or T-cells and rarely 
detected in diseases other than B-CLL, PLL, and HCL, demonstrating its value for 
diagnosis. The antigen also has implications for treatment, as monoclonal anti-cCLLa 
antibodies have been found to have clonal-specific cytoxicity. 
 
Maiese RL, Braylan RC [1997]. Detection of low levels of B-cell lymphoproliferative 
disorders. In: Marti GE, Vogt RF, Zenger VE editors. Proceedings of the USPHS 
workshop on laboratory approaches to determining the role of environmental 
exposures as risk factors for B-cell chronic lymphocytic leukemia and other B-cell 
lymphoproliferative disorders. Atlanta, GA, pp 61-68. 
 
This report discusses the utility of flow cytometry in detection of B-cell monoclonality. 
Normally B-cells in the tissue or the periphery are polyclonal; that is, they consist of a 
mixture of cells expressing kappa or lambda surface immunoglobulin light chains, where 
the κ/λ ratio is about 1.5:1. B-cell lymphomas and B-CLL are clonal in origin, expressing 
only one light chain. When examining normal tissue or blood via flow cytometry, a 
bimodal peak is observed when staining for κ or λ surface immunoglobulin. In B-cell 
lymphoma or B-CLL, however, only one peak is observed, demonstrating the mutually 
exclusive expression of a single light chain.  
 
Marti GE, Muller J, Stetler-Stevenson M, Caporaso N [1997]. B-cell monoclonal 
lymphocytosis in three individuals living near a hazardous waste site. In: Marti GE, 
Vogt RF, Zenger VE editors. Proceedings of the USPHS workshop on laboratory 
approaches to determining the role of environmental exposures as risk factors for B-
cell chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. 
Atlanta, GA, pp 37-50. 
 
Eleven individuals were found, during the course of ten studies, to have a B-CLL like 
phenotype. Additional laboratory testing was completed on three of the 11 individuals to 
confirm monoclonality, since B-CLL and B-cell NHL (B-NHL) arise from malignant 
expansion of monoclonal B-cells. BCML was detected in all three. In light of these 
results, the authors stress the need to determine the incidence of BCML with or without 
CD5 expression in the normal adult population. The authors also speculate about the 
possible course of this disease: 1) BCML is transient and will disappear 2) BCML is 
stable or 3) BCML will progress to lymphoproliferative disease. If the latter is true, 
BCML could serve as a predictor for B-CLL. 
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Sarasua SM, Vogt RF, Middleton DC, et al. [1997]. ‘CLL-like’ B-cell phenotypes 
detected in superfund studies: epidemiologic methods and findings. In: Marti GE, 
Vogt RF, Zenger VE editors. Proceedings of the USPHS workshop on laboratory 
approaches to determining the role of environmental exposures as risk factors for B-
cell chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. 
Atlanta, GA, pp 7-18. 
 
Since 1991, ATSDR has carried out studies to assess the health consequences related to 
living near hazardous waste sites. In the course of completing 10 studies where immune 
testing was performed (5,868 participants combined), the researchers found that 11 
individuals exhibited a “B-CLL like” phenotype characterized by a high proportion of B-
cells relative to all lymphocytes, reduced staining of CD20 and/or CD45, and presence of 
CD5 on the surface of mature B-cells. All 11 individuals with the B-CLL like phenotype 
were over 45 years of age, yielding an overall prevalence of B-CLL like phenotype in 
those over age 40 (1,499 subjects) of 0.7%. The prevalence of the B-CLL like phenotype 
was greater, though not significantly, among those living closer to hazardous waste sites 
compared to those living farther (>5 miles) from hazardous waste sites (prevalence 
ratio=1.8, 95% CI=0.5-6.9). Further investigation into these cases revealed that 1 person 
had been previously diagnosed with CLL. As the estimated incidence of CLL among 
those age 50 and over is 5 per 100,000, less than 1 case of CLL would be expected, thus 
the 1 case of CLL fits with the known data. However, the finding of 11 B-CLL like cases 
was not anticipated; the researchers believe this “could indicate an emerging epidemic of 
B-CLL or simply a slow and uncertain progression from laboratory abnormalities to 
clinical disease.”  
 
Vogt, RF, Meredith NK, Powell J, et al. [1997]. Laboratory results in eleven 
individuals with B-CLL like phenotypes detected in environmental health studies. 
In: Marti GE, Vogt RF, Zenger VE editors. Proceedings of the USPHS workshop on 
laboratory approaches to determining the role of environmental exposures as risk 
factors for B-cell chronic lymphocytic leukemia and other B-cell lymphoproliferative 
disorders. Atlanta, GA, pp 19-35. 
 
Flow cytometry is useful in characterizing the expression of receptor proteins on the 
surface of a lymphocyte, a process known as lymphocyte phenotyping. In an ATSDR 
study series (10 studies) examining the effects of living near hazardous waste sites, a “B-
CLL like” phenotype was observed in 11 of 5,868 combined study participants. The 
lymphocyte phenotype (LPT) was marked by a high proportion of B-cells relative to total 
lymphocytes, with expression of CD5 on the B-cell along with reduced expression of 
CD45 and/or CD20. Such a profile is abnormal, as CD5 is usually highly expressed only 
by T-cells. Also, lymphocytes usually stain more brightly than other leukocytes for CD45; 
however, some of the CLL-like profiles showed reduced staining of this marker (such 
reduced staining is typical of certain types of B-CLL.) Furthermore, CD20 is normally 
expressed at high levels on mature peripheral B-cells, which make up about 25% of 
peripheral blood lymphocytes in adults. B-cells, on the other hand, account for the 
majority of peripheral lymphocytes in B-CLL patients and stain only slightly for CD20. 
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Montserrat E, Bosch F, Rozman C. [1997]. B-cell chronic lymphocytic leukemia: 
recent progress in biology, diagnosis, and therapy. Ann Oncol 8 (Suppl 1):S93-S101. 
 
Criteria for establishing a diagnosis of CLL are: 1) absolute lymphocytosis in peripheral 
blood: >5x109 (National Cancer Institute/Working Group) or >10x109 (International 
Workshop on CLL) 2) lymphocytes are mostly small and mature in appearance 3) 
expression of the characteristic phenotype (SmIg+/-, CD5+, CD19+, CD20+, CD23+, 
FMC7-/+, CD22-/+) and 4) bone marrow infiltration (>30% of lymphocytes in bone 
marrow aspirate, or consistent pattern in bone marrow biopsy). Three morphologic 
subtypes of CLL exist (FAB group): 1) typical or classic CLL (<10% atypical 
lymphocytes) 2) mixed CLL/ prolymphocytic leukemia (PL) (11-54% prolymphocytes in 
blood) and 3) atypical CLL (variable proportion of atypical lymphocytes in blood with 
<10% prolymphocytes). An association between trisomy12 and the atypical phenotype 
has been reported, as has an association between deletions in chromosome 6 and 
prolymphocytes in the blood. This review article also highlights that “chromosome 
abnormalities prevail in the advanced phases of the disease and in most cases are acquired 
events” and that karyotypic evolution, often related to disease progression, is found in 14-
40% of CLL cases. 
 
Montserrat E, Rozman C [1995]. Chronic lymphocytic leukemia: present status. Ann 
Oncol 6:219-235.  
 
A review of the current information on CLL, the article discusses the epidemiology and 
the biology of CLL. Discussed in the review is the variability of CLL among populations: 
CLL occurs less frequently in Asian populations and accounts for only 3-5% of all 
leukemia in Asians. The review references Nishiyama et al.1969 who found that the 
incidence of CLL is low even in Asians who have emigrated to the US. In terms of the 
biology of CLL, this article clarifies that “although earlier studies indicated that B-CLL 
lymphocytes were arrested at an early stage of development, studies with anti-idiotypic 
reagents and mitogenic stimulation have shown that the CLL B-lymphocyte can 
differentiate.” Also emphasized in this review is the fact that most cases of CLL are 
diagnosed in an asymptomatic state, “at the Postgraduate School of Hematology in 
Barcelona, the proportion of patients diagnosed in an early stage has increased from 40% 
in the early 1970s to about 70%.” 
 
Gale RP, Caligaris-Cappio F, Dighiero G, et al. [1994]. Recent progress in chronic 
lymphocytic leukemia. Leukemia 8:1610-1614. 
 
The authors report on the sixth International Workshop on Chronic Lymphocytic 
Leukemia held in 1993; oncogenes were discussed in detail at the meeting. It is unclear 
which oncogenes are the cause or consequence of CLL. Abnormalities have been noted 
with retinoblastoma (RB) and P53 (15% of cases), BCL1, BCL2 and BCL3 (5% of cases), 
and other oncogenes (1% of cases). “Most abnormalities, such as MYC [a known 
oncogene] are likely to be a consequence. Others such as P53 and RAS, are likely to be 
late steps in leukemia development. However, data from other cancers, especially 
lymphomas, suggest that one or more oncogene abnormalities may cause CLL. The most 
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likely candidate is a gene linked to RB on chromosome 13.” Another issue raised in the 
meeting was that of G0 arrest. “CLL is often regarded as an accumulative disease: the 
clonal excess of B-cells is thought to result from extended B-cell survival rather than 
increased proliferation. Consequently, it is important to understand why CLL B-cells 
accumulate in G0.” Possible mechanisms responsible for the G0 arrest include the 
following: abnormal phenotype, defective mitogen responsiveness, defective cytokine 
production or response, and impaired apoptosis. The authors state that “in CLL, BCL2 
over-expression inhibits apoptosis resulting in the accumulation of B-cells in G0”. 
 
Radovanovic Z, Markovic-Denic LJ, Jankovic S [1994]. Cancer mortality of family 
members of patients with chronic lymphocytic leukemia. Eur J Epidemiol 10:211-213. 
 
This matched case-control study compared cancer mortality among family members of 
CLL cases with cancer mortality among family members of controls. 119 new CLL cases 
were identified from 4 hospitals in Serbia in 1989. The cases were approached and 
administered the study questionnaire before their CLL diagnosis was revealed to them. 
Controls were matched to cases on sex, age, and place of residence and were administered 
the same form, which requested a listing of all 1st ,2nd ,3rd and 4th degree blood relatives, 
along with their age at the time of the questionnaire or age at death and cause of death. 
Matched ORs were calculated; the OR for leukemia was 5.50 (95% CI=1.44-20.97). SMR 
analyses were also performed. The SMR for leukemia among the 1st and 2nd family 
members of CLL cases was 2.04 (95% CI=0.99-3.09); no leukemia cases were observed 
among the 1st and 2nd degree family members of the controls. 
 
Okazaki M, Luo Y, Han T, et al. [1993]. Three new monoclonal antibodies that 
define a unique antigen associated with prolymphocytic leukemia/ non-Hodgkin’s 
lymphoma and are effectively internalized after binding to cell surface antigen. 
Blood 81:84-94. 
 
Monoclonal antibodies SN8, SN8a and SN8b, were generated via immunization of mice 
with PLL antigen. The SN8 series appears to bind a novel epitope on gp40/49. These 
monoclonal antibodies may serve as an important diagnostic tool, as they were able to 
distinguish between different types of leukemias and lymphomas. SN8 reacted with all 8 
of the B-cell PLL (B-PLL) samples and 9/12 of the B-NHL samples; however, it did not 
react well with samples of B-CLL, HCL, or non-T/non-B ALL. The SN8 antibodies may 
also have implications for use as a mechanism to deliver cytotoxic agents to tumor targets, 
due to their tumor specificity. Finally, further studies of these antibodies may reveal 
information regarding the pathogenesis of B-PLL and B-NHL. 
 
Murmane JP, Kapp LN [1993]. A critical look at the association of human genetic 
syndromes with sensitivity to ionizing radiation. Semin Cancer Biol 4:93-104. 
 
Factors that may influence the response to radiation were reviewed. Such factors include: 
variability within genes which may affect amount of cell damage, ability to respond to and 
repair cell damage, tolerance to DNA mutations, ability to eliminate free radicals, 
presence of mutations affecting cell structure and cell cycle regulation, and heterozygosity 
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for mutations in tumor suppressor genes. Various disorders, such as RB and Wilm’s 
tumor, have been examined to determine if these diseases increase sensitivity to radiation. 
AT is thus far the only syndrome that has demonstrated sufficient evidence of 
clastogenicity (chromosome breakage) and cytotoxicity induced by ionizing radiation. 
Clinical characteristics of AT are radiosensitivity, immunodeficiency, ataxia (neurological 
problems), and telangiectasia (dilated blood vessels). AT patients are also predisposed to 
develop cancer; cancer occurs in 25-38% of patients. It has been postulated that the 
radiosensitivity observed in AT patients may arise from a defect in DNA repair or a defect 
in DNA recombination. Regarding AT heterozygotes, the general consensus is that these 
individuals show a slight increase in radiosensitivity.  
 
Nilsson K [1992]. Human B-lymphoid cell lines. Human Cell 5:25-41. 
 
Several tumor cell lines have been developed to study B-cell tumors in the laboratory. 
Cell lines exist for most of the B-cell leukemias, B-lymphomas and myeloma; 
unfortunately no authentic cell line exists for CLL and PLL. Immortalization of B-CLL 
cells using infection with EBV has been attempted with limited success; only a few lines 
were able to be produced in this manner. These lines differ from in vivo CLL tumors due 
to the presence of EBV. “The reason why B-CLL cells are refractory to immortalization 
by EBV is not known but is not due to any of the following: an absence of EBV receptor 
expression, a defect in EBV-receptor binding, EBV uptake, or the expression of CD23 and 
EBNA. Walls et al. found that B-CLL cells became arrested in the GI/S phase of the cell 
cycle and did not express the transformation-associated LMP antigen or circularize EBV 
DNA, features suggesting that they were different from normal B-cells in their interaction 
with EBV. ” 
 
Rosenblatt KA, Koepsell TD, Daling JR, et al. [1991]. Antigenic stimulation and the 
occurrence of chronic lymphocytic leukemia. Am J Epidemiol 134:22-28. 
 
Between 1977 and 1981, 430 incident cases of CLL were identified in Seattle, Salt Lake 
City, Atlanta, and Detroit. A case-control study design was used to test the hypothesis that 
chronic antigenic stimulation is related to CLL. Population-based controls were selected 
from the same area of residence as the cases. ORs were calculated for 18 indices of 
chronic antigenic stimulation, adjusting for age, race, sex, study area, and education level. 
Cases more frequently reported syphilis exposure than did controls (OR=5.0, 95% CI=2.0-
12.9). The authors speculated this association might be due to arsenic treatment, as arsenic 
treatment has been associated with other diseases of the blood forming organs. To further 
analyze the possible effect of arsenic exposure, stratification by year of the syphilis 
infection (pre or post 1943) was performed, since arsenic treatment was abandoned in 
1943. This analysis revealed an OR of 9.6 for the pre-1943 period (95% CI=2.1-43.4) and 
3.1 for the post 1943 period (95% CI=0.9-10.8). The authors also noted that immune 
suppression has been identified as a possible mechanism in CLL development, and that 
syphilis may cause immune suppression. In addition to syphilis, significant associations 
with tuberculosis (OR=1.9, 95% CI=1.0-3.7) and urinary tract infections (OR=1.4, 95% 
CI=1.1-1.9) were observed. Viral fever blisters also demonstrated a significantly elevated 
OR of 1.3 (95% CI=1.0-1.6). The authors concluded that “the findings of this study 
Annotated Bibliography – Chronic Lymphocytic Leukemia – July 21, 2004  
 
 
 58
provide little evidence of any general increase in risk for CLL associated with chronic 
antigenic stimulation…Furthermore, no apparent relation was found between the number 
of bacterial or viral conditions the subject reported having had and the development of 
CLL.”  
 
Butturini A, Gale RP [1990]. Oncogenes and leukemia. Leukemia 4:138-160.  
 
The relationship between oncogenes and leukemia development was addressed in this 
article. However, the role of oncogenes in terms of CLL was not discussed as “in most 
cases of acute lymphoblastic leukemia and chronic lymphocytic leukemia, oncogene 
abnormalities are uncommon.” Relevant background information on oncogenes was 
provided in this paper; including differentiation of oncogenes by classes: growth factors, 
growth factor receptors, signal transducers, nuclear, and recessive oncogenes. Recessive 
oncogenes differ from the other types “in that it is their absence rather than abnormal 
expression that is correlated with tumorigenicity.” 
 
Morrison WH, Hoppe RT, Weiss LM, et al. [1989]. Small lymphocytic leukemia. J 
Clin Oncol 7:598-606. 
 
Small lymphocytic lymphoma (SL), a disease similar in morphology to CLL, makes up 
4% of all malignant lymphomas. “It is often stated that SL is the solid tumor counterpart 
of CLL and that with time, SL patients usually progress to CLL.” From 1963-1983, 54 
patients diagnosed with SL were treated at the Stanford University Medical Center. 
Similar to the rate of 15% CLL progression as previously observed by Pangalis et al. 
(1977), ten of the Stanford patients (19%) went on to develop CLL. Patients with higher 
initial lymphocyte counts were significantly more likely to develop CLL than those with 
lower counts. The authors postulate the SL may be a precursor state for CLL.  
 
Gale RP [1988]. Current issues in chronic lymphocytic leukemia. Nouv Rev Fr 
Hematol 30:263-265. 
 
The author contemplates the answers to three issues in CLL etiology. The first issue is 
whether CLL is a leukemia or a preleukemia. For example, CML is a preleukemia 
characterized by normally regulated growth and differentiation, but T-cells are in excess. 
CML almost always leads to an acute phase, AML, which is considered a leukemia due to 
the fact that growth is not regulated and differentiation is abnormal. It has been 
established that CLL arises from a clonal proliferation; however, whether the growth is 
normally regulated is unknown. It is also unknown whether the CD5 positive B-cell, 
characteristic of B-CLL, is a distinct subset or if it is also present as a rare, immature 
population of B-cells. “In the former instance CLL need not be interpreted as exhibiting a 
block in differentiation whereas the latter instance implies blocked differentiation. 
Presently most data support the second hypothesis.” Hypothetically, if CLL were a 
preleukemia, the author offers plausible reasons why so few patients experience leukemia, 
namely that a) the transforming step is rare or b) the transforming step is not rare but the 
latency period is long. Another issue the author raises is where the CLL transformation 
occurs, “most data suggest that in B-CLL the leukemia clone is restricted to B-cells; T-
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cells and myeloid cells are seemingly not involved.” The final point Gale reflects on 
concerns whether immunodeficiency is secondary to CLL. Gale has “postulated that the 
initial lesion in CLL might be a non-malignant T-cell abnormality. This could lead to 
polyclonal expansion of the CD5 subset of B-cells and eventually lead to expansion or 
transformation of one clone. This would account for the T and B-cell abnormalities 
characteristic of B-CLL as well as explain the high incidence of polyclonal autoimmune 
antibodies.” 
 
Kipps TJ, Tomhave E, Chen PP, Carson DA [1988]. Autoantibody-associated κ light 
chain variable region gene expressed in chronic lymphocytic leukemia with little or 
no somatic mutation. J Exp Med 167:840-852. 
 
In a previous study the authors found that 5 of 20 κ light chain expressing CLLs reacted 
with a murine monoclonal antiidiotypic antibody, 17.109, which is specific for a cross-
reactive idiotype associated with rheumatoid factor and other IgM autoantibodies. Stable 
idiotype expression was indicated from results of flow cytometric analysis, where the 
expression of 17.109 was directly proportional to the level of surface immunoglobulin κ 
chain. To further assess this relationship, sequence analysis on the genes encoding the 
immunoglobulin κ chain was done on 2 unrelated individuals whose cells were previously 
shown to react to 17.109. The analysis showed no evidence of sequence heterogeneity in 
the CLL clones. Also, the sequences expressed by the malignant T-cells of both patients 
were homologous to their germline Vκ. According to the authors these results suggest: 
“(a) that the malignant CD5+ B-lymphocytes in CLL use the same Vκ gene that has been 
highly associated with IgM autoantibodies and (b) that the expression of V genes is stable 
in CLL, in contrast to other B-cell malignancies examined to date.” The investigators 
hypothesize that several CLL cases “represent malignancies of autoreactive CD5 B-cells 
that use a restricted set of conserved V genes” which may have implications for 
immunotherapy with antiidiotypic antibodies.  
 
Butturini A, Gale RP [1988]. Oncogenes in chronic lymphocytic leukemia. Leukemia 
Res 12:89-92. 
 
Proto-oncogenes are a family of genes present in all eukaryotic cells, which are generally 
regarded as regulators of cell growth and development. Viral homologs of proto-
oncogenes act in the pathogenesis of retroviruses, where the oncogene may contain 
deletions or insertions compared to the normal cellular homolog. Alternatively, 
retroviruses may not contain oncogenes in their genome, but rather act as a promoter or 
enhancer of the cellular proto-oncogenes. Retroviruses do not appear to be responsible for 
leukemia in humans, with the exception of the association of human T-cell lymphotrophic 
virus-1 (HTLV-1) with ATL and the association of human T-cell lymphotropic virus-2 
(HTLV-2) with atypical hairy cell leukemia (neither virus is known to carry a viral 
oncogene with a normal cellular homolog). To examine the role of oncogenes in CLL 
pathogenesis, potential oncogenes were identified via the NIH/3T3 transformation assay 
and from chromosome mapping of cytogenic abnormalities. Using the NIH/3T3 method, 
Ki-ras has been implicated as an oncogene. Trisomy 12 is the most common chromosomal 
abnormality observed in CLL patients, occurring in 50% of cases. Trisomy 12 individuals 
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have a third copy of chromosome 12, and thus an extra copy of the Ki-ras gene. Other 
cytogenic abnormalities are seen in CLL patients, however they are rare. Such 
abnormalities and their envisaged oncogenes include t (11; 14) translocation leading the 
rearrangement of bcl-1, and 14q11-q32 abnormalities leading to rearrangement of tcl-1. 
The authors ponder the reasons why oncogenes are seen less commonly in CLL than in 
other leukemias. “One explanation is that relatively few cases have been studied. If 
trisomy 12 and therefore an additional copy of Ki-ras are important, then almost 50% of 
patients can be envisaged as having oncogene abnormalities. Another possibility is that 
oncogenes play a lesser role or no role in CLL. This could reflect the concept that CLL is 
a disorder of accumulation rather than proliferation.”  
 
Schrek R, Best WR, Stefani S [1988]. Relationship between in vitro and in vivo 
radiosensitivity of lymphocytes in chronic lymphocytic leukemia. Acta Haemat 
80:129-133. 
 
About 25% of all CLL patients are resistant to chemotherapy, 50% of those with advanced 
stages of CLL are nonresponsive to chemotherapy. This aim of this research was to 
develop a method to detect CLL patients likely to be nonresponsive to chemotherapy. 
Schrek et al. found previously that “in vitro radioresistant lymphocytes from CLL patients 
at the time of diagnosis was associated with the resistance of patients to both radiotherapy 
and chemotherapy.” This research demonstrated a correlation between in vitro 
radiosensitivity of the lymphocytes of patients with CLL and in vivo response to RT. The 
authors conclude that testing cells in vitro may predict nonresponsiveness to RT, which in 
turn may indicate resistance to chemotherapy.  
  
Linet MS [1984]. Chronic lymphocytic leukemia and multiple myeloma in husband 
and wife.  Am J Med Sci 288:21-24. 
 
This case of CLL in a husband and MM in a wife affords the researcher the opportunity to 
examine common environmental exposures as cause for the cancers. After interviewing 
the wife, four potential exposures were noted: 1) the wife painted the house interior once a 
year and used paint remover every few years to remove paint layers 2) the wife sprayed 
insecticide once a week to control cockroaches 3) the husband worked as an embalmer 
and the wife washed the work uniform a few times a week 4) the couple lived adjacent to 
a plant involved in the manufacturing of diesel engine parts. The most suspicious 
exposure, according to the author, is the weekly insecticide spraying. Benzene, which is 
found in some pesticides, has been implicated in the development of both CLL and MM.  
 
Hull MT, Griep JA [1980]. Mixed leukemia, lymphatic and myelomonocytic. Am J 
Clin Pathol 74:473-475.  
 
A case of mixed lymphatic and myelomonocytic leukemia was reported in a 76 year old 
man. Only 21 such cases have been documented since the first known occurrence in 1906. 
The authors summarize that “mixed leukemia is a rare phenomenon that occurs mainly in 
elderly patients who have CLL in whom terminal blastic leukemia of either monocytic or 
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myelocytic type develops. Many of these patients had prior exposure to either ionizing 
radiation or alkylating agents during the course of their chronic lymphocytic leukemias.” 
 
Rozynkowa D, Rupniewska Z, Stepien J [1976]. T lymphocytes in chronic 
lymphocytic leukemia. Annals Med Sect Pol Acad Sci 21:121-138. 
 
This article concludes that “1. The lymphocytes in the peripheral blood in CLL are 
characterized by a late occurrence of the peak of blastic transformation under the 
influence of PHA [phytohemagglutinin]. They consist of a fraction of late-reacting cells to 
PHA and blasts arising by secondary proliferation of early-reacting cells. Lymphocytes of 
the late-reacting fraction occur also in the lymphocyte cultures of healthy subjects. 2. 
….this fraction may be classified as normal thymus dependent lymphocytes. 3. The 
admixture of late-reacting lymphocytes to PHA which are incapable of producing E 
rosettes suggests participation in this fraction of yet another subpopulation. 4. 
Approximate estimation of the magnitude of early and late-reacting fraction to PHA 
permits the conclusion that the pool of normal T lymphocytes in the circulating blood is 
not diminished in the early years of untreated chronic lymphocytic leukemia.” 
 
Gunz FW, Gunz JP, Veale AMO, et al. [1975]. Familial leukemia: a study of 909 
families. Scand J Haematol 15:117-131. 
 
Leukemia patients in the Sydney, Australia area were identified and a survey of leukemia 
in family members was completed via a questionnaire/interview. The occurrence of 
leukemia in 909 families was studied and compared to expected rates based on the New 
South Wales population. Of the 909 (200 CLL) patients, 72 had relatives with leukemia. 
For the CLL subtype, 16 of the patients had relatives with leukemia of which 7 were first 
degree relatives (43.7%). Among the 7 CGL patients with relatives with leukemia, only 1 
was a first degree relative. Additionally, only one instance of concordance between 
subtypes of leukemia was observed among the CGL families, whereas with CLL 6 of the 
families exhibited concordance. The authors suggest that “familial leukemia was of 
greater importance in CLL than CGL.” Overall, the O/E ratios for leukemia for first 
degree relatives and for other relatives were 2.43 and 2.15, respectively. This analysis was 
not performed by leukemia subtype. 
 
XI. General Radiation/Radiobiological Effectiveness Factor 
 
Darby SC, Inskip PD [1995]. Ionizing radiation: future etiologic research and 
preventive strategies. Environ Health Persp 103 Supp 8:245-249. 
 
Radiobiological effectiveness factor (RBE) is discussed in this review of ionizing 
radiation. Animal data have shown that cancer risk from penetrating low low-energy 
transfer (LET) radiation is lower for prolonged exposure than for acute exposure of 
equivalent dose. Thus when extrapolating risk from protracted exposures using data from 
acute exposures, the risk estimates have often been divided by a dose-rate effectiveness 
factor. A RBE factor between 2 and 10 has been suggested from available animal data. 
The authors note that preliminary data do not support dose-rate factors as large as 10. 
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“Estimates of the excess relative risk per Sv for all cancers combined are very similar for 
nuclear workers and atomic bomb survivors, while leukemia risk estimates differ by a 
factor of about three to four.” 
 
Voelz GL [1991]. Health considerations for workers exposed to plutonium. Occup 
Med 6:681-694. 
 
This article reviewed the basis for the argument that plutonium may be related to 
lymphopoietic diseases. “About 3-7% of Pu deposited in human bone is located in the 
bone marrow, which raises a question about the risk of inducing leukemia or 
myeloproliferative disorders. These diseases are not a significant finding in the dog 
studies; however high doses of Pu result in considerable damage to hematopoiesis and 
bone marrow function in mouse experiments.” 
 
Freeman SE, Ormiston-Smith HM [1994]. The biological hazard of plutonium. 
Medicine and War 10:106-126. 
 
In this review of the hazards of plutonium, the author cites the Kadhim et al. (1994) study 
of chromosome instability after plutonium irradiation. The chromosome abnormalities 
seen by Kadhim et al. “suggested that exposed (and surviving) stem cells transmit to their 
daughter cells some chromosomal instability that may result in some visible cytogenetic 
aberration many cell cycles later. They suggest that it is possible that the instability could, 
on occasions, disrupt a region of the genome involved in leukemic transformation.” This 
review also mentions that “estimates of leukemia risk are based on epidemiological data 
for LET radiations, taking into account the enhanced effectiveness of high LET radiations 
such as alpha particles. It is suggested, however, that there may be unique, initial 
radiogenic damage induced only by high LET radiations. If this should be so then the 
RBE of alpha particles compared with low LET radiations would not be between 3 and 
50, as is currently believed, but could approach infinity. Such a suggestion would 
complicate epidemiological studies, where a correlation between dose and effect is sought, 
since a low dose of alpha irradiation might be leukemogenic if a single track through a 
target T-cell were to be effective. It is likely, however, that the initial radiogenic damage 
would need some form of ‘promotion’, so that the damaged cells would have an advantage 
over undamaged cells.” 
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